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Summary 
Alzheimer’s Disease (AD) is the most common cause of dementia, accounting for as much as 
80 % of all dementia cases, estimated to affect over 46 million people worldwide. AD is a 
disease that robs affected individuals of memory and cognition that affects both the 
individual and the family and friends – without any cure at sight, AD is also one of the most 
costliest and deadliest disease. It is characterized by progressive neurodegeneration which 
results in substantial neuron loss and brain atrophy explaining the cognitive decline and 
memory problems. Behavioral symptoms manifest as memory lapses and subtle personality 
changes in early-stage AD and progress to profound cognitive and memory decline in late-
stage AD. Lack of curative therapy for AD after more than 100 years since its first 
description can at least in part be attributed to its complex etiology. In the last three decades, 
significant progress has been made in understanding the genetic, biochemical and molecular 
basis of the disease. These advancements have yielded a few therapeutic options that are 
under clinical trials, which are designed to delay progression and eventually cure the disease. 
Nevertheless, we still have not pinpointed the exact cause/causes for AD so that we can 
develop definitive cures for the disease. My thesis aims to understand the role of membrane 
trafficking pathways in regulation of Aβ levels and thereby the potential patho-mechanisms 
that underlie both the familial/early and late-onset AD (LOAD). 
 
Studies on Familial AD (FAD) mutations have proven beyond doubt that excessive Aβ 
production is the driver of the pathogenesis observed in FAD. However, with an absence of 
such mutations, the causal factor of amyloid accumulation in LOAD has remained 
unidentified. Evidences suggest that impaired amyloid clearance could be the cause of 
amyloid build-up in LOAD. By applying cell and systems biology techniques I set out to 
investigate this at the cellular level. Using state-of-the-art screens, I identified Rab11 as a 
novel positive regulator of Aβ production through regulation of recycling endosomes. In 
addition, I also discovered a critical role for lysosomes in clearance of Aβ levels. Through the 
findings on Rab7 and Presenilin-2, I demonstrate that the lysosomal pathway is the major 
route for Aβ degradation. Based on this study, I propose that in LOAD the lysosomal 
pathway is critically vulnerable and that, environmental or genetic factors targeting the 
lysosomal pathway can significantly contribute to LOAD risk. 
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Rab11: a novel regulator for Aβ production 
How neurons use their membrane trafficking to release neurotransmitters, growth factors or 
how they internalize nutrients is fairly well known. We hypothesized, that since most of the 
players in Aβ production are membrane associated, membrane trafficking in the cells should 
play an important role in Alzheimer’s disease. To identify trafficking pathways that regulate 
Aβ, we performed a screen where we deleted all the Rab-GTPases in human genome and 
assessed their influence on the levels of Aβ. We identified Rab11 as the top positive 
regulators of Aβ levels. Mechanistic characterization revealed that Rab11 regulated the 
endosomal recycling of β-secretase, the first enzyme in the Aβ production pathway, to the 
plasma membrane without affecting APP trafficking. My results show that normally β-
secretase is replenished to the cell-surface from where it is re-internalized for successive 
rounds of Aβ production in a Rab11 dependent manner. Absence of Rab11 thus impaired this 
cycle and reduced Aβ levels. Interestingly, exome sequencing revealed a significant genetic 
association of a Rab11A variant with late-onset AD patients, and protein interaction-network 
analysis identified Rab11 as a component of the late-onset AD risk network, suggesting a 
causal link between Rab11 and AD. By integrating these findings to existing literature on 
Rab function a “roadmap” for Aβ metabolism was created that illustrates that the membrane 
trafficking process is a complex process that regulates Aβ production. 
 
Rab7: a novel regulator for Aβ clearance 
Aβ levels are determined not just by production but through clearance mechanisms as well. In 
FAD, specific genetic mutations increase the production of Aβ peptide but in the late-onset 
AD, evidence suggests that its clearance may play the crucial role. So, what are the cellular 
mechanisms that affect clearance of Aβ? After having identified membrane trafficking 
regulators that are involved in Aβ production, I focussed on screening for trafficking 
regulators involved in Aβ clearance. An RNAi screen for all Rab-GTPases in a microglial 
cell line (BV2) identified Rab7 as a novel regulator of Aβ clearance. Microglia are resident 
macrophages of the brain and involved in the clearance of Aβ that is produced by neurons. 
Rab7 silencing in BV2 microglia led to a significant increase in Aβ uptake. Mechanistically, 
although Rab7 silencing increased Aβ uptake, the engulfed Aβ was shown to be 
accumulating in enlarged vesicles, reminiscent of lysosomes. Rab7 silencing perturbed the 
normal distribution of lysosomes and reduced lysosomal enzymatic activity, a key indicator 
of lysosomal function. Rab7 silencing impaired lysosomal clearance and thus increased 
overall protein aggregates in these cells. Interestingly, Rab7 silencing also increased total-tau 
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and phospho-tau levels in primary neurons. This indicates that both Aβ and tau can be 
degraded intracellularly by the lysosomal pathway and validates the relevance of this 
pathway in AD pathogenesis. Since the lysosomal pathway is linked to autophagy and 
nutrient sensing, our results suggest that nutrient intake and metabolism could affect 
Alzheimer’s disease risk. 
 
PS2: an unexpected negative regulator of Aβ levels 
The role of the lysosomal degradation pathway in the regulation of Aβ levels and its 
importance in AD was further reinforced by findings on presenilin 2 (PS2), which constitutes 
one of the two possible catalytic subunits of the γ-secretase complex. In an unbiased genome-
wide RNAi screen for human proteases, we unexpectedly identified PS2 as a negative 
regulator of Aβ levels. In the AD field, PS2 is often considered as the “insignificant cousin” 
of PS1, which is regarded as the main catalytic component of γ-secretase and which has over 
200 mutations associated with FAD. Similarly, albeit in lower numbers, PS2 also has 
mutations that are associated with FAD, thus making PS1 and PS2 both positively involved 
in AD risk. However, my results now identify a completely novel function for PS2 in that it is 
involved in Aβ clearance through the lysosomal pathway. PS2 deficiency reduced both 
lysosomal number and function (increased lysosomal pH) and thus impaired Aβ degradation. 
We asked whether the increased lysosomal pH observed upon PS2 silencing was due to the 
dysregulation of lysosomal Ca2+ levels. Indeed, PS2 depletion reduced the lysosomal Ca2+ 
levels in a TRPML1-dependent manner and this led to an increase in lysosomal pH. Since, 
microglia are the main cell-type that degrade Aβ in the brain we next asked whether PS2 is 
also important in regulating lysosomal function and Aβ degradation in microglia. Indeed, PS2 
depletion in BV2 microglia reduced lysosomal number and function and thus impaired Aβ 
degradation.  
 
These results show, for the first time, that there is a functional dichotomy between the two 
presenilin paralogues, PS1 and PS2. While PS1 is largely responsible for Aβ production in 
the endosomes, PS2 controls Aβ clearance in lysosomes and thus contributes to homeostatic 
control of Aβ levels. Our results also suggest that disturbances in this homeostatic 
mechanism could affect Aβ accumulation and thus confer the risk to develop AD. 
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GSAP: a controversial regulator of Aβ production 
A study in 2010 by He and colleagues reported the identification of a novel γ-secretase 
activating protein (GSAP). He and colleagues claimed that GSAP is processed from a 
holoprotein to a 16 kDa active form by a yet unidentified protease. They further observed that 
GSAP interacts with the γ-secretase complex to selectively regulate β-amyloid peptide 
generation from APP, without affecting Notch cleavage. This was an exciting finding in the 
field as inhibiting GSAP or the protease that cleaves full-length GSAP provided an 
opportunity to inhibit γ-secretase and Aβ production without interfering with Notch cleavage. 
Many of the side-effects observed in clinical trials for γ-secretase inhibitor were attributed to 
its inhibition of Notch cleavage. Thus, replicating this important finding about GSAP and 
identifying the protease that cleaves GSAP was an exciting opportunity. 
 
To our surprise, I found that processing of GSAP is not required for Aβ production. In fact, I 
did not observe any cleaved GSAP product in multiple cell lines, including the ones tested by 
He and colleagues – thus we failed to replicate their main findings. Mechanistically, we 
found out that rather than specifically regulating γ-cleavage of APP, GSAP regulated the 
levels of full length APP. This was further supported from our observation that GSAP 
silencing affected APP processing by all three proteases, i.e., α, β- and γ-secretases. This 
effect on the processing is likely due to reduced APP levels and not because of GSAP’s effect 
on the secretases. He and colleagues also showed that imatinib, an anti-cancer drug, reduced 
Aβ levels by inhibiting the GSAP-γ-secretase interaction. We on the other hand observed that 
imatinib reduced Aβ levels even in the absence of GSAP. Other studies that support our 
findings have also been published since then confirming our failure to replicate these. The 
exact mechanism of how GSAP regulates APP levels is not clear yet. Nevertheless, our 
results caution the validity of GSAP as a therapeutic target in Alzheimer’s disease and reflect 
on the necessity of independent replication of scientific observations. 
 
Collectively, our studies on membrane trafficking and Aβ metabolism have identified several 
novel regulators of Aβ levels both at the level of production as well as for clearance. These 
findings will help to bridge some of the knowledge gaps in AD pathogenesis and potentially 
open new therapeutic avenues and prevention strategies. Our studies also demonstrate the 
importance of systems cell biology-based investigation in unraveling the molecular 
complexity of AD. Lastly, the study on GSAP and Aβ reinforce the importance of robust 
validation and of reproducibility in science. As my personal contribution to enhance data 
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visibility and thereby facilitate reproducibility in science I have published all my articles in 
open access journals  	
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Zusammenfassung 
Die Alzheimer Krankheit (Alzheimer Demenz; AD) ist die häufigste Form der Demenz und 
umfasst ca. 80% aller Demenzfälle. Nach derzeitigen Schätzungen leben über 46 Millionen 
Menschen weltweit mit Demenz. AD ist gekennzeichnet durch eine fortschreitende 
Neurodegeneration, welche zu ausgeprägtem Hirnschwund und Verlust kognitiver 
Funktionen führt. Verhaltenstechnisch manifestiert sich die Krankheit in der frühen Phase in 
gelegentlichen Gedächtnisproblemen und leichten Persönlichkeitsänderungen, welche in der 
späteren Phase zu einem zunehmenden Verfall der kognitiven Fähigkeiten und der 
Gedächtnisleistung voranschreiten. Das Fehlen einer kurativen Therapie über 100 Jahre nach 
der ersten Beschreibung des Krankheitsbildes kann zumindest teilweise der komplexen 
Ätiologie der Alzheimer Krankheit zugeschrieben werden. In den vergangenen drei 
Jahrzehnten wurden bedeutende Fortschritte im Verständnis der genetischen, zellulären und 
molekularen Grundlagen der Krankheit gemacht. Diese Fortschritte haben bereits einige 
therapeutische Ansätze hervorgebracht, welche in klinischen Studien getestet wurden mit der 
Hoffnung, den Krankheitsverlauf zu verlangsamen und letztendlich die Krankheit zu heilen. 
Jedoch wurde die genaue Ursache für AD noch immer nicht identifiziert, auf deren Basis wir 
eine definitive Heilmethode entwickeln könnten. Meine Doktorarbeit hat zum Ziel, die Rolle 
der Signalwege des Membrantransports für die Regulierung der Aβ Mengen zu erforschen 
und darauf aufbauend die möglichen Pathomechanismen, welche der familiären/frühen Form 
von AD (FAD) und der sporadischen/späten Form (late-onset Alzheimer Demenz; LOAD) 
zugrunde liegen, besser zu verstehen. 
 
Die Erforschung von Mutationen, welche die familiäre Form der Alzheimer Krankheit (FAD) 
verursachen, haben zweifelsfrei belegt, dass eine übermässige Produktion von Aβ der 
wichtigste Pathomechanismus in FAD ist. Solche Mutationen fehlen jedoch in LOAD und 
der kausale Faktor für die Akkumulation von Amyloid ist hier noch nicht identifiziert. 
Forschungsergebnisse deuten darauf hin, dass ein beeinträchtigter Abbau von Amyloid die 
Ursache für dessen Anhäufung in LOAD sein könnte. Mittels zellbiologischer und 
systembiologischer Techniken begann ich daher, dies auf zellulärer Ebene genauer zu 
untersuchen. In einem Screening für Proteine des Membrantransportes, welche Aβ regulieren, 
identifizierte ich Rab11 als einen neuen positiven Regulator der Aβ Produktion. Ergebnisse 
zu Rab7 und PS2 zeigen ausserdem, dass der lysosomale Verdau der Hauptweg für den 
intrazellulären Abbau von Aβ ist. Unsere Ergebnisse lassen vermuten, dass der lysosomale 
Signalweg in LOAD eine wichtige Rolle spielen könnte und dass Umweltfaktoren oder 
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genetische Faktoren, die den lysosomalen Abbauweg beeinträchtigen, signifikant zum LOAD 
Risiko beitragen könnten. 
 
Rab11: Ein neuer Regulator der Aβ Produktion  
Es ist bereits recht gut untersucht wie Nervenzellen ihren Membrantransport nutzen um 
Neurotransmitter und Wachstumsfaktoren freizusetzen oder um die Nährstoffaufnahme zu 
regulieren. Da die meisten Proteine, die an der Produktion von Aβ beteiligt sind, Membran-
assoziiert sind, stellten wir die Hypothese auf, dass der Membrantransport in den Zellen eine 
wichtige Rolle in der Alzheimer Krankheit spielt. 
 
Um Transportwege zu identifizieren welche Aβ regulieren führten wir in einem AD Zell-
Modell ein RNAi-Screening für alle Rab-GTPasen im humanen Genom durch und 
analysierten deren Effekte auf die Aβ Menge. Wir identifizierten Rab11 als wichtigsten 
positiven Regulator des Aβ-Spiegels. Eine mechanistische Charakterisierung zeigte, dass 
Rab11 das endosomale Recycling der β-Sekretase, dem ersten Enzym in der Aβ Produktion, 
reguliert, ohne den Transport von APP zu beeinflussen. Meine Ergebnisse zeigen, dass die β-
Sekretase normalerweise an die Zelloberfläche zurücktransportiert wird, von wo aus sie in 
einer Rab11-abhängigen Weise erneut internalisiert wird und für weitere Runden der Aβ-
Produktion zur Verfügung steht. Der Knockdown von Rab11 beeinträchtigte diesen Zyklus 
und reduzierte somit den Aβ-Spiegel. Interessanterweise zeigte eine Exom-Sequenzierung 
eine signifikante genetische Assoziation einer Rab11A-Variante mit LOAD, und eine 
Proteininteraktions-Netzwerkanalyse identifizierte Rab11 als Bestandteil des LOAD-
Risikonetzwerks, was auf einen kausalen Zusammenhang zwischen Rab11 und AD hindeutet. 
Durch Integration unserer Ergebnisse in die bestehende Literatur zur Funktion von Rab-
Proteinen wurde eine "Roadmap" für den Aβ-Metabolismus erstellt in welcher ersichtlich 
wird, dass der Membrantransport zur Regulation von Aβ einem komplexen Wegenetz folgt. 
 
Rab7: Ein neuer Regulator des Aβ Abbaus 
Aβ-Spiegel werden nicht nur durch die Produktion, sondern auch durch Abbaumechanismen 
bestimmt. Bei der früh einsetzenden Form der AD erhöhen genetische Mutationen die 
Produktion des Aβ-Peptids, aber in der späten Form der AD gibt es Hinweise darauf, dass der 
Abbau eine entscheidende Rolle spielt. Welches sind also die zellulären Mechanismen, die 
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den Abbau von Aβ beeinflussen? Nachdem ich Regulatoren des Membrantransports 
identifiziert hatte, die an der Aβ Produktion beteiligt sind, konzentrierte ich mich auf das 
Screening von Regulatoren, die am Aβ-Abbau beteiligt sind. Ein RNAi-Screening für alle 
Rab-GTPasen in einer Mikroglia-Zelllinie (BV2) identifizierte Rab7 als wichtigen Regulator 
des Aβ Abbaus. Mikroglia sind die Makrophagen des Gehirns und sind dort am Abbau von 
Aβ beteiligt, welches von Neuronen produziert worden ist. Rab7-Silencing in BV2-Mikroglia 
führte zu einem signifikanten Anstieg der Aβ-Aufnahme. Mechanistisch zeigte sich, dass das 
aufgenommene Aβ sich in vergrösserten Vesikeln ansammelte, welche Ähnlichkeit mit 
Lysosomen hatten. Lysosomen. Rab7-Silencing störte die normale Verteilung von 
Lysosomen und reduzierte die lysosomale Enzymaktivität, ein wichtiger Indikator der 
lysosomalen Funktion. Rab7-Silencing beeinträchtigte auf diese Weise den lysosomalen 
Abbau und erhöhte die Menge an Proteinaggregaten in diesen Zellen. Interessanterweise 
erhöhte der Knockdown von Rab7 auch die Menge an Tau-Protein und die Phospho-Tau-
Konzentration in primären Neuronen. Dies deutet darauf hin, dass sowohl Aβ als auch Tau 
via den lysosomalen Weg intrazellulär abgebaut werden können, und bestätigt die Relevanz 
dieses Abbaumechanismus für die AD Pathogenese. Da der lysosomale Stoffwechselweg 
eine wichtige Rolle bei der Autophagie spielt und auch eng an die Nährstoffaufnahme 
gekoppelt ist legen unsere Ergebnisse nahe, dass Nährstoffaufnahme und Stoffwechsel das 
Alzheimer-Risiko beeinflussen könnten. 
 
PS2: Ein unerwarteter negativer Regulator des Aβ-Spiegels 
Die Bedeutung des lysosomalen Abbauweges für die Regulation des Aβ-Spiegels und seine 
Rolle in AD wurde weiter verdeutlicht durch Befunde zu Presenilin 2 (PS2), eine von zwei 
möglichen enzymatischen Untereinheiten des γ-Sekretase-Komplexes. In einem Genom-
weiten RNAi-Screening für Proteasen identifizierte ich unerwarteterweise PS2 als einen 
negativen Regulator von Aβ. Im AD Forschungsfeld wird PS2 oft als "unbedeutender 
Cousin" von PS1 wahrgenommen, welches als funktionell bedeutendere katalytische 
Komponente der γ-Sekretase betrachtet wird, die über 200 mit FAD assoziierte Mutationen 
aufweist. Jedoch gibt es auch FAD Mutationen in PS2, wenn auch in geringerer Anzahl. 
Meine Ergebnisse zeigen nun eine völlig neue Funktion von PS2 in der Regulation von Aβ 
unter Beteiligung der Lysosomen. PS2-Silencing verringerte sowohl die Anzahl an 
Lysosomen als auch ihre Funktionstüchtigkeit (erhöhter lysosomaler pH-Wert) und 
beeinträchtigte damit den Abbau von Aβ. Ich untersuchte als nächstes, ob der erhöhte 
lysosomale pH-Wert, der beim PS2-Silencing beobachtet wurde, auf eine Dysregulation des 
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lysosomalen Ca2+-Spiegels zurückzuführen sei. Tatsächlich reduzierte die PS2-Depletion die 
lysosomale Ca2+-Konzentration in TRPML1-abhängiger Weise und dies führte zu einem 
Anstieg des lysosomalen pH-Wertes. Da der zelluläre Abbau von Aβ im Gehirn vor allem 
durch Mikroglia durchgeführt wird, untersuchte ich als nächstes, ob PS2 auch in Mikroglia 
für die Regulierung der lysosomalen Funktion und den Aβ Abbau wichtig ist. Tatsächlich 
reduzierte die PS2-Depletion auch in BV2-Mikroglia die lysosomale Zahl und Funktion und 
somit den Aβ Abbau.  Diese Ergebnisse zeigen zum ersten Mal, dass es eine funktionelle 
Dichotomie zwischen den beiden Presenilin-Paralogen PS1 und PS2 gibt. Während PS1 
hauptsächlich für die Aβ Produktion in den Endosomen verantwortlich ist, kontrolliert PS2 
den Aβ Abbau in Lysosomen und trägt somit zur homöostatischen Kontrolle des Aβ-Spiegel 
bei. Unsere Ergebnisse deuten auch darauf hin, dass Störungen in diesem homöostatischen 
Mechanismus die Aβ Akkumulation beeinflussen könnten und somit ein Risiko für die 
Entwicklung von AD bergen. 
 
GSAP: ein umstrittener Regulator der Aβ Produktion  
Eine Studie von He und Kollegen aus dem Jahr 2010 berichtete über die Identifizierung eines 
neuen γ-Sekretase-aktivierenden Proteins (GSAP). Er und seine Kollegen behaupteten, dass 
GSAP von einer noch nicht identifizierten Protease aus einem Holoprotein zu einer aktiven 
16 kDa-Form prozessiert wird. Sie beobachteten ferner, dass GSAP mit dem γ-Sekretase 
Komplex interagiert, um selektiv die Produktion von β-Amyloid Peptid aus APP zu 
regulieren, ohne die Prozessierung von Notch zu beeinflussen. Dies war ein spannender 
Befund, da die Hemmung von GSAP oder der Protease, welche das Holoprotein spaltet, eine 
Möglichkeit versprach, γ-Sekretase und damit die Aβ Produktion zu inhibieren, ohne die 
Spaltung von Notch zu stören. Viele der Nebenwirkungen, die in klinischen Studien für den 
γ-Sekretase-Inhibitor beobachtet wurden, wurden seiner hemmenden Wirkung auf die Notch-
Spaltung zugeschrieben. Daher erschien die Replikation dieses wichtigen Befundes über 
GSAP und die Identifizierung der Protease, die GSAP spaltet, eine wichtige und spannende 
Aufgabe. 
 
Zu meiner Überraschung zeigten meine Ergebnisse jedoch, dass die Spaltung von GSAP für 
die Aβ Produktion nicht erforderlich ist. Auch konnte ich kein GSAP-Spaltprodukt 
identifizieren, obwohl ich mehrere Zelllinien getestet habe, einschliesslich der von He und 
Kollegen verwendeten Linie. Ihre Haupterkenntnisse waren also nicht reproduzierbar. 
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Mechanistisch zeigte sich, dass GSAP nicht wie ursprünglich berichtet spezifisch die 
Spaltung von APP durch γ-Sekretase reguliert, sondern die Menge an APP selbst 
beeinflusste. Dies wurde zudem durch unsere Beobachtung gestützt, dass GSAP-Silencing 
die APP-Verarbeitung durch alle drei Proteasen, d.h. α-, β- und γ-Sekretasen, beeinflusste. 
Dieser Effekt auf die Verarbeitung ist höchstwahrscheinlich auf die verringerten APP-Level 
zurückzuführen und nicht auf die Wirkung von GSAP auf die Sekretasen. He und seine 
Kollegen zeigten auch, dass Imatinib, ein Anti-Krebs-Medikament, Aβ-Spiegel durch 
Hemmung der GSAP-γ-Sekretase-Interaktion reduzierte. Wir haben jedoch beobachtet, dass 
Imatinib die Aβ-Spiegel sogar in Abwesenheit von GSAP reduziert. In der Zwischenzeit 
wurden weitere Studien veröffentlicht, welche unsere Ergebnisse stützen. Der genaue 
Mechanismus, über welchen GSAP den APP-Spiegel reguliert, ist noch nicht klar. 
Nichtsdestotrotz lassen unsere Ergebnisse Zweifel an der Validität von GSAP als 
therapeutisches Target für die Alzheimer Krankheit aufkommen und sie verdeutlichen die 
Notwendigkeit einer unabhängigen Replikation von wissenschaftlichen Beobachtungen. 
 
Zusammenfassend haben unsere Studien zum Membrantransport und zum Aβ-Metabolismus 
mehrere neue Regulatoren von Aβ identifiziert, sowohl auf Ebene der Produktion als auch 
beim Abbau. Diese Ergebnisse tragen dazu bei einen Teil der Wissenslücke hinsichtlich der 
Pathogenese von AD zu schliessen und eröffnen möglicherweise neue therapeutische Targets 
und Präventionsstrategien. Unsere Studien zeigen auch, wie wichtig Systembiologie-basierte 
Untersuchungen zur Aufklärung der molekularen Komplexität von AD sind. Weiterhin 
verdeutlichen die Studien zu GSAP und Aβ die Bedeutung einer robusten Validierung 
wissenschaftlicher Ergebnisse. Als persönlichen Beitrag zur Verbesserung der 
Datensichtbarkeit und zur Erleichterung der Reproduzierbarkeit in der Wissenschaft habe ich 
alle meine Artikel in Open-Access-Zeitschriften veröffentlicht. 
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1. Introduction	
 
1.1 Introduction to Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) is the most prevalent form of dementia. It is a progressive 
neurodegenerative disorder that is characterized by significant loss in cognition and 
intellectual capacity and affects millions of people the world over. In 1906, Alois Alzheimer, 
the German psychiatrist after whom the disease is named, first described the disease based on 
his observation of a 55-year old female patient (Alzheimer et al., 1995). AD has become one 
of the most pressing health issues in western countries and, as life expectancy continues to 
rise, the number of people affected by this devastating disease is poised to increase 
significantly in the near future (Pfeil et al., 2012; Prince et al., 2016). More than 5% of the 
elderly population aged 65 years or above suffer from AD. In the year 2000, this level of 
prevalence represented a total of 4.5 million affected individuals in the US alone (Hebert et 
al., 2003). According to more recent findings, in 2011, prevalence of AD in Switzerland in 
people above the age of 64 was almost 8% (Pfeil et al., 2012). The likelihood of developing 
AD rises sharply with increasing age, doubling approximately every 5 years over the age of 
65 and affecting almost one fifth of elderly people aged 85 years or above (Prince et al., 
2016). Early symptoms of AD are frequently hard to distinguish from normal age-related 
cognitive dysfunction and include memory loss and problems in retaining and recalling 
recently acquired information. Transition from mild to moderate AD is characterized by an 
increase in severity of existing symptoms that includes progressive memory impairment, 
cognitive dysfunction and a progressive deterioration of language function. In the terminal 
stages of the disease, the decline in cognitive performance is so severe that patients need 
assistance even for the most routine activities (Winblad et al., 2016). The diagnosis for AD is 
based on a detailed analysis of the clinical history along with physical (including 
neuroimaging) and neuropsychological analysis of the patient. Although, in recent years there 
has been a vast improvement in the accuracy of diagnosis, a definitive diagnosis for AD is 
only possible upon analysis of post-mortem brain tissue. Since the exact etiology of AD is 
currently unknown, curative drugs are difficult to develop. The current focus of treatment for 
AD is to slow the progression of symptoms and improve cognition. 
 
1.2 Anatomical and pathological characteristics of the disease 
AD is characterised by the selective damage in brain areas important for cognition and 
memory. Earliest alterations in AD affect the regions involved in episodic memory, 
specifically, in the hippocampus and entorhinal cortex (Braak and Braak, 1991). In the 
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damaged areas of an AD brain, the dysfunction and loss of neurons is associated with 
characteristic pathological hallmarks that increases the vulnerability of these regions. These 
pathological hallmarks are presence of extracellular proteinaceous deposits called amyloid 
plaques and intraneuronal cytoskeletal structures known as neurofibrillary tangles (NFTs) 
(Braak and Braak, 1991; Rogers and Friedman, 2008; Serrano-Pozo et al., 2011). 
Specifically, amyloid deposition is observed in the regions of the default mode network, 
regions thought to be active in terms of basal synaptic activity, thus tying synaptic activity 
and amyloid deposition (Sperling et al., 2009).  
 
1.3 Molecular basis of the disease 
1.3.1 Amyloid pathology 
Amyloid pathology is characterized by the presence of extracellular neuritic plaques 
composed predominantly of amyloid β (Aβ). It is found abundantly in the amygdala, 
hippocampus and neocortex in AD brain. Apart from extracellular plaques, amyloid 
deposition in AD also occurs frequently within cerebral vessels and is known as cerebral 
amyloid angiopathy (CAA) (Selkoe, 2001). Based on analysis of post-mortem brains it was 
observed that more than 80% of AD patients have Aβ within blood vessel. Specifically, small 
arterioles, capillaries and venules in the cerebral cortex often contain amyloid deposits 
(Serrano-Pozo et al., 2011).  
 
1.3.2 Amyloid production 
Amyloid plaques predominantly consist of a peptide termed β-amyloid (Aβ). It is present 
either in its soluble monomeric/oligomeric conformation or in the insoluble plaque form and 
is causally associated to the neurodegeneration observed in AD. Therefore, studying the 
processes that regulate amyloid peptide formation is critical for our understanding of AD. Aβ 
is produced from a membrane protein called Amyloid precursor protein (APP) by the action 
of two secretases. During the production of Aβ, APP is first cleaved by β-site amyloid 
precursor protein cleaving enzyme 1 (BACE1), also known as β-secretase. This is followed 
by cleavage by another secretase complex known as the γ-secretase (Figure1).  
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Figure 1: APP processing. APP undergoes cleavage by α-secretase to release sAPPα and 
αCTF, in the non-amyloidogenic pathway (left, in green). APP undergoes cleavage by β-
secretase to generate sAPPβ and βCTF in the amyloidogenic pathway (right, in red). In the 
amyloidogenic pathway, βCTF is cleaved by γ-secretase to generate Aβ peptide (adapted 
from Müller et al., 2017). 
 
1.3.2.1 Amyloid precursor protein 
Amyloid precursor protein (APP) is a type 1 transmembrane protein, with a large 
extracellular domain, and is widely expressed in the brain at high levels. APP mRNA can 
undergo alternative splicing to generate many isoforms, of which the 695 amino acid form 
(APP695) is the predominant isoform in the brain (Bayer et al., 1999). APP is involved in a 
diverse range of biological functions that include nervous system development, synaptic 
function and plasticity, and cell survival among others (Muller et al., 2017). APP is produced 
in the endoplasmic reticulum (ER) and it undergoes maturation (glycosylation) in the Golgi 
complex. It is then routed to the plasma membrane from where it is endocytosed into 
endosomes (Small and Gandy, 2006). Several studies have shown that APP gets cleaved by 
β-secretase predominantly in endosomes and that endocytosis of APP and β-secretase is a key 
determinant for Aβ production (Kinoshita et al., 2003; Rajendran et al., 2006; Sannerud et al., 
2011). The endosome with its low pH (pH 5.0-6.0) provides an optimal environment for β-
secretase activity, which reflects the dependence of Aβ production on endocytosis. APP can 
also be cleaved by another secretase, known as α-secretase. α-secretase cleavage of APP 
prevents the production of the toxic Aβ peptide and the cleavage has been shown to occur at 
the plasma membrane (Lichtenthaler, 2011).It is generally accepted that APP cleavage by γ-
secretase to generate Aβ also occurs in post-golgi compartments, i.e in endosomes. 
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1.3.2.2 β-secretase 
In 1999, some years after APP processing was characterized, several groups independently 
discovered that the β-secretase activity for APP cleavage is conferred by the β-site amyloid 
precursor protein cleaving enzyme 1 (BACE1) (Sinha et al., 1999; Vassar et al., 1999; Yan et 
al., 1999). BACE1 is a transmembrane protein that belongs to the pepsin-like family of 
aspartyl proteases. BACE1 exhibits all the properties of a luminal protease that can cleave 
APP at the extracellular ectodomain and cleavage of APP by BACE1 was found necessary 
for the generation of Aβ peptide (Vassar et al., 2009). BACE1 is ubiquitously expressed even 
though its activity is highest in the brain. In vivo studies with APPTg/BACE1KO bigenic 
mice provided further proof that BACE1 activity is indeed necessary for Aβ production and 
development of amyloid pathology in the APPTg mice (Luo et al., 2001; Ohno et al., 2004). 
Identification of a familial AD associated mutation, known as the Swedish mutation 
(APPsw), that results in massive increase in the affinity of APP to BACE1 further cemented 
BACE1’s status as the major β-secretase involved in Aβ production and AD (Citron et al., 
1992). BACE1 is localized in many different organelles, but its activity is reported to be 
highest in Golgi and endosomes, organelles that have an acidic pH and thus provide optimal 
environment for BACE1 activity. This organelle-dependent variation in BACE1 activity can 
be regulated by pathways that regulate BACE1 trafficking. Interestingly, BACE1 has a 
dileucine motif in its transmembrane domain, which is crucial for its internalization into 
endosomes. BACE1 trafficking and subcellular localization via its dileucine binding motif is 
regulated by proteins belonging to the GGA family (He et al., 2005; von Arnim et al., 
2006).Due to is central role in Aβ production, contribution of BACE1 to amyloid pathology 
in AD has been intensely studied. Studies have shown that BACE1 levels in the brain 
increase with age and stress (Fukumoto et al., 2004; Velliquette et al., 2005). It is important 
to note that aging is the biggest risk factor for sporadic AD and hence elevated BACE1 levels 
during aging might be an important mediator of amyloid pathology in AD. Moreover, Aβ 
itself is thought to initiate a positive feedback loop that increases BACE1 levels (Zhao et al., 
2007). Whether this increase in BACE1 levels also increases the cleavage of other BACE1 
substrates and contribute to the AD pathogenesis is not yet clear.  
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1.3.2.3 γ-secretase 
The C-terminal fragments that are produced upon the cleavage of APP by either α- or β-
secretase are subsequently cleaved by γ-secretase, a large protein complex composed of four 
subunits: Aph-1, Nicastrin, Presenilin-1 and -2 (PS1, PS2) and Pen2. Sequential cleavage of 
APP first by β-secretase and then by γ-secretase generates Aβ. Like β-secretase, γ-secretase 
also cleaves many substrates other that APP. For example, Notch cleavage by γ-secretase is a 
very well established signaling process that plays an important role during and after 
development (Selkoe and Kopan, 2003). Hence, therapeutic strategies involving inhibition of 
β- or γ-secretase need to take this into account. Despite these constraints, γ-secretase has been 
considered a promising therapeutic target and several drugs have undergone clinical trials 
albeit with no clear beneficial effects. In fact, results from clinical trials have shown γ-
secretase inhibition to cause considerable side effects and even worsening of cognition and 
behavior. For instance, in 2012 a phase III clinical trial for Semagacestat was halted due to 
adverse side effects such as skin cancer and infection coupled with no clinical benefit. Phase 
II clinical trial with Avagacestat, another γ-secretase inhibitor, was also stopped due to 
reports of cerebral microbleeds and skin cancer (Hung and Fu, 2017).These side effects of γ-
secretase inhibition can be attributed to the fact that γ-secretase activity is also important for 
the cleavage of several physiological substrates such as Notch, Ephrin, Cadherin etc. The 
take home message from these studies is that we need to understand the biology of γ-
secretase and its functions much better to be able to design better/specific therapeutic 
strategies. For example, one aspect of γ-secretase complex that warrants deeper 
understanding is the heterogeneity of the complex that can result from the presence of two 
homologs of Presenilin (PS1 and PS2) and two homologs of Aph1 (Aph1a and Aph1b). In 
vitro evidence for presence of spatially distributed γ-secretase heterogeneity further cements 
the idea that such a heterogeneity could also exist at the organismal level (Hebert et al., 
2004).  Yet another study suggested that γ-secretase heterogeneity at the level of Aph1 is 
important for target specificity (Acx et al., 2017; Dejaegere et al., 2008). What remains 
poorly understood is the biological consequence of γ-secretase heterogeneity at the level of 
PS1 and PS2. Thus, continued studies to understand the cellular biology of the individual 
components of APP processing machinery are much needed. 
 
1.3.3 Amyloid Clearance 
β-amyloid (Aβ) is a physiological product of cellular metabolism and like many other cellular 
metabolites its systemic level is regulated by both pathways that produce and pathways that 
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clear Aβ.  Clearance of Aβ is mediated by several processes that occur parallelly. These 
include enzymatic degradation of Aβ, efflux of Aβ from the brain and cell-mediated 
clearance. I will discuss cell-mediated clearance at a later stage in this chapter.   
 
1.3.3.1 Enzymatic degradation of Aβ 
Enzymatic degradation of Aβ is carried out by a varied group of proteases that act in concert 
to counterbalance the production of Aβ by degrading it. These proteases can be broadly 
classified in the following categories: metallo proteases, serine proteases, aspartyl proteases, 
cysteine proteases and threonine proteases (Leissring, 2016). Several studies have 
demonstrated that enzymatic degradation of Aβ contributes significantly to the determination 
of cerebral Aβ levels (Eckman and Eckman, 2005; Farris et al., 2007; Leissring, 2008; Turner 
and Nalivaeva, 2007). To give an example, Farris and colleagues measured brain interstitial 
fluid (ISF) in mice lacking Neprilysin (NEP), one of the key metalloproteases involved in Aβ 
degradation. Deletion of NEP led to doubling of steady-state Aβ levels and a significant 
increase in the half-life of Aβ in ISF (Farris et al., 2007). Additionally, studies have reported 
NEP overexpression to reduce monomeric Aβ levels and Aβ plaques in the J20 line of APP 
transgenic mice by as much as 90 % (Leissring et al., 2003; Meilandt et al., 2009). Although, 
NEP overexpression did not reverse the learning and memory deficits observed in the J20 
APP transgenic mice (Meilandt et al., 2009). This was attributed to the finding that though 
NEP overexpression reduced monomeric Aβ and Aβ plaques, there were no changes in the 
level of oligomeric Aβ after NEP overexpression (Meilandt et al., 2009). Endothelin-
converting enzyme 1 and 2 (ECE1 and ECE2) are also metalloproteases that have been 
shown to degrade Aβ. A key difference though is that unlike NEP, ECE1 and ECE2 have an 
acidic pH optimum and thus function primarily in intracellular acidic organelles (Eckman et 
al., 2003). Matrix-metalloproteinases (MMPs), specifically MMP2 and MMP9, are bona fide 
Aβ degrading enzymes and have been shown to be degrading both monomeric as well as 
fibrillar Aβ (Yan et al., 2006). Insulin-degrading enzyme (IDE) is another metalloprotease 
that has been extensively studied for its role as an Aβ degrading enzyme. IDE has been 
shown to degrade exclusively the monomeric forms of Aβ and is predominantly present in 
the cytosol (Falkevall et al., 2006). Additionally, in vivo deletion of IDE have shown to 
substantially increase cerebral Aβ levels in APP transgenic mice (Farris et al., 2003). 
Plasmin, a serine protease has been shown to degrade Aβ, both monomeric as well as fibrillar 
(Tucker et al., 2000). Cathepsin B (CatB), is the only cysteine protease that has been shown 
to degrade Aβ in vivo (Mueller-Steiner et al., 2006). CatB is highly enriched in the 
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endolysosomal degradation pathway and shows optimal activity at acidic pH. Another 
protease that efficiently degrades Aβ at acidic pH is Cathepsin D, an aspartyl protease. Like 
CatB, it is also highly enriched in the acidic endolysosomal degradation pathway. CatD KO 
mice show an increase in steady-state Aβ levels as well as accelerated onset of plaque 
formation (Saido and Leissring, 2012). Altogether, the presence of a wide range of proteases 
capable of degrading Aβ suggests that maintenance of systemic Aβ levels is not only a 
function of its production but also its degradation. 
 
1.3.3.2 Efflux mechanisms to clear Aβ from the brain 
1.3.3.2.1 Efflux across the blood brain barrier 
A key process of amyloid clearance is its efflux out of the brain parenchyma into the blood 
across the blood brain barrier (BBB). Endothelial cells connected by tight junctions form the 
critical barrier component in the BBB. These endothelial tight junctions prevent passive 
diffusion of Aβ into the blood. Specialized transporters at the BBB are required for the efflux 
of Aβ out of the brain. Lipoprotein receptor-related protein 1 (LRP1), a low-density 
lipoprotein receptor (LDLR) family protein, has been shown to be the main transporter for 
the efflux of Aβ across the BBB (Bell et al., 2007; Deane et al., 2004; Shibata et al., 2000). 
There are other studies that dispute the significance of LRP1 as a predominant transporter for 
Aβ efflux from the brain (Ito et al., 2010). Nevertheless, several studies have shown that 
LRP1 levels in brain microvessels are reduced, along with an increase in cerebral and brain 
amyloid in aging, both in mouse models and patients with AD (reviewed in Zlokovic, 2011) 
(Zlokovic, 2011). There is thus a strong indication for a link between reduced efflux of Aβ by 
LRP1 and increased amyloid accumulation in the brain. Lipoprotein receptor-related protein 
2 (LRP2), another member of the LDLR family, associates with Clusterin (also known as 
ApoJ) to efflux Aβ across the BBB into circulation (Pascale et al., 2011). Apart from the 
LDLR family proteins, ATP-binding cassette (ABC) transporters, specifically ABCA1 and 
ABCB1, have also been shown to be involved in Aβ efflux from the brain. Unlike ABCB1, 
which directly transports Aβ from the brain into circulation, ABCA1 is thought to aid Aβ 
efflux by regulating ApoE lipidation. Lipidated ApoE binds Aβ efficiently which can then be 
transported from the brain by LRP1 or ABCB1 (Fitz et al., 2012; Tarasoff-Conway et al., 
2015). 
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1.3.3.2.2 Efflux through the interstitial fluid bulk-flow 
Interstitial fluid (ISF) bulk-flow into the lymphatic system is another important route for Aβ 
efflux from the brain. Earlier studies in mice had posited efflux across the BBB to be the 
main route for Aβ efflux from the brain (Shibata et al., 2000; Zlokovic, 2004). More recent 
studies have disputed this earlier claim and attribute a much larger contribution for ISF bulk-
flow in Aβ efflux from the brain (Iliff et al., 2012; Kress et al., 2014). Aβ in the ISF is 
drained into the cerebrospinal fluid (CSF) sink and the perivascular space by bulk-flow. 
Several factors affect perivascular drainage pathways that clear Aβ from the brain, 
specifically, ApoE isoform status, arterial age and arterial pulsation. These mechanisms in 
turn can also be regulated by the body’s homeostatic mechanisms, particularly, those that are 
active during sleep. Sleep has been shown to be a positive regulator of amyloid clearance 
from the brain by the virtue of its influence on ISF bulk flow (Xie et al., 2013).  Perivascular 
drainage of Aβ has been shown to be impaired in AD (Weller et al., 2008). Another critical 
route for interstitial Aβ is its drainage via the glymphatic system, a process where astroglial 
channel proteins along the lymphatic system regulate the ISF bulk-flow. The astroglial 
Aquaporin4 (AQP4) channel has been shown to be vital in regulating glymphatic ISF bulk-
flow. Aβ clearance along the perivascular pathway was reduced by as much as 65 % in Aqp4 
knockout mice (Iliff et al., 2012). Interestingly, glymphatic clearance has been shown to be 
reduced upon aging, thus suggesting a role for this route of Aβ clearance in late-onset AD 
(LOAD) (Kress et al., 2014). As mentioned earlier, ISF bulk-flow also drains Aβ into the 
CSF sink. Aβ in CSF can then be absorbed either into blood circulation through the arachnoid 
villi and Blood CSF Barrier (BCB) or into the lymphatic system, through the perineuronal 
spaces (Pascale et al., 2011; Silverberg et al., 2003). The recently discovered meningeal 
lymphatic system might provide another route for Aβ ISF bulk-flow, though the exact 
contribution of this pathway is yet to be determined (Louveau et al., 2015). 
 
1.3.4 Tau pathology 
1.3.4.1 Structure and function 
Tau is a microtubule associated protein found abundantly in mature neurons. In humans, Tau 
exists as six molecular isoforms and is encoded on chromosome 17 (Neve et al., 1986). The 
tau isoforms occur as a result of alternative splicing of the tau pre-mRNA. The six isoforms 
differ molecularly at two levels. First, in the presence of either three (3R) or four (4R) 
microtubule binding repeats (R) in the carboxy-terminal region. Second, in the presence of 
one (1N), two (2N) or zero repeats (0N) at the amino-terminal. This gives rise to the six tau 
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isoforms, three types of 3R tau (1N3R, 2N3R, 0N3R) and three types of 4R tau (1N4R, 
2N4R, 0N4R). Tau is a natively unfolded protein with very little secondary structure, mostly 
composed of random coil with short hydrophobic motifs forming β-sheet structures in the 
microtubule binding repeats (Gustke et al., 1994; Mukrasch et al., 2009; Schweers et al., 
1994). The aggregation property of tau is attributed to these β-sheet structure-forming motifs. 
The most well-established role for tau is its interaction with tubulin, which promotes the 
assembly of tubulin into microtubules. Moreover, tau interaction with the microtubules also 
helps to stabilize the structure (Weingarten et al., 1975). Some of the other functions 
attributed to tau are dependent on its primary role in promoting and stabilizing microtubules. 
Tau depletion in cultured neurons suppressed neurite outgrowth (Caceres et al., 1991), a 
finding that was also reproduced in tau knockout mice (Dawson et al., 2001). Tau was also 
shown to regulate axonal transport in cultured cells and mouse models (Ebneth et al., 1998; 
Probst et al., 2000).  
 
1.3.4.2 Phosphorylation and de-phosphorylation mechanisms 
Tau is a phosphoprotein and its microtubule assembly promoting activity is modulated by the 
degree of its phosphorylation. There are 85 potential phosphorylation sites in the longest 
isoform of tau (2N4R) and for roughly half the number of sites phosphorylation has been 
demonstrated experimentally (Hanger et al., 2009a). The most abundant phosphorylation sites 
in tau are serine/threonine sites that are flanked by proline sites. Specifically, there are 17 
such sites that have also been shown to be abnormally hyperphosphorylated in AD by 
proline-directed Ser/Thr kinases. These kinases include extracellular-signal-regulated kinase 
2 (Erk2), a Mitogen-activated protein kinase, glycogen synthase 3 (GSK3) and cyclin 
dependent protein kinase (CDK5) (Hanger et al., 2009b). Other Ser/Thr kinases include 
Prader-Willi/Angelman region 1 (PAR1) kinase, protein kinase A (PKA) and 
calcium/calmodulin-dependent protein kinase II (CaMK II). Tau can also be phosphorylated 
by tyrosine kinases such as LCK, FYN and ABL1. Interestingly, excessive phosphorylation 
of tau at the threonine position has been shown to promote tau aggregation (Rosseels et al., 
2015). Phosphorylation of tau regulates tau function by several different mechanisms. 
Phosphorylation of tau at the KXGS motif reduces its affinity to microtubules, whereas 
phosphorylation at the flanking region of tau can result in detachment of tau from 
microtubules. Hyperphosphorylation of tau can also result in tau mis-trafficking from axons 
to the somatodendritic compartment, leading to synaptic dysfunction (Hoover et al., 2010; 
Thies and Mandelkow, 2007). Tau phosphorylation can also affect its degradation by the 
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proteasome complex or authophagy (Dickey et al., 2007). The levels of phosphorylated tau 
are not only regulated by the kinases that phosphorylate tau but also the phosphatases that 
directly interact with tau and dephosphorylate it. Ser/Thr protein phosphatases are abundant 
in the brain and thus they have a critical role in regulating tau function. Protein phosphatases 
1, 2A, 2B, 2C and 5 (PP1, PP2A, PP2B, PP2C and PP5) are the phosphatases involved in tau 
dephosphorylation. PP2A is the predominant tau dephosphatase as it accounts for almost 70% 
of the tau phosphatase activity in humans. Moreover, activity of PP2A has been shown to be 
reduced in AD brains (Gong et al., 1993). PP2A activity reduction in AD has been attributed 
to several reasons, including reduced protein levels, increased inhibition and perturbation of 
subcellular localization (Gong et al., 1993; Sontag et al., 2004). 
 
1.3.4.3 Tau mutations 
The identification of mutations in tau that cause Frontotemporal dementia with parkinsonism 
linked to chromosome 17 (FTDP-17) provided the first evidence that mutated tau alone can 
lead to neurodegeneration (Hutton et al., 1998). Since then several mutations in tau have been 
identified in both the exonic and in the intronic region of the human tau gene, with some 
mutations also implicated in Corticobasal degeneration (CBD) and Progressive supranuclear 
palsy (PSP) (Coppola et al., 2012; Kouri et al., 2014). Almost all the mutations linked to 
FTDP-17 are missense or splicing mutations that are clustered in or around the microtubule 
binding domain. Tau proteins with mutations in these regions have reduced affinity for 
microtubules and have an increased propensity to form aggregates. Mechanistic 
characterization of some of these mutations revealed that mutations such as R406W, V337M 
and G272V make the tau protein a more favorable substrate for the phosphorylating kinases 
and hence lead to hyperphosphorylation (Alonso Adel et al., 2004). Many of the silent 
mutations in tau result in alternative splicing of the exon 10 and consequently increase the 
4R/3R ratio (Lee et al., 2001). However, how these altered ratio leads to increased tau 
aggregation is still not clear.  
 
1.3.4.4 Homeostatic control of tau levels 
Homeostatic control of tau levels is achieved by maintaining a balance between tau synthesis, 
processing and degradation. Tau is an intracellular protein and hence intracellular protein 
degradation pathway play an important role in maintaining tau levels. Nevertheless, tau can 
be released in the extracellular space, particularly during neuronal death and neuronal 
activation (Avila et al., 2014; Yamada et al., 2014). Degradation of intracellular tau is 
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mediated mostly by the autophagy-lysosome pathway and the proteasome pathway (Avila et 
al., 2014). Impairment of the autophagy-lysosome pathway by addition of chloroquine leads 
to increased levels of full-length tau (Bednarski and Lynch, 1996). Conversely, stimulation of 
autophagy by rapamycin treatment or serum starvation led to reduction in tau levels and tau 
aggregates (Wong et al., 2008). Tau is a small, unfolded and cytosolic protein and hence it is 
an ideal cargo for proteasomal degradation. Indeed, studies have shown that tau can be 
degraded by the both the ubiquitin-dependent as well as the ubiquitin-independent 
proteasomal pathway (David et al., 2002; Hamano et al., 2009). To date no specific 
transporter for tau efflux across the BBB has been identified, suggesting that clearance of 
extracellular tau from the brain happens predominantly via ISF bulk flow and CSF 
absorption. Tau clearance from ISF and CSF is thought to follow the same routes as Aβ. 
Nevertheless, the processes that regulate extracellular tau clearance warrant further studies to 
further our understanding of AD. 
 
1.4 Cellular basis of the disease 
1.4.1 Neuronal contribution 
Neurons are the most profoundly affected cell type in AD brains. Neuronal dysfunction and 
its gradual degeneration is directly linked to the cognitive and memory deficits observed in 
AD. However, it is important to note that neurons are not innocuous bystanders that are 
targeted by Aβ. In fact, in the brain neurons are the chief source of Aβ. The core components 
necessary for Aβ production, i.e, APP, BACE1 and γ-secretase, are highly expressed in 
neurons. All the components involved in Aβ production are membrane proteins and hence, 
regulation of membrane trafficking pathways is thought to be intimately linked with 
regulation of Aβ levels. The focus of this thesis is to understand the role of membrane 
trafficking pathways in the maintenance of amyloid levels. Below, I will briefly discuss our 
current understanding in this regard.  
 
1.4.1.1 Production pathways  
1.4.1.1.1 Role of membrane trafficking in production of Aβ 
APP is a transmembrane protein that is cleaved by β- and γ-secretase, which are also 
membrane proteins, to generate Aβ. Apart from β-secretase, α-secretase can also cleave APP 
and since the α-cleavage is within the Aβ region, α-cleavage prevents the formation of Aβ. 
Whether APP is cleaved by α- or β-secretase depends on the localization of APP. α-secretase 
can cleave APP already at the plasma membrane. β-secretase on the other hand cleaves APP 
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predominantly in the endosomes as it needs the acidic pH of the endosomes to be optimally 
active. Studies have convincingly shown that endocytosis is necessary for β-secretase 
cleavage of APP and Aβ production and that redirecting APP from the membrane to 
endosomes influences the relative α- and β-cleavage of APP (Daugherty and Green, 2001; 
Ehehalt et al., 2003; Kinoshita et al., 2003; Refolo et al., 1995). APP and BACE1, the bona 
fide β-secretase, both need to be endocytosed from the plasma membrane for them to interact 
with each other. We know that APP from the cell membrane is internalized by both clathrin-
dependent as well as raft-dependent endocytosis (Koo and Squazzo, 1994; Schneider et al., 
2008). On the other hand, BACE1 is internalized through an ADP ribosylation factor 6 
(ARF6) dependent pathway (Sannerud et al., 2011). This indicates that after endocytosis, 
APP and BACE1 must meet each other in a compartment within the cell. It is now clear that 
APP and BACE1, though internalized separately, meet and interact with each other in early 
endosomes. 
 
1.4.1.1.2 Early and recycling endosomes in the production of Aβ 
Once endocytosed APP can be trafficked to different intracellular routes which include early 
endosomes, recycling endosomes, late endosomes, lysosomes or even back to the golgi. In 
the search for the precise subcellular compartment where APP is cleaved by β-secretase our 
lab analyzed the site of maximal interaction between them by Fluorescence resonance energy 
transfer (FRET). The maximum intermolecular interaction between APP and β-secretase was 
shown to occur in the early endosomes. Additionally, data from live imaging of surface 
labeled APP and β-secretase confirmed that early endosomes are the major site of β-cleavage 
of APP (Rajendran et al., 2006). After β-cleavage of APP, the liberation of Aβ peptide from 
β-C terminal fragment (CTF) requires an additional cleavage by the γ-secretase complex. 
Localization studies with GFP fused β-CTF showed that γ-secretase cleavage of β-CTF also 
occurs in early endosomes (Kaether et al., 2006). From the above-mentioned studies we can 
conclude that early endosomes are the major cellular site for Aβ production. A more recent 
study on understanding the mechanism of APP and BACE1 localization and interaction 
posited the recycling endosomes as the intracellular compartment where APP and BACE1 
meet (Das et al., 2013). Recycling endosomes are elongated structures that deliver cargoes 
from early endosomes back to the plasma membrane. Das and colleagues showed that in 
cultured hippocampal neurons APP is normally present in golgi-derived vesicles whereas 
BACE1 is present in recycling endosomes. Upon neuronal activation, APP is traffickedby a 
clathrin-dependent mechanism into recycling endosomes where it meets BACE1 (Das et al., 
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2013). They further showed that APP and BACE1 also interact with each other in these 
recycling endosomes and that this interaction is significantly attenuated when APP carries the 
protective Icelandic mutation, A673T (Das et al., 2016). Thus it is evident that Aβ is 
produced in intracellular organelles (early/recycling endosomes) and that regulators of their 
residence in these structures are potential modifiers of Aβ levels. 
 
1.4.1.1.3 Aβ release mechanisms 
Aβ is produced in endosomes and rapidly released into the extracellular space.  Much of the 
Aβ that is generated in endosomes can be sorted to multivesicular bodies (MVBs). It was 
shown that Aβ is released from these MVBs via its fusion with the plasma membrane. It was 
shown that through MVB fusion only a fraction of the Aβ is released in association with 
exosomes (Rajendran et al., 2006), with the bulk being released as soluble Aβ. Nevertheless, 
there is evidence that this released exosomal Aβ could contribute to amyloid plaque 
formation (Yuyama et al., 2008). A more recent study suggested that autophagy, apart from 
its role in degradation, also plays a role in secretion of Aβ. Though the exact mechanism by 
which autophagy leads to Aβ secretion is not clear (Nilsson et al., 2013). Though not much is 
known about the regulators of Aβ release, intracellular cholesterol accumulation has been 
implicated in Aβ secretion. Increased cholesterol accumulation leads to decreased Aβ 
secretion and consequently increased intracellular Aβ (Runz et al., 2002). Further 
investigation to understand the regulation of Aβ secretion is much needed. 
 
1.4.1.2 Clearance pathways - intracellular endo-lysosomal proteolysis in amyloid 
clearance 
Neurons are the major cell type that produce Aβ in the brain. Nevertheless, neurons also have 
the machinery that can degrade the Aβ produced in intracellular compartments. The endo-
lysosomal pathway is the major pathway by which neurons are thought to degrade Aβ. 
Lysosomes are the cells major degradative organelle and are ubiquitously present in all cell 
types. Lysosomes are the terminal degradative organelle for both, cargoes that are routed via 
the endocytic pathway as well as the ones that are routed via the autophagic pathway. Aβ is 
produced in the endosomes and hence can be trafficked to the lysosomes via the endocytic 
pathway. In the endocytic pathway, the cargoes are endocytosed from the extracellular lumen 
and lead to formation of early endosomes (EE), site of Aβ production, which then mature to 
late endosomes (LE).  Both autophagosome (from the autophagic pathway) and LE finally 
deliver their contents to lysosomes, where they are degraded by the proteases present in them. 
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Lysosomes are characterized by a lower pH compared to other cellular organelles and the 
lower pH facilitates the lysosomes to digest the cargoes with the help of pH dependent 
hydrolases. As mentioned earlier, autophagy also depends on functional lysosomes to 
regulate degradation of cargoes. Autophagy also has been shown to be a key regulator of Aβ 
clearance (Nilsson and Saido, 2014). Aβ has been shown to be present in autophagosomes 
which eventually depend on lysosomes to degrade their cargo (Yu et al., 2005). Moreover, β-
CTF has also been shown to be targeted to degradation via autophagy in AP2/PICALM 
dependent manner (Tian et al., 2013). Thus, a functional autophagic pathway must at least in 
part regulate Aβ metabolism in neurons. 
 
1.4.2 Microglial contribution 
1.4.2.1 Role of phagocytosis in the removal of amyloid 
Microglia are the resident brain macrophages that have critical roles in maintenance of CNS 
homeostasis during development and later stages in life. Microglial phagocytosis is called 
upon in several physiological and pathophysiological situations such as synapse elimination, 
axonal and myelin debris removal and clearance of potentially toxic peptides such as Aβ 
(Paolicelli et al., 2011; Sierra et al., 2013). Once phagocytosed, the cargoes are eventually 
degraded in lysosomes. Data from both human patients and AD mouse models suggests that 
microglia are present in the immediate vicinity of amyloid plaques and are often found 
surrounding them (Lai and McLaurin, 2012). Since microglia are not major contributors of 
Aβ production, their presence around plaques was proposed to be for the phagocytosis of 
these plaques. Indeed, in vitro evidence indicates that microglia can efficiently phagocytose 
fibrillar Aβ through many different receptors, including Toll-like receptor 2 and 4 (TLR2 and 
TLR4) and Scavenger receptor A1 (SCARA1) (Frenkel et al., 2013; Liu et al., 2012; Paresce 
et al., 1996). However, the role of microglia as scavengers of Aβ in vivo is disputed. Studies 
from AD mouse models have shown that though microglial cells were associated with 
plaques, they do not phagocytose Aβ from these plaques (Stalder et al., 2001). A possible 
explanation for this is that in aging AD mice there is a marked decrease in phagocytic genes 
compounded with an increase in pro-inflammatory cytokines (Hickman et al., 2008). More 
recent evidence indicates that microglia do have the capacity to phagocytose Aβ in vivo and 
that there must be cell intrinsic and extrinsic factors which influence the microglial 
phagocytic capacity (Paolicelli et al., 2017).  
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1.4.2.2 Role of phagocytosis in synaptic pruning and synapse loss 
Conventionally, microglia were considered as scavenger cells that are active only during 
injury or pathological manifestations. However, our current understanding of the role of 
microglia in the brain is constantly evolving. Studies indicate that microglial processes 
actively contact synapses and survey the environment even in an uninjured brain 
(Nimmerjahn et al., 2005; Wake et al., 2009). Microglia were found to actively phagocytose 
synapses during normal brain development. In fact, microglial phagocytosis of synapses was 
shown to be an essential part of synaptic pruning, a process that is vital in efficient brain 
connectivity (Paolicelli et al., 2011). Microglial synaptic pruning is a highly regulated 
process that is mediated by the complement system, specifically complement receptor 3 
(CR3) and its ligand C3. Mice lacking either CR3 or C3 show decreased microglial synaptic 
pruning, increase in synaptic density and behavior deficits (Schafer et al., 2012). Decreased 
synaptic pruning due to impaired microglial phagocytosis also has disease relevance. 
Reduced synaptic pruning in mice lacking chemokine receptor Cx3cr1 led to decreased 
synaptic transmission and connectivity and the behavioral changes were reminiscent of 
autism-spectrum disorder (Zhan et al., 2014). It is plausible that hyperactive microglia due to 
amyloid accumulation may lead to indiscriminate synapse loss and thus add to the 
pathological mechanisms of amyloid aggregation/plaques. Further studies in this direction 
could provide vital clues into the complex mechanism of amyloid pathology in AD. 
 
1.4.2.3 Regulation of microglial clearance mechanisms 
Microglial cells are the professional phagocytes of the brain both in physiological and 
pathological situations. The process of microglial phagocytosis can be categorized into three 
basic steps. These are Step 1: Find the target, Step 2: Eat the target and Step 3: Digest the 
target. Regulation of microglial clearance can occur at any of these steps, although the 
threshold for whether microglia should phagocytose a target or not is established in the first 
two steps. Microglial processes are very dynamic and they continuously survey the 
environment around them. Microglia can either by chance or in response to a chemoattractant 
find a target that carries the so called ‘eat me’ signal (Sierra et al., 2013). One type of 
signaling molecule that regulate microglial clearance are nucleotides such as ATP and UDP, 
which are released by apoptotic cells (Elliott et al., 2009). Another type of signal that 
microglial cells recognize are ligands called fractalkine which are also released by apoptotic 
cells (Truman et al., 2008). Yet another type of signal are cannabinoids that are secreted by 
neurons in pathological conditions. These are recognized by cannabinoid receptors on 
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microglial membranes and leads to their migration towards the target (Walter et al., 2003). 
Much of the regulation of microglial clearance occurs at step 2, i.e. Eat the target. Here, 
microglia engage with their target by means of tethering and engulfing, a process that is 
regulated by receptor-ligand interactions. For instance, Aβ phagocytosis depends on the 
interaction of Aβ with receptors like SCARA1 and TLR2 that are present on microglia. These 
receptors recognize the ‘eat me’ signal exhibited by the target cell or molecule and thus 
initiate the process of phagocytosis. The triggering receptor expressed on myeloid cells 2 
(TREM2) is another example of receptor that has been shown to trigger phagocytosis. 
Variants of TREM2 have been identified as risk factors for AD (Guerreiro et al., 2013; 
Jonsson et al., 2013). Interestingly, a recent study reported that TREM2 promotes Aβ 
phagocytosis by upregulating CD36 receptors on microglia and it is plausible that AD 
variants of TREM2 are inefficient in promoting Aβ phagocytosis (Kim et al., 2017). 
 
1.4.3 Synaptic pathology 
Synaptic loss is the best neuropathological correlate to the degree of cognitive decline 
observed in AD (Terry et al., 1991). Synapse loss is also a relatively early phenomenon in 
AD progression. Markers of synapse pathology or loss are potential biomarkers for early 
diagnosis of AD and I will discuss them later in this chapter. Compared to amyloid plaques, 
oligomeric species of Aβ correlate better with cognitive decline due to AD. In fact, Aβ 
oligomers have been shown to induce synaptic dysfunction and degeneration. Since synapses 
are an indispensable unit of neuronal communication, it is plausible that loss of synapses 
trigger a cascade of events that lead to neuron loss and cognitive decline. The mechanisms by 
which Aβ affects synaptic function and integrity are thought to be related to its effect on N-
Methyl-D-aspartate (NMDA) receptor functioning and thereby on inhibition of long term 
potentiation (LTP) (De Felice et al., 2007). Though, the effect of Aβ oligomers on NMDARs 
is thought to require several other participating receptor proteins like p75 neurotrophin 
receptor (p75NTR), frizzled etc. Elucidating the precise molecular events that lead to 
synaptic dysfunction and synapse loss is an active area of research in AD. 
 
1.5 Genetic basis of the disease 
1.5.1 Familial AD  
Aging and familial history of AD are the biggest risk factors for AD. More than 95% of all 
AD cases occur in individuals above the age of 60 years and are classified as late-onset AD 
(LOAD). The remaining 5% of cases are classified as familial AD (FAD) and patients can be 
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as young as 30 years old. Several genes implicated in FAD have been reported and all of 
them are involved in Aβ processing. These include mutations in the amyloid precursor 
protein (APP), the substrate, and in presenilins (PS1 and PS2), the catalytic units of the γ-
secretase complex. Most of the FAD mutations lead to increased production of Aβ, with a 
shift towards Aβ42 peptide, which is the most toxic species of Aβ. These findings emphasize 
that the amyloid cascade hypothesis is central to the pathogenesis observed in FAD. 
 
1.5.1.1 APP mutations 
1.5.1.1.1 Disease causing mutations 
The human APP gene is located on the chromosome 21. Duplications of chromosomal region 
containing the APP gene have been reported to cause an autosomal-dominant form of AD 
and CAA (Rovelet-Lecrux et al., 2006; Sleegers et al., 2006). Moreover, 26 pathogenic 
missense mutations of APP have been reported (Tcw and Goate, 2017). A double mutation 
(K670N/M671L) located at the N-terminus of Aβ and the β-secretase, respectively, was 
identified in a Swedish family with familial AD (Mullan et al., 1992) and was shown to 
increase production of total Aβ in vitro. Ten pathogenic mutations have been identified 
within the Aβ sequence, including D678N, E682K (Leuven mutation), A692G (Flemish 
mutation) and E693G (Arctic mutation). The different mutations within the Aβ domain have 
been shown to have a varied effect on APP processing and Aβ itself (Haass et al., 1994; 
Wisniewski et al., 1997). Fourteen mutations have been reported in the C-terminal Aβ 
domain and these mutations affect the activity of the secretases, resulting in pathological 
processing of APP. 
 
1.5.1.1.2 Protective mutation 
The A673T mutation in APP is the only protective mutation that was reported after a whole-
genome sequencing analysis of an Icelandic cohort. The mutation was shown to be protective 
against AD and age-related cognitive decline (Jonsson et al., 2012). The A673 residue is 
located close to the primary β-secretase cleavage site and is within the Aβ region. In a 
cellular model, the A673T mutation was shown to reduce Aβ production by approximately 40 
% compared to wild-type APP (Jonsson et al., 2012). Further evidence of a specific reduction 
in β-secretase cleavage in the A673T variant of APP in primary neurons substantiated the Aβ 
reducing effect of this protective mutation (Benilova et al., 2014; Maloney et al., 2014). 
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1.5.1.2 Presenilin mutations 
According to ‘www.alzforum.org’, more than 200 mutations in PS1 and PS2 among FAD 
patients have been identified. The majority of the presenilin mutations are located in and 
around the transmembrane domain of the protein. FAD PS1/2 mutations are some the most 
devastating mutations as the age of disease onset ranges between 35 to 55 years. It has been 
reported that at least some presenilin mutations alter the interaction of APP and presenilin 
such that they increase production of Aβ42 compared to other Aβ species (Szaruga et al., 
2017). The increased ratio of Aβ42/Aβ40 then leads to an increase in aggregation of the Aβ 
peptides due to the high aggregation propensity of Aβ42. This mechanism of action of the 
mutations fit well with the amyloid cascade hypothesis. Since presenilin is required for Aβ 
production, it was initially thought that most of the presenilin mutations must be toxic gain-
of-function mutations. However, several studies in cell lines reported that presenilin 
mutations decrease the cleavage of notch, cadherin and syndecan and thus reflect loss of 
function of the γ-secretase complex (Baki et al., 2001; Bentahir et al., 2006; De Strooper, 
2007; Schroeter et al., 2003). In fact, a recent study analyzed 138 pathogenic PS1 mutations 
in a γ-secretase cell-free assay and showed that about 90 % of the mutations lead to reduced 
Aβ42 as well as Aβ40 levels (Sun et al., 2017). This further confirms that most of the 
presenilin mutations are indeed loss of function mutations. Then how does this relate to the 
clinical findings that FAD patients with PS mutations have an increased amyloid load? The 
general consensus is that the loss-of-function mutations of presenilins lead to incomplete 
digestion of APP-CTFs, leading to relative increase in longer isoforms of Aβ. Since the 
relative increase in Aβ42 and not the total increase of Aβ is the driving force behind amyloid 
aggregation, FAD PS mutations can therefore lead to increased amyloid load despite a loss of 
function at the γ-secretase activity level. An alternative amyloid-independent explanation for 
the FAD PS1 mutations and their pathogenicity is the fact that presenilins are implicated in a 
diverse range of functions in the brain and loss of these functions triggers neurodegeneration 
(Shen and Kelleher, 2007). More research in this direction, especially studies towards 
understanding the presenilin1/2-dependent γ-secretase heterogeneity, are much needed. 
 
1.5.2 Late-onset AD 
Unlike FAD, late-onset AD (LOAD) cannot be attributed to mutations in a single gene and 
hence the amyloid cascade hypothesis is not the default hypothesis that can explain the 
etiology of LOAD. Nevertheless, LOAD has a big genetic component and it is likely that the 
risk is distributed over many genes and hence many cellular pathways. Genetic risk factors 
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for LOAD have been identified through GWAS (see the following section). However, not 
much is known about the possible mechanisms of action of these risk genes. More studies are 
needed to determine how amyloid aggregation occurs in LOAD despite the absence of 
disease-causing mutations in the APP processing machinery. 
 
1.5.2.1 Genome-wide association studies (GWAS) on LOAD 
APOE (Apolipoprotein E) was the first identified susceptibility gene for LOAD. Compared to 
other APOE alleles, the ε4 allele (APOE4) is associated with an increased risk for LOAD 
(Pericak-Vance et al., 1991). Studies have shown that ApoE4 contributes to LOAD risk by 
negatively regulating Aβ clearance from the brain. More than a decade after the identification 
of APOE4, additional risk genes for LOAD were identified through GWAS. In GWAS, 
single nucleotide polymorphisms (SNPs) are sequenced in LOAD patients and controls. The 
frequencies of SNP variants are correlated with the phenotype and risk loci are identified 
(Lambert et al., 2009). More recent studies include additional strategies such as chromosomal 
microarrays or whole-exome sequencing (Guerreiro et al., 2013; Sims et al., 2017) to identify 
novel risk variants. Although the first generation of GWAS identified some new risk genes 
for LOAD, the variants were not replicated to be associated with risk in independent studies. 
The European Alzheimer Disease Initiative (EADI) led the second generation of GWAS that 
examined a much larger number of LOAD patients and identified risk genes that were 
replicated in independent studies (Lambert et al., 2009; Lambert et al., 2013; Naj et al., 
2017). Since then, other GWAS and meta-analysis of multiple GWAS have yielded, verified 
and replicated lists of LOAD risk genes. Although many of these genes could be linked to 
Aβ, evidences suggest that these mutations do not confer AD risk by skewing the ratio of 
Aβ species in favor of the more toxic ones (Bali et al., 2012). The finding that several of 
these genes are involved in the immune system (CLU, CR1, ABCA7 and CD33), in synaptic 
function and endocytosis (PICALM, CD33, CD2AP and BIN1), and lipid transport and 
metabolism (CLU and ABCA7) further emphasize the molecular complexity that underlie 
LOAD (Tosto and Reitz, 2013). 
 
1.5.2.2 Mutations in the neuroinflammation/microglial function-related genes 
Neuroinflammation, including microglial response to amyloid, was since long believed to 
play an important role in the pathogenesis of AD (McGeer et al., 1989). In accord, several of 
the risk genes associated with LOAD have been shown to be important in neuroinflammation 
pathways. Of these genes, CR1, CD33, and TREM2 have been studied in some detail. 
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Antibody mediated blockage of CR1 inhibits activation of microglia and decreases microglial 
phagocytosis of Aβ (Crehan et al., 2013). Another study demonstrated that CD33 levels in 
microglia is increased in AD patients and that CD33 inhibits uptake and clearance of Aβ42 in 
vitro (Griciuc et al., 2013). Wang and colleagues showed that TREM2 deficiency increases 
Aβ accumulation, which can be attributed to dysfunctional microglia that do not respond to 
amyloid plaques (Wang et al., 2015). Thus, these studies highlight the relevance of 
neuroinflammation and microglial function/dysfunction in the pathogenesis of AD. 
 
1.5.2.3 Mutations in the membrane trafficking related genes 
The importance of membrane trafficking in AD has been discussed in the earlier sections. It 
is hence not surprising that many LOAD risk genes were found to be involved in trafficking 
processes like endocytosis and lysosomal degradation. Earlier in the chapter we have seen 
that SorLA1, a LOAD risk gene, is involved in APP trafficking from endosomes to golgi and 
thus affects Aβ levels. PICALM, another LOAD risk gene, was shown to be involved in the 
endosomal trafficking of APP and possibly transport of brain Aβ across the blood brain 
barrier (Kanatsu et al., 2014; Zhao et al., 2015). In a study that is part of this thesis, we 
identified a mutation in Rab11 that significantly associates Rab11 function with LOAD, 
possibly through its regulation of BACE1 recycling (Udayar et al., 2013). BIN1, the risk gene 
only second to APOE4 in its risk for LOAD has diverse functions that include actin dynamics 
and clathrin-mediated endocytosis (Pant et al., 2009) and clathrin-mediated endocytosis is a 
crucial pathway for APP endocytosis and Aβ production. Thus, a critical role for membrane 
trafficking genes in AD is predicted by these genetic and cell biology studies in AD. 
 
1.6 Biomarkers of AD 
1.6.1 Aβ and Tau-based biomarkers 
The diagnostic criteria for AD are primarily based on biomarkers and neuropsychological 
testing. The same criteria are used to classify patients as preclinical AD, mild cognitive 
impairment (MCI) associated with AD and clinical AD (Albert et al., 2011; Sperling et al., 
2011). For AD, biomarkers that are currently under use can be broadly classified into either 
brain imaging-based markers or CSF-based markers.  Biomarker changes, specifically low 
cerebrospinal fluid (CSF) Aβ42 and positive amyloid-PET scans precede all other AD-related 
alterations. According to a hypothetical temporal model based on existing AD biomarker 
data, the chronological order of biomarker changes in AD is as follows, i) lower CSF Aβ42 
ii) increased CSF tau iii) decrease in cerebral glucose metabolism and brain atrophy (detected 
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by MRI) and iv) cognitive impairment (Selkoe and Hardy, 2016). In fact, studies in familial 
AD patients suggested that decreased levels of Aβ42 in CSF can be detected 25 years before 
any cognitive symptoms are manifested (Bateman et al., 2012). The decrease in CSF Aβ42 is 
thought to be due to its decreased clearance from the brain into the CSF sink and /or its 
increased aggregation in the brain as amyloid plaques (Stefani et al., 2005; Zetterberg et al., 
2010). Aβ also serves as a brain imaging marker for AD as brain amyloid load can be 
visualized by positron emission tomography (PET) scans of Pittsburg compound-B (PiB), a 
11C-labelled dye that binds amyloid (Klunk et al., 2004). Total tau and phospho-tau are two 
other validated markers for diagnosis of AD. Total tau levels in CSF increase during normal 
aging, though this increase is significantly higher in AD patients (Sjogren et al., 2001). 
Increase in total tau levels in CSF can also be used to classify MCI patients as MCI-stable or 
MCI-to-AD (Blennow, 2004). Tau can be hyperphosphorylated at many different sites and 
often the phosphorylated tau species are dysfunctional. Tau phosphorylation at position 181 
(pTau181) is significantly higher in AD patients compared to control (Hampel et al., 2010). 
The general consensus is that only with a combination of Aβ42 and total/phospho-tau 
(pTau181) measurement in CSF can sporadic AD be diagnosed with a sensitivity of more 
than 95 % and specificity of more than 85 % (Blennow, 2004; Blennow et al., 2010; 
Marksteiner et al., 2007).  
 
1.6.2 Synaptic biomarkers 
Loss of synapses is the best correlate to the cognitive deficits observed in AD. Synapse loss 
occurs relatively early in the disease, much before neurodegeneration and cognitive decline. 
Thus, indicators of synapse dysfunction or loss could be used as potential biomarkers for 
early diagnosis of AD. Improvements in ELISA based assays to detect synaptic proteins with 
high sensitivity has led to several studies that have measured the changes in levels of 
different synaptic proteins in CSF from AD patients. Currently, there is no validated 
biomarker of synaptic dysfunction/loss that is sensitive and specific enough to be used as 
diagnostic marker in AD. Nevertheless, there are some very interesting candidate biomarkers. 
Meta-analysis of synaptic pathology reported in 417 publications confirmed that synapse loss 
in specific brain regions is indeed an early event in AD and that presynaptic markers were 
affected more than postsynaptic markers in AD (de Wilde et al., 2016). The presynaptic 
protein synaptosomal-associated protein 25 (SNAP25) is one such marker. SNAP25 is 
involved in vesicle fusion at the synapsis and are important for proper synapse functioning. In 
three separate cohorts, CSF levels of SNAP25 were found to be higher in AD compared to 
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controls (Brinkmalm et al., 2014). CSF levels of synaptotagmin 1, another presynaptic 
protein, was shown to be higher in AD patients as well as in patients with MCI. Interestingly, 
synaptotagmin 1 levels in CSF correlated with both total-tau and phospho-tau levels in AD 
patients and thus can be a potential addition to the CSF biomarker profile in AD (Ohrfelt et 
al., 2016). Studies have shown that CSF levels of neurogranin, a postsynaptic protein 
involved in synaptic plasticity, is increased in AD patients and that it can be used to predict 
MCI to AD conversion (Kester et al., 2015; Kvartsberg et al., 2015; Thorsell et al., 2010). A 
recent large cohort study confirmed that CSF neurogranin levels are indeed increased in AD 
patients. The study reported that high CSF neurogranin levels correlated with brain atrophy in 
AD and with amyloid plaque load in preclinical AD. Moreover, high CSF neurogranin level 
could predict rates of cognitive decline in patients with early symptomatic AD (Tarawneh et 
al., 2016). Another study reported that high CSF levels of neurogranin appeared to be specific 
for AD when compared to other neurodegenerative diseases such as frontotemporal dementia 
and Parkinson’s disease (Wellington et al., 2016). Addition of CSF neurogranin levels to 
existing repertoire of AD biomarkers promises to complement and further increase the 
sensitivity of the diagnosis.  
 
1.6.3 Systems biology-driven biomarker profiles 
AD is a complex disease that entails the convergence of a complex maze of cellular pathways 
and processes that eventually lead to neurodegeneration and memory loss. The ideal systems 
biology-based biomarker profiling for AD would involve integrating mRNA, non-coding 
RNA, proteins and metabolites changes over a period. Biomarker profiles generated from 
such an approach have the potential to be more robust and sensitive compared to 
conventional biomarkers that are based on isolated pathways or processes. Due to the nature 
of the disease, generating such a biomarker profile based on affected tissues is an inherent 
limitation. In AD, tissues that are used for studying disease pathogenesis come from post-
mortem brain samples and hence do not reflect the early stages of disease. An alternative 
approach to circumvent this issue would be to develop biomarker profiles based on analysis 
of blood or plasma samples. This approach has its own limitations as blood carries the 
molecular signatures from all the different tissues. Any such biomarker profiling study would 
require a combination of sophisticated computational tools along with sensitive and specific 
measurement assays (Lausted et al., 2014).  
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1.7 Therapeutic strategies  
1.7.1 Current status 
The main goal of therapeutic strategies for AD is to improve cognition and slow the 
progression of disease. The treatments available at present do not cure the disease per se. In 
recent years, significant efforts and resources have been devoted to the development of better 
treatment strategies, which may eventually lead to a cure. According to ‘www.alz.org’, there 
are currently five drugs approved by the U.S. Food and Drug Administration (FDA) for the 
treatment of AD. These are donepezil, galantamine, rivastigmine, memantine and 
combination of donepezil and memantine. The first three drugs are cholinesterase inhibitors 
that increase the levels of acetylcholine by inhibiting cholinesterase. Memantine is a NMDA 
receptor antagonist that is believed to protect cells from excess glutamate by partially 
blocking the NMDA receptor. All these drugs are symptomatic as without knowing the 
definitive cause it is difficult to design drugs that cure the disease. Because of the significant 
progress in our understanding of amyloid and its metabolism, anti-amyloid strategies are on 
the rise. Aβ is causally associated with the neurodegeneration observed in AD and hence, 
anti-Aβ therapies that either inhibit the production (by inhibiting β- or γ-secretase) or clear 
the amyloid load via Aβ immunotherapy offer an exciting possibility to reduce the amyloid 
load and improve the cognitive function (Selkoe and Hardy, 2016). One of the major hurdles 
in developing an effective therapy involving β- or γ-secretase inhibitor is that both the 
secretases cleave many other substrates and thereby play an important role in many 
physiological processes during development and beyond (Hemming et al., 2009; Kuhn et al., 
2012; Willem et al., 2006; Wolfe, 2008). Our lab has addressed this issue by developing a 
modified version of β-secretase inhibitor that is more specific and efficient compared to the 
unmodified version of the inhibitor. The strategy behind the development of the inhibitor is 
explained in the following section. Aβ immunotherapy offers an exciting opportunity to 
target amyloid directly and slow the progression or possibly cure AD. A big advantage for 
Aβ immunotherapy is that compared to β- or γ-secretase inhibitors, antibodies against Aβ 
specifically target Aβ without interfering with other physiologically relevant substrates. 
Aducanumab, a human monoclonal antibody that targets aggregated Aβ, has emerged as one 
of the most promising immunotherapy candidate at present. After demonstrating its efficacy 
in AD mouse models, the antibody was used in a Phase 1b trial in a small cohort of 165 
patients with prodromal or mild AD. Monthly intravenous infusions of aducanumab for a 
year reduced brain Aβ and slowed cognitive decline in the treated patients. This antibody is 
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currently under Phase 3 trials. Nevertheless, keeping in mind the complexity of the disease, 
new therapeutic approaches and strategies need to be pursued. 
 
1.7.2 Therapies based on novel insights into membrane trafficking in AD  
The absence of effective therapies for AD is primarily due to the complex nature of the 
disease. Much of the therapeutic interventions tested in the recent past included inhibitors 
against either γ-secretase or β-secretase. These inhibitors proved to be ineffective and several 
of them caused major side-effects. Some of the reasons for these failures are delayed 
therapeutic intervention, inefficient drug targeting strategies and pan-inhibition of the 
secretase functions. Understanding the trafficking pathways involved in regulation of Aβ 
production offers the possibility to address some of above mentioned limitations. For 
instance, the knowledge that β-secretase cleaves APP in early endosomes was ingeniously 
used by Rajendran and colleagues to design a novel therapeutic strategy for efficient 
inhibition of β-secretase (Ben Halima et al., 2016; Rajendran et al., 2008). Rajendran and 
colleagues began with a transition-state inhibitor against β-secretase which binds and 
inactivates only the active conformation of β-secretase. Since β-secretase is active in 
endosomes they reasoned that targeting the inhibitor to these endosomes will make them 
inhibit β-secretase more efficiently. They designed a membrane-tethered version of the 
originally free and soluble inhibitor to target it to the intracellular compartments, in this case 
endosomes. They linked the inhibitor to a sterol moiety to create a membrane-anchored β-
secretase inhibitor that readily partitioned into cholesterol-rich domains on endosomal 
membrane. β-secretase is also known to be enriched in these cholesterol-rich domains. As 
predicted, the membrane-anchored β-secretase inhibitor was shown to be more potent in 
inhibiting β-secretase both in flies and in mice (Rajendran et al., 2008).  
 
Another approach stemming from membrane trafficking studies that was demonstrated to be 
a viable therapeutic option for AD is boosting the level/function of the endocytic pathway. 
Mecozzi and colleagues demonstrated that stabilizing the retromer complex by novel 
pharmacological chaperones, R33 or R55, lowers Aβ level in mouse primary neurons 
(Mecozzi et al., 2014). The Aβ lowering effect of the drugs was attributed to the reduced 
endosomal residence time of APP. The rationale behind the explanation is that reduced 
endosomal residence time will lower the rate of Aβ production and consequently lower Aβ 
levels. Recently, retromer stabilization with R33 was shown to also reduce pathogenic tau 
phosphorylation in human stem cell models of AD (Young et al., 2018). These studies are 
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particularly interesting as retromer deficiency, specifically that of vacuolar protein sorting-
associated protein 26 and 35 (VPS26 and VPS35) has been reported in late-onset AD patients 
(Small et al., 2005; Wen et al., 2011). Thus, furthering our understanding of membrane 
trafficking processes involved in AD promises novel therapeutic avenues to fight this 
complex and devastating disease. 
 
1.8 Systems biology approaches to understand membrane trafficking complexity in AD 
The basic components that generate Aβ in vitro comprise APP, β-secretase and the γ-
secretase complex in a lipid vesicle with optimal pH (Edbauer et al., 2003). In intact cells and 
organisms these basic components are dependent and regulated by many processes and 
signaling pathways. Therefore, a systems biology approach that integrates information about 
the role of different genes, signaling and metabolic pathways that regulate APP processing 
and Aβ levels is crucial in our understanding of the complex cellular events that underlie AD.  
 
Our lab has previously shown that internalization of APP to early endosomes is necessary for 
it’s processing by β- and γ-secretases and that these occur predominantly in early endosomes 
(Rajendran et al., 2008). Hence, membrane trafficking to and away from early endosomes 
must have a critical role in determining the residency of these components and hence Aβ 
levels. In support of this rationale is the fact that trafficking regulators that retrieve Aβ 
relevant cargoes from early endosomes to the Golgi are implicated in AD Proteins belonging 
to the GGA family have been shown to retrieve β-secretase from endosomes to Golgi and 
their depletion leads to increased amyloidogenic processing of APP (Tesco et al., 2007). 
Interestingly, mutations in SorLA 1 (a sortilin related receptor 1) that causes failure in 
retrieving APP from early endosomes and leads to an increase in Aβ production has been 
found to confer risk for late-onset AD (Andersen et al., 2005; Rogaeva et al., 2007). It is 
likely that there are many other proteins that regulate the trafficking of APP processing 
machinery along the biosynthetic/endocytic pathway and thereby potentially modify the risk 
for AD. The aim of this thesis is to identify all the essential trafficking pathways that are 
involved at various stages in APP metabolism. 
 
1.8.1 Rab GTPase 
Rab proteins are small GTPases belonging to the Ras superfamily. They are monomeric G 
proteins that regulate vesicular trafficking in the biosynthetic, endocytic and degradation 
routes in the cell. Thus, they enable cargo sorting and distribution to the different subcellular 
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compartments. Rab GTPases are reversibly attached to cell membranes by hydrophobic 
geranylgeranyl group. They can switch between the inactive GDP-bound form to the active 
GTP-bound form and thus mediate vesicular fusion or fission. GDP to GTP exchange is 
achieved by Rab-specific GTP exchange factors called GEFs whereas the hydrolysis of GTP 
to GDP is achieved by the GTPase activating proteins, called GAPs (Fig. 3). There are about 
60 Rab proteins and about 40 Rab-GAPs in the human proteome. These diverse Rabs also 
serve as membrane identity markers, as specific Rabs are involved in specific trafficking 
route. For example, Rab3 is a very well established regulator in the biosynthetic pathway and 
exocytosis and mediates trafficking from the Golgi-ER to plasma membrane (Zahraoui et al., 
1989). Interestingly, Rab3A, one of the Rab3 isoform was shown to be involved in 
anterograde transport of APP (Szodorai et al., 2009). 
 
 
Figure 3: The Rab GTPase cycle. Rab proteins can be converted into GTP-bound form by 
GEFs and are the active form in most cases. Rab-GTP can be converted to the Rab-GDP form 
by the action of GAPs, which is in most cases the inactive form (adapted from Stenmark and 
Olkonen, 2001) (Stenmark and Olkkonen, 2001). 
 
The biology of Rab proteins provide multiple ways to study its function. Like for most genes, 
siRNA targeting specific Rab mRNA can be used to deplete mRNA and subsequently protein 
levels of the particular Rab. Additionally, overexpression of Rab-GAP plasmids can deplete 
the active form of Rab proteins and increases the inactive, GDP-bound form, thereby 
preventing their normal function (Fig. 3). Such Rab-GAP screens have been performed to 
identify regulators of several cellular processes such as cilia formation, toxin uptake and 
endocytosis. Yet another way to study Rab function is to use mutant Rab plasmids where the 
Rabs are either locked in its GTP-bound form (dominant active) or GDP-bound form 
(dominant-inactive). Overexpression of the dominant active or dominant negative form leads 
to specific Rab activation or inactivation respectively. Thus, using Rab siRNA library, Rab-
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GAP library and mutant Rab proteins plasmids, we aimed to study APP processing and create 
a “road map” for β-amyloid production and degradation.  
 
1.8.2 RNAi screens 
RNA interference (RNAi) is an endogenous process in cells by which small RNA molecules 
prevent gene expression by targeting the corresponding mRNA molecule. It is known to exist 
in many eukaryotes, including plants and animals. Since its discovery, RNAi has developed 
rapidly into a valuable tool for genetic studies that does not require alterations at the genomic 
level. The small interfering RNA molecule (so called siRNA) can be introduced into cells by 
techniques such as electroporation, microinjection and liposome transfection. Due to the 
relative ease and efficiency of the system RNAi screens have been successfully performed in 
many model systems, for instance, Caenorhabditis elegans, drosophila embryos and several 
mammalian cell lines. These studies have led to significant advancement in our 
understanding of processes such as embryonic development, cell signaling, aging and viral 
infection mechanisms (Mohr et al., 2010; Prudencio and Lehmann, 2009; Seyhan and Rya, 
2010). RNAi screens in mammalian cultured cells are carried out predominantly by using 
liposome-mediated transfection to introduce the siRNA in these cells. Several companies 
provide customizable or off-the-shelf siRNA libraries that can be readily transfected into 
cells. Combined with a faster, efficient and robust sample analysis platform (like the 
multiplexing assay introduced below), RNAi screens provide a powerful yet simple method 
to perform genome-wide analysis in cells. One noticeable limitation of the RNAi screens are 
the potential false-positives due to siRNA off-target effects. In recent times, there has been a 
vast improvement in the design of individual siRNA molecules to minimize or practically 
eliminate off-target effects. In our RNAi screens, we use a pool of 3-4 different siRNAs to 
target a particular gene to achieve efficient knockdown. After carefully selecting our hit 
candidates we deconvolute the analysis by performing the knockdown with individual 
analysis separately. We then look at the result of each of the individual knockdown and only 
when the results are consistent across the different siRNAs we proceed with further 
characterization. This approach further minimizes any potential false-positives in our RNAi 
screen. A robust and efficient RNAi screen depends as much on the sample assaying 
techniques as it does on the knockdown method itself. Below, I will introduce the 
multiplexing assay system that we have developed in our lab. 
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1.8.3 Multiplexing assays to screen for regulators of Aβ production and clearance 
As mentioned above, one of the key components of the RNAi-screens is a medium to high-
throughput ELISA assay that can measure Aβ and other relevant metabolites efficiently.  In 
the past, our lab has successfully established and used an efficient high-throughput ELISA 
assay to study the effect of genes (by RNAi) and cellular pathways (by chemical inhibitors) 
on the production of Aβ (Rajendran et al., 2006; Rajendran et al., 2008). Our lab further 
extended this approach to generate a high-throughput multiplexing assay (Udayar et al., 
2013). This assay parallelly measures the different Aβ species as well as the β-cleaved 
ectodomain of APP (sAPPβ). A major advantage of this assay is that we get insights into the 
possible role of the gene/small inhibitor under study. Parallel measurement of Aβ and sAPPβ 
provides information whether a gene affects β-cleavage of APP (cases where sAPPβ levels is 
affected) or γ-cleavages (cases where Aβ levels is affected but not sAPPβ levels). This 
information helps in designing the further experiments for mechanistic characterization more 
efficiently. We can categorize the hits as either β-cleavage affecting or γ-cleavage affecting. 
For the ones that fall in the β-cleavage category we can design experiments to analyze APP 
or BACE1 levels, their localization, BACE1 activity etc. For the ones that fall in the γ-
cleavage category we can analyze the levels of the different components of the γ-secretase, γ-
secretase assembly, its activity and so on. Another major advantage of the multiplexing assay 
is that it measures Aβ and sAPPβ from a single sample and hence greatly minimizes sample 
and assay induced variations. In this multiplexing assay system, we can also combine the 
measurement of Aβ and sAPPα (product of α-cleavage of APP) or any desired combination 
of metabolites. This gives us a powerful tool to dissect the role of genes in the maintenance 
of Aβ levels more efficiently.  
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2. Objectives of the thesis 
To study the membrane trafficking pathways involved in the production and clearance of Aβ 
peptides in neurons and microglia. 
 
Recent advances suggest that cell biological knowhow is vital in understanding the etiology 
of AD and for therapeutic interventions. By curating a “road map” for Aβ metabolism, this 
study contributes significantly to our understanding of AD.  
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Abstract 
Alzheimer’s disease (AD) is characterized by cerebral deposition of β-amyloid (Aβ) peptides, 
which are generated from amyloid precursor protein (APP) by β- and γ-secretases. APP and 
the secretases are membrane-associated, but whether membrane trafficking controls Aβ levels 
is unclear. Here, we performed an RNAi screen of all human Rab-GTPases, which regulate 
membrane trafficking, complemented with a Rab-GTPase-activating protein screen, and 
present a roadmap of the membrane trafficking events regulating Aβ production. We identify 
Rab11 and Rab3 as key players. While retromers and retromer-associated proteins control 
APP recycling, we show that Rab11 controlled β-secretase endosomal recycling to the plasma 
membrane and thus affected Aβ production. Exome sequencing revealed a significant genetic 
association of a Rab11A variant with late-onset AD patients, and network analysis identified 
Rab11A and Rab11B as components of the late-onset AD risk network, suggesting a causal 
link between Rab11 and AD. Our results reveal new trafficking pathways that regulate Aβ 
levels, and show how systems biology approaches can unravel the molecular complexity 
underlying AD.  
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Introduction 
Alzheimer’s disease (AD) is the most common form of dementia and is characterized by the 
cerebral deposition of Aβ peptides in the form of amyloid plaques (De Strooper, 2010; 
Frisoni et al., 2011). The amyloid cascade hypothesis postulates that Aβ peptides trigger a 
series of pathological events leading to neurodegeneration (Huang and Mucke, 2012; Selkoe, 
2011b). Aβ-peptides are liberated from the transmembrane amyloid precursor protein (APP) 
by the sequential actions of β-secretase and γ-secretase (Thinakaran and Koo, 2008; Willem 
et al., 2009). β-secretase activity is conferred by a transmembrane aspartyl protease, also 
termed BACE1 (β-site APP cleaving enzyme 1) (Vassar et al., 1999) whereas γ-secretase is a 
multimeric transmembrane protein complex composed of Presenilin-1 (PS1)/ Presenilin-2 
(PS2), Nicastrin, Aph-1 and PEN-2 (Annaert and De Strooper, 2002; Selkoe and Wolfe, 
2007). Familial mutations in APP, PS1 or PS2 that increase the production of the 
amyloidogenic Aβ42 peptide, have been associated with early-onset AD (Borchelt et al., 
1996; Duff et al., 1996). However, there is only limited insight into the cause of late onset 
AD, which contributes to more than 95% of cases. Genetic modifiers of late onset AD may 
also regulate Aβ production, raising the possibility that genes regulating APP metabolism 
might impact the risk for AD (Andersen et al., 2005; Rogaeva et al., 2007; Selkoe, 2011a).  
Several lines of evidence support an important role for membrane trafficking in the 
amyloidogenic processing of APP and hence in AD pathogenesis (Rajendran and Annaert, 
2012; Thinakaran and Koo, 2008). APP and BACE1 are transmembrane proteins that are 
synthesized in the endoplasmic reticulum (ER), matured in the Golgi complex and then 
transported to the plasma membrane and into endosomes via endocytosis (Small and Gandy, 
2006; Thinakaran and Koo, 2008). The endolysosomal compartment has been implicated as 
one of the major sites for Aβ generation (Cataldo et al., 2000; Haass et al., 1992; Koo and 
Squazzo, 1994). Recent work has revealed that BACE1 cleavage of APP occurs 
predominantly in early endosomes, and endocytosis of APP and BACE1 is essential for β-
cleavage of APP, and Aβ production (Kinoshita et al., 2003; Rajendran et al., 2006; Sannerud 
et al., 2011). The pH of endosomes (pH 4.0-5.0) is optimal for BACE1 activity, which also 
explains the requirement for endocytosis (Kalvodova et al., 2005; Vassar et al., 2009). In 
contrast, α-secretase cleavage of APP, which precludes Aβ production, occurs at the plasma 
membrane (Lichtenthaler, 2011). Components of the γ-secretase complex are also 
synthesized in the ER, but their assembly and maturation requires the coordinated regulation 
of the ER-Golgi recycling circuit (Spasic and Annaert, 2008).  
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We previously showed that β-cleavage of APP occurs in a Rab5-EEA1 positive membrane 
compartment and that endocytosis is essential for Aβ generation (Rajendran et al., 2006). 
Targeting a transition-state BACE1 inhibitor to endosomes inhibited Aβ production in 
cultured cells and mice (Rajendran et al., 2008). Interestingly, proteins that belong to the 
retromer family, which transport cargo from early endosomes to the Golgi, have also been 
implicated in AD (Rogaeva et al., 2007; Small et al., 2005). These AD risk genes regulate the 
residency of APP and BACE1 in the early endosomal compartment therefore regulating Aβ 
generation (Siegenthaler and Rajendran, 2012). Similarly, proteins of the GGA family have 
been shown to traffic BACE1 from endosomes to the Golgi, and their depletion led to 
increased amyloidogenic processing of APP (He et al., 2005; Tesco et al., 2007; von Arnim et 
al., 2006). While APP is known to be routed from endosomes to golgi via the retromer- and 
retromer associated proteins including SORL1 and VPS26 proteins (Andersen et al., 2005; 
Morel et al., 2013; Small and Gandy, 2006; Rogaeva et al., 2007; Small et al., 2005; 
Siegenthaler and Rajendran, 2012), nothing much is known about BACE1 recycling from 
endosomes. A better understanding of the specific trafficking mechanisms involved in Aβ 
production will thus provide further insights into disease pathogenesis and potentially provide 
novel therapeutic strategies for treating this currently untreatable disease. 
 
Rab GTPases regulate many aspects of membrane protein trafficking, acting as membrane 
organizers on cellular compartments that mediate vesicular trafficking and aid in vesicle 
fusion (Seabra et al., 2002). They regulate vesicular trafficking both in the biosynthetic and 
endocytic routes, enabling cargo sorting within the different membrane compartments (Zerial 
and McBride, 2001). Rab GTPases switch between an inactive GDP-bound form and an 
active GTP-bound form, which enables vesicular fusion (Stenmark and Olkkonen, 2001). 
While GDP-GTP exchange is mediated by Rab-specific GTP exchange factors (GEFs), GTP 
hydrolysis is achieved by the GTPase activating proteins, (GAPs) (Barr and Lambright, 
2010). In humans, there are 60 Rab proteins and 39 RabGAPs. Overexpression of RabGAPs 
depletes the active form of Rab proteins and increases the inactive, GDP-bound form, thereby 
preventing their normal function (Yoshimura et al., 2007). 
 
Here, we systematically analyzed the role of the cell’s major membrane trafficking processes 
in Aβ production by the combined use of RNA interference (RNAi)-mediated silencing of all 
Rab GTPase proteins and an overexpression screen of the RabGAPs.  
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Results 
Development of a multiplexing platform to quantitatively assay sAPPβ and Aβ levels 
We first developed a multiplexing assay to quantitatively screen for Aβ and sAPPβ, the two 
products of the amyloidogenic processing of APP (Figure 1A), from a single sample. 
Simultaneous measurements of Aβ and sAPPβ from a single sample in the same well would 
indicate whether a ‘hit’ affected the β-cleavage of APP (changing sAPPβ levels) or the γ-
cleavage/ fate of Aβ (changing Aβ levels) (Figure 1B). Thus, inter-measurement variations 
are avoided, which increases the sensitivity and signal-to-noise ratio allowing high-
throughput measurements. We used an electrochemi-luminescence (ECL) assay platform as it 
provides high sensitivity and robust signal detection. In each well of a 384-well plate, one 
spot of anti-Aβ40 and one of anti-sAPPβ antibodies were separately spotted (Figure 1C). 
Two other spots were coated with BSA for background and non-specific binding controls. 
Upon binding to the analytes in the samples, electrochemical signals from the ruthenium-
labeled respective secondary antibodies were detected through an image-based capture. Since 
the captured antibodies are spatially positioned at distinct spots in the well, the values 
corresponded to the amount of the analyte bound to the specific capture antibody. As a proof 
of principle, we studied the binding of synthetic Aβ40 and recombinant sAPPβ in the same 
well. We incubated different concentrations of synthetic Aβ peptides in the assay plate and 
found a linear dependency of the signal to the amount of peptide used at concentrations lower 
than 50ng/ml. At concentrations above 50ng/ml, we observed saturation (Figure 1D). Similar 
saturation kinetics were observed with recombinant sAPPβ protein, suggesting that this 
system perfectly recapitulates binding reactions. When only Aβ was added to the well, 
background signals were observed for sAPPβ, and vice versa. When both Aβ and sAPPβ 
were added in the same well, specific signals were detected (Figure 1D), demonstrating a 
high degree of specificity and no cross-reactivity between the two analytes. In addition, 
electrochemiluminescence detection allowed us to detect concentrations as low as 10-100 
picograms of Aβ and sAPPβ.  
 
We then proceeded to see if Aβ and sAPPβ could be measured from cultured cells and 
neurons from transgenic mice. Both Aβ and sAPPβ could be measured from HEK and HeLa 
cells stably expressing the pathogenic Swedish mutant of APP, which causes familial early 
onset AD (Figure 1E). Conditioned medium collected at different times shows that both Aβ 
and sAPPβ gradually accumulated in a time-dependent manner (Figure 1E). Increase in the 
volume of the conditioned supernatants produced a linear increase in the measurements 
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demonstrating assay robustness (Figure S1). We could also quantify sAPPβ and Aβ in 
cortical neurons from mice expressing human APP with Arctic/Swedish (Arc/Swe) mutations 
(Figure 1E). Sample swapping (Figure 1F) experiments showed that no significant signal was 
observed for the β-cleaved ectodomain of Swedish APP (sAPPβsw) when measured with the 
plate coated in capture antibodies, which recognized the β-cleaved ectodomain of wild-type 
APP (sAPPβwt). Similarly, no signal was obtained for sAPPβ when we swapped the 
sAPPβwt supernatants on the sAPPβsw-coated plates. However, robust signals for Aβ were 
detected in all conditions. Thus, the assay is highly specific for both Aβ and sAPPβ.  
 
RNAi screen of human Rab proteins identifies novel proteins involved in Aβ and 
sAPPβ  production 
To study the role of all human Rab proteins in the regulation of amyloidogenic APP-
processing, we first performed an RNAi screen in cells that robustly produce Aβ and 
sAPPβ (Rajendran 2006, Rajendran 2008), and assayed these products using the multiplexing 
electrochemiluminescence assay system (Figure 2A, 2B). We included APP, BACE1 and 
Pen2 (a subunit of the γ-secretase) as positive controls. As expected, silencing of APP and 
BACE1 decreased both Aβ and sAPPβ levels, whereas silencing of Pen2 decreased Aβ 
levels, but not sAPPβ levels (Figure 2A, 2B), further validating the assay. Quantification was 
based on the electrochemiluminescence counts, normalized to the cell viability counts and 
relative to that of the scrambled control (medium GC containing siRNA oligo (MedGC)). 
Apart from Rab36, silencing of the other Rab proteins did not significantly alter cell viability 
(Figure S1B). The screen identified Rabs that significantly decreased both Aβ and 
sAPPβ (Figure 2A and B), including Rab3A, Rab11A, Rab36 and Rab17  (Figure S2A, B). 
Rab36, a GTPase involved in late endosome positioning, was a top hit in the screen, 
decreasing both Aβ and sAPPβ (Figure 2C). A secondary validation screen reproduced all the 
selected hits (Figure S2C). Knockdown efficiency of the relevant genes was confirmed by 
RT-PCR (Figure S2D). Though our analysis accounts for toxicity, and quantifies Aβ and 
sAPPβ as a relative count of viable cells, Rab36 depletion was consistently toxic in all the 
screens  (Figure S1B). Therefore, we removed it from further analysis. 
 
Rab11A, the major Rab protein involved in the slow recycling of cargo proteins from early 
endosomes to the cell surface (Sonnichsen et al., 2000), was the second top hit in our 
analysis. In addition, silencing of the isoform, Rab11B, also reduced Aβ levels (Figure 2A). 
Interestingly, all the isoforms of Rab3, except Rab3C, decreased both Aβ and sAPPβ levels. 
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Rab3 proteins are involved in synaptic function (Schluter et al., 2004) and in the fast axonal 
transport of APP (Szodorai et al., 2009). Silencing of Rab3A and 3B decreased overall APP 
levels, suggesting that Rab3 plays a role in the trafficking and maintenance of APP levels 
(Figure S2E). 
 
Silencing of Rab44, Rab6A and Rab10 decreased Aβ levels without affecting sAPPβ (Figure 
2C), implying that these GTPases affect either γ-secretase cleavage or the fate of Aβ. 
Interestingly, knockdowns of several Rabs also increased both sAPPβ and Aβ levels. To 
understand how these trafficking pathways contributed to both Aβ and sAPPβ levels, we 
plotted the normalized values of Aβ and sAPPβ values from the screen in a 2-dimensional 
plot and observed a largely correlative curve for both the values, indicating that the Rab 
proteins responsible for regulating β-cleavage are also responsible for controlling Aβ levels 
and that any perturbation at the level of BACE1 cleavage of APP is the rate-limiting step in 
Aβ production (Figure 2D).  
 
RabGAP overexpression screen identifies overlapping hits with the Rab RNAi screen 
As RNAi can have off-target effects leading to false positive results, we complemented our 
RNAi screen with an overexpression screen of all 39 RabGAPs in the human genome, which 
suppress Rab function by accelerating the hydrolysis of GTP. In this screen, we 
overexpressed each RabGAP in the same cellular system used for the RNAi screen and 
quantitatively measured Aβ, sAPPβ levels and cell viability (Figure 3; Figure S1). Many 
RabGAPs were found to affect sAPPβ and Aβ levels (Figure 3). RN-TRE, a GAP which has 
previously been shown to affect amyloidogenic processing of APP (Ehehalt et al., 2003) 
reduced both Aβ and sAPPβ. TBC1D10B, a GAP for Rab35, Rab27A, Rab22A, Rab31 and 
Rab3A, decreased both Aβ and sAPPβ (Frasa et al., 2012). However, only Rab3A silencing 
via RNAi decreased Aβ and sAPPβ (Figure 2, 3). EVI5, a RabGAP for Rab11 (Frasa et al., 
2012; Laflamme et al., 2012), decreased both Aβ and sAPPβ. In addition, one other RabGAP 
for Rab11, namely TBC1D15, decreased both Aβ and sAPPβ. Intriguingly, TBC1D14, which 
alters Rab11 localization and subsequently delays recycling of Transferrin to the plasma 
membrane (Longatti et al., 2012), decreased Aβ levels (Figure 3C). These results 
independently identified Rab11 as an important regulator of sAPPβ and Aβ production. 
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Epistasis mini-array profiling identifies distinct trafficking routes 
We next analyzed whether the identified Rabs regulated Aβ production through the same 
trafficking pathway or through distinct mechanisms. To this end, we performed an epistasis 
mini array profiling (EMAP) screen (Schuldiner et al., 2005) wherein we silenced all the hits 
against all the hits in a 14 x 14 matrix, to determine whether a combined knockdown gives 
rise to an aggravating (non-interacting) or alleviating (interacting) phenotype (i.e. β-cleavage 
of APP). Here again, single knockdowns of either Rab3A or Rab11A decreased sAPPβ levels 
(Figure S3). However, when they were silenced together, a further decrease (an aggravating 
phenotype) was observed, which indicates that Rab3A and Rab11A act independently and 
contribute to β-cleavage via distinct trafficking routes. Most of the genes that were identified 
as hits did not interact with each other, with the exception that a double knockdown of 
Rab10/ Rab23 or Rab10/ Rab25 showed an alleviating phenotype, suggesting that these Rabs 
regulate the same membrane trafficking pathways.  
 
Validation of Rab11A as a hit 
Since Rab11A was identified as one of the strongest hits in both the RNAi screen and the 
RabGAP screen, we independently validated this finding in a different cellular model. siRNA 
mediated silencing of Rab11A in HEK cells stably expressing wtAPP led to a strong 
reduction of both Aβ and sAPPβ levels (Figure S4A), similar to the effect observed upon 
silencing of Rab11A in HeLa cells stably expressing sweAPP (Figure 4A). Consistent with 
this, Western blotting analysis with anti-APP C-terminus antibodies revealed a strong 
reduction in β-C-terminal fragment (CTF) levels (C99) with increase in α-CTF levels (Figure 
4B). This suggests that Rab11A silencing markedly affected β-cleavage of APP and also Aβ 
levels. Western blotting with anti-Rab11A antibodies showed that Rab11A silencing 
efficiently knocked down the protein (Figure 4B) (with > 90% efficiency). In addition, 
Rab11A silencing led to a decrease in all three species of Aβ (Aβ38, 40 and 42) (Figure 4C), 
and reduced amyloid levels in the cell lysates suggesting that Rab11A regulates Aβ 
production rather than secretion (Figure S4B). Silencing of Rab11A using 4 different siRNAs 
singly also led to a decrease in Aβ without affecting cell viability, thus demonstrating the 
specificity of the observed effect (Figure 4D). All siRNAs against Rab11A also silenced 
Rab11A expression (Figure 4D inset). 
 
To further validate these results, we employed a different strategy to interfere with Rab11 
function. Since Rab-proteins exist in both a GTP-bound and GDP-bound form, we 
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overexpressed the GDP-locked (dominant negative; DN) mutant forms of Rab11A (the 
ubiquitously expressed isoform) and Rab11B (the isoform highly expressed in neurons) in 
cells to phenocopy the effect of Rab11 silencing. Similar to silencing of Rab11A, 
overexpression of Rab11A-DN reduced Aβ and sAPPβ levels significantly. Overexpression 
of Rab11B-DN (which would also interfere with the function of WT-Rab11) also 
significantly reduced Aβ and sAPPβ levels (Figure 4E).  
 
Finally, we assessed the effect of silencing the expression of evolutionarily conserved Rab11 
family-interacting proteins on β-cleavage of APP in the cells (Lindsay and McCaffrey, 2002). 
Knock down of four of the five FIP family proteins (Shiba et al., 2006), with the exception of 
Rab11FIP1 (retromer-like), decreased sAPPβ levels  (Figure 4F). Thus, not only Rab11 but 
also Rab11-interacting proteins, which were identified as Rab11-effector proteins, reduced β-
cleavage of APP.  
 
Rab11 silencing in primary neurons from WT and APP transgenic mice reduce Aβ 
levels 
We next studied if Rab11 also regulated Aβ production in the neuronal context. Silencing 
Rab11A and Rab11B in primary neurons isolated from APP transgenic mice significantly 
decreased both sAPPβ and Aβ levels (Figure 4G). Both RT-PCR and Western blotting 
analysis show efficient silencing of Rab11A and 11B (Figure S4C, D and Figure 4H). 
Knockdown of Rab11A and Rab11B in primary neurons isolated from WT mice again 
reduced Aβ (both Aβ40 and Aβ42) levels (Figure 4I-J). Moreover, silencing either Rab11A 
or Rab11B also significantly decreased Aβ levels (Figure S4E). Thus, Rab11 is crucial for β-
cleavage and Aβ generation.  
 
Rab11 controls membrane trafficking of BACE1  
We hypothesized that Rab11 must regulate either at the level of APP or at the level of 
BACE1. Rab11 silencing or Rab11A DN expression did not affect the total cellular levels of 
APP or BACE1 (Figure 4B and Figure S4F respectively). To analyze protein localization, we 
performed live cell imaging of cells transfected with either APP-YFP or BACE1-YFP using a 
wide-field microscope maintained under a temperature-controlled environment. BACE1-YFP 
prominently localized to the perinuclear endocytic recycling compartment (ERC), and was 
also found in numerous highly motile vesicular and tubular structures dispersed throughout 
the cell (Figure 5A). Inspection of individual carriers revealed rapid transport of tubulo-
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vesicular structures along a curvy linear trajectory, suggesting active transport along 
microtubules. Indeed, brief treatment of cells with the microtubule disrupting reagent 
nocodazole inhibited dynamic transport of BACE1, and induced the formation of enlarged 
immobile vesicles (not shown). The distribution and dynamics of BACE1 trafficking, but not 
of APP, was markedly altered by expression of Rab11AS25N, the dominant negative mutant of 
Rab11 (Rab11A DN)  (Figure 5A). The length of the BACE1-positive tubular carriers 
emanating from the ERC was significantly enhanced by Rab11A DN overexpression, but 
remained highly dynamic, suggesting that GTPase activity of Rab11 is involved in the fission 
of BACE1 tubular carriers and/or their tethering and fusion with the target.  
 
Rab11 GTPase is involved in recycling many cargos from the ERC, including the recycling 
endosome marker transferrin receptor (TfR) (Sonnichsen et al., 2000). TfR as well as 
internalized transferrin becomes associated with a distinct tubular network in cells expressing 
Rab11 DN (Choudhury et al., 2002; Wilcke et al., 2000). To address whether BACE1 follows 
the recycling route from recycling endosomes, we first checked whether BACE1 colocalizes 
with TfR. BACE1 significantly co-localized with TfR (Figure 5B). Not only the steady state 
levels of TfR, but also internalized transferrin colocalized with BACE1 in Rab11 
compartments (data not shown). In control cells and those transfected with Rab11A WT, 
BACE1-YFP colocalized with TfR in the ERC as well as in numerous vesicles and short 
tubulo-vesicular carriers (Figure 5B). However, in cells expressing Rab11A DN, BACE1 and 
TfR were found in elongated tubular structures that emanated from the ERC (Figure 5B). 
Neither the prominent perinuclear localization of APP in the TGN nor the dynamics of APP-
positive structures was disturbed by Rab11A DN expression (Figure 5A). Thus, BACE1 
localization and trafficking is akin to that of TfR, which requires recycling via the Rab11-
mediated pathway for transferrin internalization. Since Rab11 regulates the recycling of TfR 
through the slow recycling route, it may also regulate the recycling of BACE1 thus affecting 
both the cell surface as well as the early-endosomal trafficking of BACE1. 
 
Rab11 affects the recycling of BACE1 
Since BACE1 accumulated in elongated tubulo-vesicular structures in cells expressing 
Rab11A DN, we hypothesized that under these conditions, BACE1 is unable to be trafficked 
to the plasma membrane and thus is unavailable for re-internalization to early endosomes, the 
site of β-amyloid production. To test this, we performed two different experiments. First, we 
tested if Rab11A regulated cell surface levels of BACE1 using FLAG-tagged BACE1 (Figure 
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S5A). Here we used both FACS (Fluorescent Activated Cell Sorting) as well as 
immunofluorescence on cells transfected with either control or Rab11A DN expressing 
plasmids. Cells expressing Rab11A DN indeed displayed reduced cell surface levels of 
BACE1 (Figure 6A and B). Similar results were obtained using imaging of cell surface 
labeled BACE1 in HeLa (Figure 6C) and primary neurons (Figure 6D). Rab11A DN did not 
reduce the total levels of BACE1 (Figure S4F) in line with the observations that under 
Rab11A DN expressing conditions, BACE1 accumulates in the tubulo-vesicular 
compartments and is not re-routed to degradative compartments.  
 
Next, we specifically looked at the effect of Rab11A in the recycling pool of BACE1 using a 
quantitative ratiometric assay to measure recycling by differential labeling. To this end, cells 
were labeled with Alexa 647-conjugated M1 anti-FLAG for 30 min at 37˚C, to allow 
antibodies to bind surface BACE1 and be internalized. After internalization, cells were 
incubated with Alexa 488-conjugated secondary antibodies for 30 min at 37˚C, to detect 
internalized anti-FLAG-bound receptors that recycled to the surface. In the Rab11A DN 
expressing cells, BACE1 recycling was significantly decreased, confirming that Rab11 
functions to recycle BACE1 from the endosomes to the plasma membrane (Figure 6E). 
Quantitation of the fluorescence signal clearly revealed that the recycling pool of BACE1 is 
markedly decreased in cells expressing Rab11A DN. Two parallel controls were used: a 
surface control, where cells both incubations were performed at 4˚C, and an endocytosis 
control, where the first incubation was at 37˚C and the second at 4˚C (Figure S5B). Cells 
without BACE1 did not show any labeling under these conditions. 
 
Together these results suggest that vesicular trafficking regulated by Rab11 GTPase is 
critically important for the homeostatic regulation of BACE1 trafficking and Aβ production 
in endocytic organelles.  
 
Rab11 genetic variability in Late-onset Alzheimer’s disease 
We used exome sequencing data from 170 neuropathologically assessed controls and 185 
late-onset AD patients to study if variants in Rab11A were associated with disease risk. Our 
results revealed a significant association of a variant in Rab11A (rs117150201, uncorrected p 
value = 0.01), thus establishing a potential association between Rab11 and AD (Table 1).  
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Network analysis of GWAS genes linked to late-onset AD identifies Rab11A and 
Rab11B as interacting proteins 
To determine whether other genes linked with late onset AD (LOAD) risk also acted via 
Rab11, we used protein-protein interaction (PPI) network analysis to study the interaction 
partners of proteins linked to LOAD risk. We used the protein products of top 10 genes 
linked to LOAD (Alzgenes; www.alzgene.org) and created a two-level depth interactome of 
these proteins. In the cluster with Bin1, a risk gene that is strongly associated with LOAD 
risk, we identified both Rab11A and Rab11B and their interacting proteins, Rab11FIP1-5 
(Fig. S6). In our RNAi-based screen, Rab11A, Rab11B and all the FIPs (except for FIP1) 
regulated β-amyloid levels further supporting the findings that the LOAD risk gene, Bin1 
could contribute to amyloid production via Rab11. Interestingly the Bin1 cluster also 
included Arf6, a known player in BACE1 endocytosis to early endosomal compartments 
(Sannerud et al., 2011) and GGA3, which regulates early endosomal residency of BACE1 
(Tesco et al., 2007), further supporting the link between Bin1, Rab11 and BACE1 
endocytosis and recycling. These results from this unbiased network analysis strongly link 
Rab11 to late-onset AD risk.  
 
New Rabs and membrane trafficking pathways in amyloid secretion 
Using a systems approach, our screen also identified other regulatory active Rabs and 
provides new insights into membrane trafficking pathways that play crucial roles in amyloid 
production and secretion. This allowed us to present the first comprehensive roadmap for 
APP processing (Figure 7). Most of the hits were Rabs involved in the regulation of the 
trafficking either to or from early endosomes (Galvez et al., 2012), confirming the critical 
role of early endosomes in β-amyloid generation (Kinoshita et al., 2003; Koo and Squazzo, 
1994; Rajendran et al., 2006; Small and Gandy, 2006). In addition to Rab11, several other 
Rabs were identified to also regulate β-amyloid levels. Silencing of Rab2A, for instance, 
increased Aβ and sAPPβ levels (Figure 2), and the cognate GAP, TBC1D11, showed a 
similar effect (Figure 3). Rab2A is involved in the maintenance of Golgi structure and 
function. It interacts with the atypical protein kinase C (aPKC) (Tisdale, 2003) that positively 
regulates α-cleavage of APP via α-secretase (Nitsch et al., 1993).  
 
On the other side, Rab5C silencing significantly increased sAPPβ and Aβ, while the other 
Rab5 isoforms did not. Rab5C is involved in the endocytosis and recycling of cell surface 
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molecules (Onodera et al., 2012). Silencing of Rab5C dramatically increased the cellular 
levels of APP (Figure S2E), which explains the increase in sAPPβ and Aβ.  
 
The Rab proteins that have been implicated in exosome release, namely Rab27 and Rab35 
(Hsu et al., 2010; Ostrowski et al., 2010), negatively regulated Aβ and sAPPβ levels (Figure 
2). This is consistent with our previous work showing that very small amounts of Aβ can be 
released via exosomal vesicles, and suggests that the exosomal pathway is connected to an 
intracellular degradation mechanism and that inhibition of the exosomal pathway re-routes 
the cargo for effective secretion.  
 
Discussion 
To rule out potential off-target effects of the RNAi screen, we complemented it with 5 
independent experimental conditions: 1) an unbiased Rab-GAP overexpression screen. To 
our knowledge, this is the first time a paired RNAi screen (of all human Rab GTPases) and 
an overexpression screen (of Rab GTPase activating proteins (RabGAPs)) was performed. 2) 
Rab11 DN phenocopied the effect of RNAi of Rab11, 3) All 4 different siRNAs against 
Rab11 decreased Aβ levels, 4) Rab11 RNAi had the same effect in many different cells 
including primary neurons, and finally 5) silencing Rab11-associated proteins such as EHD 
or FIPs produced similar effect.  
 
The results from our RNAi, RabGAP and EMAP screens provide a valuable list of all the 
human Rab proteins that affect Aβ and sAPPβ levels and their nature of interaction. We also 
silenced different isoforms of a particular Rab by means of RNAi and indeed, in many cases, 
we found isoform specific effects on Aβ levels.  
 
Silencing of Rab4A, Rab6A and Rab10 decreased only Aβ. Conversely, silencing of Rab8A, 
Rab25, Rab14 and Rab34 significantly increased only Aβ. Such Aβ specific effects are likely 
the result of either an altered γ-secretase cleavage of APP or a change in secretion and/or 
degradation of the produced Aβ. Of particular interest is Rab8, which increased Aβ levels 
when depleted in cells. Rab8 is involved in various physiological functions such as 
exocytosis and cilia formation. Interestingly, expression of a mutant Presenilin-1 (A260V) in 
PC12 cells dramatically decreased Rab8 levels thus affecting trafficking via Golgi (Kametani 
et al., 2004).  We also identified some hits that specifically decreased sAPPβ levels without 
affecting Aβ. While this at first seems counter-intuitive, it implies the possibility that specific 
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Rabs play a role in the release/secretion of sAPPβ without affecting the processing of APP. 
However, we see a clear overall correlation of sAPPβ and Aβ which suggests two things: a) 
β-cleavage is rate-limiting and thus determines cellular and secreted Aβ levels, or b) 
compartments that define β-cleavage are also involved in γ-cleavage of APP to generate Aβ 
(Kaether et al., 2006; Rajendran et al., 2006).  
 
We identified Rab11 as a main regulator of APP processing. Both by ECL assays and 
through Western blotting to study APP processing, we show that BACE1-mediated 
processing of APP is affected in Rab11-silenced cells. Interestingly, while we see a 
significant reduction in C99 levels, C83 levels are increased. This could be due to an 
increased α-cleavage of APP or C99 or could also represent a defect in γ-secretase cleavage 
demonstrating that Rab11 recycling endosomes play a crucial role in APP processing and Aβ 
production. Indeed, Rab11 has been shown to interact with γ-secretase component, Presenilin 
(Dumanchin et al., 1999; Wakabayashi et al., 2009). However, we did not observe any 
influence of Rab11A on the activity or localization of γ-secretase (data not shown).  
 
APP endocytosis is mediated by the YENPTY cytosolic motif and is regulated by both 
cholesterol-dependent and clathrin-mediated endocytic pathways (Perez et al., 1999; 
Schneider et al., 2008). Similarly, endocytosis of BACE1 has been shown to be both clathrin-
dependent and clathrin-independent via the ADP-ribosylation factor 6 pathway (Prabhu et al., 
2012; Sannerud et al., 2011). So far, early endosomes, TGN and the plasma membrane have 
been suggested to contribute to β-amyloid production (Choy et al., 2012; Chyung and Selkoe, 
2003; Rajendran et al., 2006; Sannerud et al., 2011). While APP is known to be routed from 
endosomes to Golgi via the retromer and associated proteins (Andersen et al., 2005; Morel et 
al., 2013; Small and Gandy, 2006; Rogaeva et al., 2007; Small et al., 2005; Siegenthaler and 
Rajendran, 2012), nothing much is known about BACE1 recycling from endosomes. 
 
Our results now identify the Rab11-dependent slow recycling pathway as a novel trafficking 
route involved in Aβ generation. A recent study showed that synaptic activity mediates the 
convergence of APP and BACE1 in acidic microdomains that colocalize with Transferrin 
receptor (TfR)(Das et al., 2013). Since this study did not look at co-localization of APP and 
BACE1 in Rab11 compartments and that a significant proportion of TfR is also found in 
early endosomes (Sonnichsen et al., 2000), the interaction most likely occurs in early 
endosomes as TfR is internalized from the plasma membrane to early endosomes and then is 
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recycled to the plasma membrane via Rab11-positive vesicles. Several studies suggest that 
early endosomes are the compartments where BACE1 cleaves APP, also in the neuronal 
context (Choy et al., 2012; Chyung and Selkoe, 2003; Rajendran et al., 2006; Sannerud et al., 
2011). The fact that retromer-associated proteins or GGA3 regulate Aβ levels is due to their 
involvement in sorting of APP or BACE1 respectively, from early endosomes and not 
recycling endosomes (Andersen et al., 2005; Morel et al., 2013; Siegenthaler and Rajendran, 
2012; Tesco et al., 2007). Furthermore, early endosomes are acidic (Maxfield and Yamashiro, 
1987) and recycling endosomes are not as they lack functional vacuolar ATPase (Gagescu et 
al., 2000; Schmidt and Haucke, 2007). In addition, we do not observe the β-cleaved 
ectodomain of APP in Rab11-positive compartments (Rajendran et al.  2006), suggesting that 
the compartments that Das et al., observed as stations where APP and BACE1 meet are most 
likely to be early endosomes and not recycling endosomes. So, how do recycling endosomes 
contribute to β-amyloid generation? Our results now clearly show that mechanistically, 
Rab11-containing recycling endosomes mediate the recycling of BACE1 to replenish the 
pool of BACE1 in early endosomes. In support of this latter notion, our time-lapse analysis 
shows dramatic alteration of BACE1 dynamics in cells expressing Rab11A DN mutant. In 
addition, we could clearly demonstrate that recycling of BACE1 from endosomes to the 
plasma membrane (for subsequent re-internalization) is severely impaired in the absence of 
functional Rab11 using both FACS and recycling assays. In addition, Rab17, another protein 
involved in the recycling of internalized cargo also regulated sAPPβ and Aβ levels thus 
underscoring the importance of recycling endosomes in APP processing.  
 
Our screen and validation results uncover a new trafficking route involved in Aβ production. 
Since BACE1 cleavage of APP is critically involved in the pathogenesis of early onset AD 
(Yang et al., 2003) and in certain forms of sporadic AD (Jonsson et al., 2012), we propose 
that Rab11-mediated recycling route represents a novel drug target for AD, which is 
supported by our exome sequencing results and the unbiased protein-protein interaction 
network analysis. Interestingly, Eps15 homology domain-containing (EHD) proteins, which 
form complexes with Rab11 via Rab11FIP2, were independently identified as critical 
regulators of dynamic BACE1 trafficking and axonal sorting in hippocampal neurons. 
Moreover, knockdown of EHD1 or EHD3 significantly reduced Aβ levels in primary neurons 
[Buggia-Prévot et al., in press]. The network model suggests that the interaction of Bin1 with 
Rab11 is via Arf6, a known player in BACE1 endocytosis to early endosomal compartments 
(Sannerud et al., 2011) and GGA3, a protein that regulates early endosomal residency of 
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BACE1 (Tesco et al., 2007) is also involved in the network, further supporting the link 
between Alzheimer’s disease risk and Rab11-mediated BACE1 endocytosis and recycling. 
 
Taken together, our results clearly establish a novel link for recycling endosomes in BACE1 
recycling, Aβ generation and AD and underscore the importance of systems level analysis in 
understanding the complexity of AD. 
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Materials and Methods 
cDNA constructs 
 
Plasmids encoding DsRed-tagged human WT Rab11A and DN mutant (S25N) (Choudhury et 
al 2002) were purchased from Addgene. C-terminally EYFP-tagged mouse BACE1 was 
generated by subcloning BACE1 cDNA (provided by Nabil G. Seidah), in-frame into the 
pEYFP-N1 vector. HA-tagged Rab11A constructs have been described (Ren et al., 1998). 
The sequence corresponding to the Flag epitope in the BACE1-FLAG construct was 
introduced after the pro-peptide cleavage site within the lumenal domain of mouse BACE1 
using the following primers: 
5’- CCGGGAGACCGACTACAAGGACGATGATGACAAGGGGGGAGGATC and 5’- 
CCGGGATCCTCCCCCCTTGTCATCATCGTCCTTGTAGTCGGTCTC. 
 
siRNA 
siRNAs were purchased from  Invitrogen (stealth siRNA).  
 
RNAi screen 
RNAi screen was performed using HeLa cells expressing the Swedish APP mutation (HeLa-
sweAPP). siRNA were transfected with a final concentration of 5nM using Oligofectamine 
(Invitrogen) as transfection reagent at a concentration of 0.3µl in a total volume of 100µl 
following manufacturer’s instructions. Each siRNA transfection was performed in 
quadruplicate. After 24 hr the transfection mix on the cells was replaced with fresh culture 
medium. 69 hr after transfection, medium was again replaced with 100 µl fresh medium 
containing 10 % Alamar blue (AbD Serotec). 72 hr after transfection, Alamar blue 
measurements were taken using SpectraMAX GeminiXS (Molecular Devices) at an 
excitation wavelength of 544nm and emission at 590nm. Supernatant was collected and 
assayed for Aβ and sAPPβ. The cells in the transfected plate were lysed with 50 µl of lysis 
buffer for 20 min on ice.  
 
RabGAP screen 
The RabGAP screen was performed in HeLa-sweAPP cells. Cells were seeded in 96-well 
plates at a density of 6000 cells/well one day before transfection. Effectene (Qiagen) was 
used as transfection reagent following manufacturer’s instruction using 2.5 µl of Effectene 
and 0.8 µl of Enhancer in a total volume of 100µl. Transfection mix was replaced with fresh 
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medium after 3.5 hr. 24 hr after transfection, medium was again replaced with fresh medium 
containing 10 % Alamar blue (AbD Serotec). 27 hr after transfection, Alamar blue 
measurements were taken using SpectraMAX GeminiXS (Molecular Devices) at an 
excitation wavelength of 544nm and emission at 590nm. Supernatant was collected and 
assayed for Aβ and sAPPβ using the Electrochemiluminescence assay (see Extended 
Methods section). The cells in the transfected plate were lysed with 30 µl of lysis buffer, 
incubated for 20 min on ice and stored at -20°C. 
 
Live cell image acquisition and processing 
Images were acquired on a motorized NikonTe2000 microscope equipped with a Cascade 
II:512 CCD Camera (Photometrics) using a 100X objective (NA 1.4). During live imaging, 
cells were maintained at 37°C in imaging medium [140 mM NaCl, 5 mM KCl, 3 mM CaCl2, 
2 mM MgCl2, 1.5mM D-glucose, and 10 mM HEPES (pH 7.4)] in a custom-designed 
environment chamber. Time-lapse images were acquired at the rate of 2 frames/sec. Images 
of fixed cells were acquired as 200 nm z-stacks, deconvolved using Huygens software 
(Scientific Volume Imaging). Extended Depth of Field plugin of ImageJ software was used to 
generate single plane projections from processed z-stacks (Rasband, 1997-2012; Forster et 
al., 2004).  
 
Recycling assay 
Cells were labeled with Alexa 647-conjugated M1 anti-FLAG for 30 min at 37˚C, to allow 
antibodies to bind surface BACE1 and be internalized. Cells were washed twice in media, 
and incubated with Alexa 488-conjugated secondary antibodies for 30 min at 37˚C, to detect 
labeled internalized receptors that recycled to the surface. Cells were fixed in 4% 
paraformaldehyde for 15 min, washed, mounted, and imaged. Cells were imaged using an 
Andor Revolution XD spinning disk system with a Nikon Eclipse Ti automated inverted 
microscope, using a 60x TIRF 1.49 NA objective. Images were acquired using an Andor 
iXon+ EM-CCD camera using Andor IQ with 488, 561, and 647 nm solid state lasers as light 
sources, using identical parameters for all images.  Confocal images were collected as tiff 
stacks and analyzed in ImageJ (National Institutes of Health, Bethesda, MD). All 
fluorescence quantitations were performed on images directly acquired from the camera with 
no manipulation or adjustments. To measure fluorescence, a region of interest was drawn 
around each cell, and the mean fluorescence in each channel recorded. In each field, a region 
of the field without cells was chosen to estimate background. Percent recycling was 
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calculated as the ratio of 488 to 647 fluorescence, after background correction. Statistical 
analyses were done using Microsoft Excel or Graphpad Prism (Graphpad Software, La Jolla, 
CA).  
 
Epistasis mini-array profiling 
Epistasis mini-array profiling (EMAP) was performed keeping the general siRNA 
transfection method the same as the one followed for the RNAi screen except that a final 
siRNA concentration of 10nM was used (5nM siRNA for each targeted gene). For the single 
knockdowns, 5 nM of the specific siRNA pool was combined with 5 nM of Scrambled 
(MedGC) siRNA. In the EMAP screen, we silenced hit 1-14 Rabs (indicated in Figure S6) vs. 
1-14 Rabs. 
 
siRNA transfection for HEK-wtAPP cells 
Lipofectamine RNAiMAX (Invitrogen) was used as transfection reagent. 24hr prior to 
transfection, cells were seeded at an initial seeding density of 3500 cells per well in a 96-well 
plate pre-coated with Poly D lysine (Sigma Aldrich). siRNAs were transfected at a final 
concentration of 5 nM by using 0.3 µl of Lipofectamine RNAiMAX(Invitrogen) in a total 
volume of 100µl. Each siRNA transfection was performed in quadruplicates. After 48 hr the 
transfection mix was replaced with fresh medium containing 10 % Alamar blue (AbD 
Serotec). 60 hr after transfection, Alamar blue measurements were taken using SpectraMAX 
GeminiXS (Molecular Devices) at an excitation wavelength of 544nm and emission at 
590nm. Supernatant was collected and assayed for Aβ and sAPPβ as described in the ECL 
section. The cells in the transfected plate were lysed with 35 µl of lysis buffer for 20 min on 
ice.  
 
Off-Target prediction of the siRNAs 
For Stealth siRNAs, the off-target effects are determined using the Smith-Waterman 
alignment methods. These off-target effects are associated with the presence of one or more 
perfect 3' untranslated region (UTR) matches with the hexamer or heptamer seed region 
(positions 2-12) of the antisense strand of the Stealth siRNA. We screen the 5', 3' and CDS 
sequence for any potential off target effects. In case there is a positive alignment this is listed 
as potential off-target effect. (Smith and Waterman, Journal of Mol. Biol. 147:195:7). 
 
Plasmid transfection 
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The plasmid transfection for Rab11 DN was performed in HeLa-sweAPP cells. 
Lipofectamine 2000 (Invitrogen) was used as transfection reagent. Cells were seeded in a 96-
well plate at an initial seeding density of 6000 cells per well 24h prior to the transfection. 0.3 
µg of plasmid DNA was was transfected using 0.3 µl of Lipofectamine 2000 in a total 
volume of 100µl. Transfection mix was replaced after 3 hr by fresh culture medium. 21 hr 
after transfection, medium was again replaced with fresh medium containing 10 % Alamar 
blue (AbD Serotec). 60 hr after transfection, Alamar blue measurements were taken. 
Supernatant was collected and assayed for Aβ and sAPPβ. The cells in the transfected plate 
were lysed with 35 µl of lysis buffer, incubated for 20 min on ice and stored at -20°C.  
 
siRNA transfection in primary neurons 
Mouse primary cortico/hippocampal neuronal cultures were prepared from embryos (E16) 
from either wildtype mice or transgenic mice expressing the human APP with the Swedish 
mutation. siRNAs were transfected at a final concentration of 100nM using 0.45 µl of 
Lipofectamine RNAiMAX (Invitrogen) as transfection reagent in a total volume of 100µl.  
 
Electrochemiluminescence detection of human Aβ 38, 40 and 42 and mouse Aβ 
For the measurement of Aβ38, 40 and 42, Aβ triplex plates were used. For the measurement 
of mouse Aβ, mouse Aβ specific ECL assay plates were used with 4G8 antibodies as 
detection antibodies enabling the detection of Aβx-38;-40,42 peptides. Pre-coated plates were 
blocked with TBST (Tris Buffered Saline containing Tween), containing 1% Blocker A, for 1 
hr at room temperature on a shaker at 750rpm. After washing, 25 µl of the cell culture 
supernatant was added to each well along with 25 µl of detection antibody followed by 
incubation for 2 hr at room temperature on a shaker at 750rpm. After washing detection was 
performed in 35 µl of 2X MSDT read buffer and read with the Sector Imager 6000. 
 
Real-time RT-PCR  
Total RNA from cultured cells or Primary neurons was isolated using TRIzol (Invitrogen) 
according to manufacturer’s instructions. 1 µg of total RNA was used to prepare cDNA using 
the iScript cDNA synthesis kit (BIO-RAD) according to the manufacturer’s recommended 
protocol. Real-time PCR was performed using iTaq Universal SYBR Green Supermix (BIO-
RAD) according to manufacturer’s instructions. Relative gene expression levels were 
calculated with the ΔΔCt method using GAPDH for normalization.  
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Cell culture and transfection 
HeLa cells expressing the Swedish mutant of APP (HeLa-swAPP) were grown as previously 
described (Bali et al., 2012). HEK-293 cells were obtained from ATCC and maintained in 
HyClone DMEM (Fisher Scientific) supplemented with 10% FBS.  Cells were plated in 24-
well plates and co-transfected with FLAG-BACE1 and wild type or S25N Rab using 
Effectene (Qiagen), using 0.2 µg plasmid DNA and according to manufacturer’s instructions.  
They were passed onto 25mm coverglass 24 hr after transfection and imaged after 48 hours.  
COS-7 cells were cultured in DMEM 10% bovine growth serum (HyClone), supplemented 
with 2 mM L-Glutamine and Penicillin/Streptomycin (Gibco). Cells were plated on poly-L-
lysine-coated 35 mm glass bottom dishes (MatTek) for live imaging or on 18 mm microscope 
coverglass for immunofluorescence staining. Cells were transfected overnight with 1µg total 
of DNA using Fugene (Roche), according to the manufacturer’s instructions. 
 
Immunofluorescence 
Cells were fixed using 4% paraformaldehyde and permeabilized for 5 min at room 
temperature, with 0.2%Triton X-100 in PBS. The coverslips were then blocked with PBS 
containing 3% BSA, 50 mM NH4Cl, and 10 mM glycine for 1 hr. Human anti-transferrin 
receptor antibody (Invitrogen) diluted in PBS 3% BSA 0.2% Tween20, was added and 
incubated for 1 hr at room temperature. Subsequently, the coverslips were incubated with 
Cy5-conjugated goat anti-mouse antibody (Invitrogen) for 1 hr at room temperature and 
mounted using Permafluor (Thermo Fisher Scientific). 
 
Alamar Blue assay 
69 hr post-transfection, the medium of transfected cells was replaced with normal  medium 
containing 10% Alamar blue. The final volume in each well was 100 µL. 3 hr after the 
medium change, cell viability was monitored using Fluoroscan Ascent Cf (Labsystems), with 
excitation wavelength 544nm and emission at 590nm. The cell viability was measured using 
the Alamar blueTM assay (Serotec Ltd., Kidlington, Oxford, UK), where the absorbance was 
monitored at the end of the reaction (after 3 hr) (Labsystems Multiscan MS UV visible 
spectrophotometer). 
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Protein-Protein Interaction Analysis of Proteins linked to late-onset Alzheimer’s disease 
The ID of the risk genes (Bertram L, McQueen M, Mullin K, Blacker D, Tanzi R. The 
AlzGene Database. Alzheimer Research Forum. Available at: http://www.alzgene.org) were 
used as input to query the String database (ww.string-db.org, University of Zurich, 
Switzerland) against the Homo sapiens datasets and the protein-protein interactome was 
visualized using cytoscape (Cytoscape™, Seatle, US).  Since our study is focused on finding 
how the genes interact with each other at different levels/depth of the network, only the data 
from Experiments, Databases & Text mining were taken into consideration. The confidence 
score was set to highest confidence to minimize the possibility of false positives. The number 
of interactors was limited to a maximum of 50. The AD risk genes were used as core nodes to 
initialize the network construction.  STRING database was queried with the individual core 
nodes to retrieve the primary nodes (First level of network construction).  Later the STRING 
database is queried with the primary nodes to extract the respective secondary nodes (second 
level of network construction). The RAB11FIP3 node is extended to one more level to have a 
better understanding on its role in the whole interactome. All the data were downloaded as 
tab delimited text files from the STRING database and imported to cytoscape for data 
integration, visualization and analysis. The data integration is carried out with the aid of 
Advanced Network Merge plugin [http://cbio.mskcc.org/~jgao/]. The organic layout is 
generated to have a better visual on the clustered structure of the graph.  
 
Western Blotting 
After 72 hr of siRNA transfection or 24 hr after plasmid transfection, cells were lysed in 
buffer containing 2% NP-40 and 0.2% SDS and protease inhibitors (Roche). Equal amounts 
of the lysate (according to the protein content quantified by BCA assay (Pierce) were run on 
4-12% BIS-TRIS gels (Invitrogen). The gel was blotted onto a nitrocellulose membrane 
(BioRad) and probed with the respective antibodies.  
Anti-APP, C-Terminal antibody: SIGMA (F3165-1MG), Anti-BACE1 antibody: Prosci 
incorporation (2253), Anti-Rab11A antibody: Abcam (ab128913), GAPDH antibody: 
Meridian Science. 
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Figure 1 
 
Figure 1: A multiplexing platform for the detection of amyloidogenic processing of 
Amyloid precursor protein (APP)  
A. Schematic of the screen. B. Cartoon of APP cleavage by β-and γ-secretases. C. Cartoon of 
Electrochemiluminescence (ECL) detection system. D. Incubation of synthetic Aβ (Aβ40, 
black) and recombinant sAPPβ (red) either individually or together gives specific signals. E. 
Supernatants from HEK (HEK-sweAPP) or HeLa cells overexpressing the Swedish mutant of 
APP (HeLa-sweAPP) and primary cortical neurons from Arc/sweAPP Tg analyzed for Aβ 
(black) and sAPPβ (white for HEK and HeLa; grey for the cortical neurons) levels (error bars 
indicate SD). F & G. Specificity of the ECL-multiplex assay platform. Signals for Aβ40 
(black) and wt-sAPPβ (grey) from conditioned medium HEK-wtAPP (F) or HEK-sweAPP 
(G) analyzed with capture antibodies specific for Aβ and wt sAPPβ. H & I. Signals for Aβ40 
(black) and swe-sAPPβ (grey) from conditioned medium of HEK-wtAPP cells (H) or HEK-
sweAPP cells (I). (Error bars indicate SD.) 
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Figure 2 
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Figure 2: RNAi screen of genome wide Rabs identify Rabs involved in regulating the 
levels of Aβ and sAPPβ. 
A & B. Graph showing the levels of Aβ (A) and sAPPβ (B) from the Rab siRNA screen. 
HeLa-sweAPP cells were transfected with Scrambled oligo (negative control), or pooled 
siRNA against APP, BACE1, PEN2 and the 60 Rabs and assayed for Aβ and sAPPβ (error 
bars indicate SEM). C. List of genes that had the strongest effect on Aβ and sAPPβ levels 
after siRNA mediated silencing along with the Z-score and t-test values. D. Two-dimensional 
plot representing the levels of Aβ and sAPPβ from the Rabs siRNA screen. Positive controls 
APP, BACE1 and PEN2 are indicated in green, and negative control Scrambled is indicated 
in blue. Rabs silencing that led to the strongest decrease in both Aβ and sAPPβ are indicated 
in red. All statistics were performed using the 2 tailed t-tests and using one way ANOVA. 
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Figure 3 
 
Figure 3: RabGAP screen identifies novel GAPs and Rabs in the regulations of Aβ and 
sAPPβ levels. 
A. Graph showing the levels of Aβ (black) and sAPPβ (grey) after RabGAP plasmid 
overexpression. HeLa-sweAPP cells were transfected with plasmid expressing       RabGAP 
fused with GFP or a plasmid expressing GFP (negative control) and assayed for Aβ and 
sAPPβ (error bars indicate SEM). B. Graphs showing Z-scores of the effects on sAPPβ and 
Aβ levels after RabGAP overexpression. C. Table showing RabGAPs that had the strongest 
effect on Aβ and/or sAPPβ levels along with its cognate Rab(s). * indicates that the 
TBC1D14 is not a GAP for Rab11 but has been shown to perturb the localization and 
function of Rab11 (Longatti et al., 2012).  
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Figure 4: 
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Figure 4: Rab11 regulates BACE1 cleavage of APP in model cell lines and primary 
neurons from wild type and APP transgenic mice 
A. HeLa-sweAPP cells were transfected with Scrambled oligo (MEDGC, negative control) or 
pooled siRNA against APP and Rab11A and assayed for Aβ (dark grey) and sAPPβ (light 
grey). (Error bars indicate SD). B. HeLa-sweAPP cells were transfected with scrambled oligo 
or pooled siRNA against Rab11A and the lysates were assayed by Western blotting as 
indicated. C. HeLa-sweAPP cells were transfected with scrambled oligo  or pooled siRNAs 
against APP and Rab11A and assayed for Aβ38 (light grey), Aβ40 (dark grey), and Aβ42 
(black). (Error bars indicate SEM). D. HeLa-sweAPP cells were transfected with scrambled 
oligo or pooled siRNA against APP, single siRNA (si1-4) against Rab11A and pooled siRNA 
against Rab11A and assayed for Aβ40 (dark grey) and cell viability (light grey) and the 
lysates were assayed by Western blotting as indicated (Inset). (Error bars indicate SD). E. 
HeLa-sweAPP cells were transfected with PCDNA 3.1 (negative control), Rab11ADN and 
Rab11BDN and assayed for Aβ40 (dark grey) and sAPPβ (light grey). (Error bars indicate 
SEM). F. HeLa-sweAPP cells were transfected with scrambled oligo or pooled siRNA 
against APP, BACE1 and Rab11FIP1-5 and assayed for sAPPβ (Error bars indicate SEM).  
G-J: Silencing of Rab11 in primary neurons from APP transgenic and wildtype mice reduces 
β-cleavage of APP and Aβ levels: G. Rab11A and B were silenced in primary cortical and 
hippocampal neurons isolated from APP transgenic mice expressing the Swedish mutation in 
APP and the secreted levels of Aβ and sAPPβ were measured. The scrambled oligo was used 
as a negative control and siRNA targeting APP as positive control. H. Western blotting with 
anti-Rab11A and anti-GAPDH antibodies from control and Rab11-silenced primary neurons. 
I. Rab11A and B were silenced in primary cortical and hippocampal neurons isolated from 
wildtype (WT) mice and the secreted levels of endogenous Aβ40 and Aβ42 were measured. 
The scrambled oligo was used as a negative control and siRNA targeting APP as positive 
control.  J. Western blotting with anti-Rab11A and anti-GAPDH antibodies from control and 
Rab11-silenced primary WT neurons. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with 
scrambled MEDGC or PCDNA3.1. All statistics were performed using the 2 tailed t-tests. 
Similar significance was also observed with one-way ANOVA analysis (Dunnett’s a 
posteriori analysis)(Supplementary Figure 14). 
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Figure 5 
 
 
 
Figure 5: BACE1 colocalizes with Rab11 compartments and its trafficking is altered 
upon Rab11 dysfunction 
A. Live-cell images of COS cells transfected with BACE1-YFP or YFP-APP along with 
empty vector (control) or Rab11A DN. Expression of Rab11A DN protein is shown in the 
insets. B. COS cells were transiently co-transfected with BACE1-YFP (green) and empty 
vector, HA-tagged Rab11A WT or S25N dominant negative mutant and fixed and stained 
with anti-HA (not shown) and TfR antibodies (red) to label recycling endosomes. The colors 
in the first two panels are green for BACE1-YFP and red for TfR.  
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Figure 6 
 
 
 
 71 
Figure 6: Rab11 regulates the surface recycling of BACE1 and is essential for 
maintenance of BACE1 cell surface levels 
A. HeLa-swAPP cells were transfected with either control plasmids or the dominant negative 
mutant of Rab11A and Flag-tagged BACE1. Cell surface levels of BACE1 were determined 
via FACS on non-permeabilized cells using anti-FLAG antibodies and Alexa-647 coupled 
secondary antibodies. B. The mean and the median intensity of the cell surface levels of 
BACE1 are lower in Rab11A DN expressing cells. C. Microscopy of cell surface BACE1 on 
non-permeablized HeLa cells expressing BACE1-Flag. Rab11A DN expressing cells have 
marked decrease in cell surface BACE1. D. Immunofluorescence of cell surface BACE1 on 
non-permeablized primary neurons transfected with BACE1-Flag. Also in neurons, Rab11A 
DN expressing cells have a marked decrease in cell surface BACE1. E. Recycling of BACE1 
is significantly decreased in Rab11A DN expressing cells. Cells were transfected with 
BACE-FLAG /Rab11A constructs (WT and DN) and incubated with Alexa647-conjugated 
M1 anti-FLAG primary antibodies for 30 min at 37°C, followed by washing and incubation 
with Alexa-488 secondary antibodies at 37°C for 30 min. This allows the primary antibody to 
bind the surface/cycling BACE1 and label the endosomal BACE population, and the 
secondary antibody to only bind the BACE1 that recycled to the surface. A ratio of the 
secondary to the primary gives the amount recycled in this time. 
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Figure 7 
 
 
Figure 7: A Roadmap of APP processing and Aβ production 
Integrated map of the Rabs identified in the screen as regulators of APP processing and Aβ 
production/secretion. Rabs indicated in green positively regulate Aβ levels and those 
indicated in red are negative regulators. Note that the majority of the Rabs regulate 
trafficking to and from early endosomes. 
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Supplementary Figure 1 
 
Supplementary Figure 1: Linearity of Aβ and sAPPβ detection and cell viability assay 
after RNAi and Rab-GAP screen. (Related to Figure 1, 2 & 3) A & B. Different volumes of 
cell culture supernatants from HeLa-sweAPP cells were assayed for Aβ40 (A) and sAPPβ (B) 
by ECL-multiplex assay. C & D. Cells from RNAi screen (C) and cells from Rab-GAP 
screen (D) were assayed for fluorescence intensity after incubation with Alamar Blue® to 
estimate cell viability. (Error bars indicate SD). 
A B
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Supplementary Figure 2 
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Supplementary Figure 2: Z score of the RNAi screen and validation of top hits. (Related 
to Figure 2 & 4) 
A & B. Graphs showing Z-scores of the effects on Aβ (A) and sAPPβ (B) levels after RNAi 
screen in HelasweAPP cells. C & D. HeLa-sweAPP cells were transfected with siRNA pool 
against Scrambled (Negative control), APP, BACE1, PEN2 and the top hit Rabs and assayed 
for Aβ (black) and sAPPβ (grey) levels (C) and the knockdown efficiency was estimated by 
RT-PCR (D). E. HeLa-sweAPP cells were transfected with Scrambled (Negative control) or 
pooled siRNA against APP, BACE1 and the top hits of the Rab RNAi screen and the cell 
lysates were run on SDS-PAGE, blotted either with anti-APP c-terminus antibody or anti-
BACE1. Both blots were reprobed with anti-GAPDH for loading control. 
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Supplementary Figure 3 
  
Supplementary Figure 3: Epistasis mini array profiling (EMAP) of the hit Rabs from 
the RNAi screen. (Related to Figure 2)  
The 14 hits identified form the RNAi screen were silenced either alone (single knockdown) 
or in the combination (double knockdown) indicated in the graph and the supernatant were 
assayed for sAPPβ levels (Error bars indicate SEM). All statistics are performed using the 2 
tailed t-tests. 
Udayar et al., Supplementary Fig. S3
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Supplementary Figure 4 
 
Supplementary Figure 4. Validation of the effects of Rab11 (Related to Figure 4& 6) 
A. HEK-wtAPP cells were transfected with Scrambled (MEDGC) or pooled siRNA against 
APP and Rab11A and the cell lysates were assayed for Aβ and sAPPβ levels. B. HeLa-
sweAPP cells were transfected with Scrambled (Negative control) or pooled siRNA against 
BACE1 and Rab11A and the cell lysates were assayed for Aβ levels. C, D & E. Primary 
cortical and hippocampal neurons from transgenic mice expressing the human APP with the 
Swedish mutation were transfected with Scrambled (Negative control) or pooled siRNA 
against Rab11A and Rab11B singly (C) or together (D) and the knockdown efficiency was 
estimated by RT-PCR. Silencing of Rab11A or Rab11B reduced Aβ levels (E). F. HeLa-
sweAPP cells were cotransfected with Control or Rab11ADN plasmids and the lysates were 
assayed by western blot and protein levels of Rab11A and BACE1 was estimated using anti- 
Rab11A and BACE1 antibodies respectively. * P < 0.05, ** P < 0.01, *** P < 
0.001compared with Scrambled (MEDGC). All statistics are performed using the 2 tailed 
ttests. 
A
Udayar et al., Supplementary Fig. S4
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Supplementary Figure 5 
Supplementary Figure 5: Validation of BACE1-Flag tagged construct and recycling 
assay. (Related to Figure 5 & 6) 
A. COS cells cultured on small glass coverslips were transfected with psport6Flag- BACE1 
and cell surface (surface) and intracellular (permeabilized) BACE1 were detected by anti-
FLAG antibody. B. Cells were transfected with FLAG-tagged BACE1 and three different 
antibody incubation conditions were used to validate the assay system. The primary antibody 
used was an Alexa647 conjugated anti-FLAG antibody and the secondary antibody was 
Alexa488 conjugated. The following three incubation conditions were followed:i) Incubation 
of both anti-FLAG and the secondary antibody at 4°C. ii) Incubation of anti-FLAG antibody 
at 37°C and secondary antibody at 4°C. iii) Incubation of both anti-FLAG and the secondary 
antibody at 37°C. 
 
 
 
A
Udayar et al., Supplementary Fig. S5
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Supplementary Figure 6 
 
 
Supplementary Figure 6: Protein-Protein interaction network analysis of the AD risk 
gene products identifies Rab11A and Rab11B as interacting partners of Bin1. 
The top Alzgenes were seeded using the multi-protein search field in STRING database and 
the clusters were analyzed. In the Bin1 containing cluster, Rab11FIPs, Rab11A and Rab11B 
were identified as interacting partners. Note that Bin1 connects to Rab11 via Arf6, a BACE1 
trafficking regulator and Rab11FIP3. GGA3, another protein that regulates BACE1 
trafficking is also present in the network. 
 
 
 
Table 1 
 
 
Table 1: Details of the cohort used for Exome Sequencing in this study. 
 
 
 
 
Udayar et al., Supplementary Fig. S6
!
Supplementary Table 3: Variants identified in the Rab11 gene in the studied cohort. 
!!Details!of!the!cohorts:!!
 
Cohort Control AD 
Number of Samples analysed 170 185 
Gender (%F) 45% 53% 
Mean age at onset in years (±SD) NA 71.3 (10.1) 
Mean age in years (±SD) 78.4 (9.7) 81.2 (10.8) 
 
 !
Chr! Pos! dbSNP! Ref! Alt! AA_CHANGE! CODON! LOCATION/EFFECT! P! OR!
15! 66161839! ! C! T! NA! NA! START_GAINED! 0.49! 0.32!
15! 66161849! ! G! C! NA! NA! UTR_5_PRIME! 1.00! 2.81!
15! 66170080! rs74845010! A! G! NA! NA! INTRON! 0.26! 1.34!
15! 66170121! ! T! C! G86! ggT/ggC! SYNONYMOUS_CODING! 0.48! 0.31!
15! 66170128! rs11556462! T! C! L89! Ttg/Ctg! SYNONYMOUS_CODING! 0.48! 0.31!
15! 66180298! rs75724883! C! T! NA! NA! UTR_3_PRIME! 0.67! 0.58!
15! 66181143! rs117150201! T! G! NA! NA! UTR_3_PRIME! 0.01! 0.47!
15! 66181154! rs77317331! C! T! NA! NA! UTR_3_PRIME! 0.78! 1.11!
15! 66181246! ! C! CTTAA! NA! NA! UTR_3_PRIME! 1.00! 2.82!
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Chapter 2 
 
RNAi screen of genome-wide Rab-GTPases identifies Rab7 as a novel regulator of Aβ 
clearance in microglia 
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Abstract 
Presence of amyloid plaques in the brain is one of the main hallmarks of Alzheimer’s disease 
(AD). Amyloid plaques are mostly composed of β-amyloid (Aβ) peptides that initially 
aggregate into oligomers and subsequently into higher order fibrillar structures. Production 
and clearance of β-amyloid (Aβ) are both determinants of amyloid build-up in the brain. 
Cellular trafficking pathways that could potentially regulate Aβ production and clearance are 
not well understood. Here, we performed an RNAi screen of all Rab-GTPases in BV2 
microglia cells and performed an Aβ uptake assay to assess the effects of loss of function of 
Rab-GTPases on Aβ clearance. We identified Rab7 a novel regulator of Aβ clearance. 
Although Rab7 silencing increased the uptake of Aβ, the engulfed Aβ was shown to be 
accumulating in Rab7 silenced cells compared to control condition. In depth analysis of 
lysosomal degradation revealed significant defects in lysosomal pathway upon Rab7 
silencing. Rab7 silencing led to altered distribution of degradative acidic organelles, reduced 
cathepsin B activity, impaired clearance of EGF and  increased general protein accumulation. 
Rab7 silencing also impaired Aβ clearance and increased Aβ levels in neurons and Hela cells. 
Rab7 silencing also increased total-tau and phospho-tau levels in primary neurons. Taken 
together, our results identify a novel role for Rab7 in clearance of Aβ both in neurons and 
microglia and thus could play a crucial role in late-onset AD.  
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Introduction 
Alzheimer’s disease (AD) is the most common cause of dementia, accounting for more than 
40 million patients worldwide. AD is characterized by progressive neurodegeneration and 
result in significant neuron loss, cerebral atrophy and cognitive decline (Selkoe and Hardy, 
2016). Behavioral symptoms manifest as memory lapses and subtle personality disorders in 
early-stage AD, which then progress to significant cognitive and memory impairment in late-
stage AD. Cerebral deposition of β-amyloid (Aβ) and tau, which are also the clinical 
hallmarks of the disease, are believed to play a causative role in AD. Findings from Familial 
AD (FAD) mutations studies have implicated excessive Aβ production to be the cause of the 
pathogenesis observed in FAD. Due to absence of such mutations, the causal factor of 
amyloid accumulation in LOAD has not yet been determined. Evidences suggest that 
impaired amyloid clearance in and from the brain could be the cause of amyloid build-up in 
LOAD.  
 
Microglia are the brain’s resident macrophages and are the chief phagocytic cells in the brain. 
Microglial phagocytosis is involved in several processes such as synapse elimination, myelin 
debris removal and clearance of toxic peptides such as Aβ (Paolicelli et al., 2011 and Sierra 
et al., 2013). In vitro evidence indicates that microglia can efficiently phagocytose fibrillar 
Aβ through different receptors, such as Toll-like receptor 2 (TLR2) and Scavenger receptor 
A1 (SCARA1) (Paresce et al., 1996 and Frenkel et al., 2013). However, not much is known 
about the cellular regulators of Aβ uptake and degradation in microglia. Identification and 
characterization of regulators of Aβ clearance in microglia will allow us to establish the 
molecular etiology of AD in greater detail. Membrane trafficking regulators are interesting 
candidates in this regard as degradation pathways in the cell rely on membrane trafficking to 
move cargoes from one compartment to the other. Rab-GTPases are master regulators of 
membrane trafficking in the cell. Manipulation of their level or function provides us a 
valuable tool to study the role of membrane trafficking in Aβ clearance. 
 
Here, we performed an RNAi screen of all Rab-GTPases in BV2 microglia cells to identify 
regulators of Aβ uptake and clearance. We identified Rab7 as a novel regulator of Aβ 
clearance. Rab7 silencing increased the uptake of Aβ, but impaired the degradation of the 
uptaken Aβ. The impairment in degradation of Aβ was due to disrupted lyosomal function in 
the absence of Rab7.  
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Results and Discussion 
RNAi screen of Rab proteins identifies Rab7 as a novel regulator of Aβ clearance in 
BV2 microglia. 
To understand the role of the distinct Rab proteins that regulate β-amyloid clearance, we 
performed an RNA interference (RNAi)-mediated silencing screen of all the Rab-GTPases of 
the genome in a BV2 microglia cells, followed by overnight (20 h) incubation of conditioned 
medium containing Aβ and analyzed the levels of residual Aβ using 
electrochemiluminescence (ECL) platform (Rajendran et al., 2008; Udayar et al., 2013). We 
identified Rab7 a novel regulator of Aβ clearance. Silencing of Rab7 in BV2 microglia led to 
the increased uptake of Aβ from the extracellular space as evident by the lowest level of 
residual Aβ upon measurement by ECL assay (Figure 1). Though the residual Aβ level 
indicates clearance from the conditioned medium, the fate of the engulfed Aβ needed to be 
investigated. To validate this finding, we used another technique to analyze Aβ uptake. We 
visualized the increased uptake of Aβ by employing TAMRA labeled Aβ for the assays. We 
clearly see that Rab7 silencing leads to an increase in uptake of Aβ (Figure 2A). Moreover, in 
an independent RNAi screen for regulators of lysosomes we found that Rab7 silencing 
showed increased levels and altered distribution of LysoTracker stained acidic organelles 
(late-endosome/lysosome) (Figure 2B). This prompted us to further investigate the 
mehanisms involved in the increased clearance of Aβ upon Rab7 sliencing. 
 
Rab7 silencing leads to impairment of lysosomal degradation pathway and impacts 
steady state Aβ levels. 
To investigate whether this increased and altered distribution of the acidic organelles had an 
impact on lysosomal function we performed cathepsin B activity assay on intact and living 
cells. We employed Magic Red assay to monitor cathepsin B activity. After 72 hours siRNA 
transfection cells were incubated with Magic Red cathepsin B substrate for 1 hour. Cleavage 
of substrate by active cathepsin B leads to accumulation of fluorescent signal. Interestingly, 
cathepsin B activity was significantly reduced upon Rab7 silencing (Figure 3A). Since 
cathepsin B is active in lysosomes, the reduced cathepsin B activity indicates a possible 
impairment in lysosomal degradation pathway. To investigate if Rab7 silencing led to a 
general impairment in lysosomal degradation, we analyzed EGF/EGFR degradation upon 
Rab7 silencing. We used TAMRA labeled EGF and performed a pulse-chase experiment to 
investigate the fate of engulfed EGF. In line with the cathepsin B activity assay, EGF/EGFR 
degradation was severely impaired upon Rab7 silencing (Figure 3B). This prompted us to 
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investigate whether general protein accumulation was affected upon Rab7 depletion. ThioS 
staining revealed a significant accumulation of β-sheet rich-aggregates in the absence of 
Rab7, indicating an increase in general protein load (Figure 3C). Moreover, steady-state Aβ 
levels were significantly increased upon Rab7 silencing in HeLa cells expressing swedish 
APP. This suggests that steady-state Aβ levels depend on lysosomal pathway and that Rab7 
could regulate this aspect of Aβ metabolism.  
 
Rab7 silencing does not alter the sensitivity of primary neurons to exogenous Aβ42. 
Since Rab7 silencing impaired lysosomal function and led to an increase in Aβ levels, we 
wondered whether Rab7 silencing also affects the level of Tau, another important player in 
Alzheimer’s Disease. We investigated if the levels of Tau, is also affected upon Rab7 
silencing. Indeed, the levels of total and phospho-Tau were significantly increased upon Rab7 
silencing in primary neurons (Figure 4A). This is particulary interesting as Tau is a 
microtubule associated cytosolic protein. It is plausible that the increased Tau levels could be 
as a result of impaired autophagosome-lysosome fusion. Tau levels have shown to be 
dependent on autophagy (Inoue et al., 2012, Chesser et al., 2013). Moreover, Rab7 has been 
shown to be involved in the late maturation of autophagosomes (Gutierrez et al., 2004, Jäger 
et al., 2004). Thus, the increased Tau levels observed upon Rab7 silencing could be due to 
impaired late maturation of Tau containing autophagic vacuoles. Next, we asked if the 
observed lysosomal defects and increased Tau levels upon Rab7 silencing render the neurons 
more sensitive to insults from exogenously added Aβ42. Neurons showed a dose-dependent 
response to the exogenously added Aβ42 evident from the reduced cell viability (Alamar 
Blue) and increased LDH release upon increasing concentration of exogenously added Aβ42 
(Figure 4B and 4C). This response was comparable between the control and Rab7 depleted 
condition (Figure 4B and 4C). We analyzed levels of synaptic protein synaptophysin and ER 
stress marker, GRp78 from primary neurons treated with exogenously added Aβ42 upon 
Rab7 silencing. Though, we observed a dose-dependent response to the exogenously added 
Aβ42 on the levels of these two proteins the effect was comparable in the Rab7 depleted and 
control conditions (Figure 4D). This suggests that exogenously added Aβ42 mediates 
neuronal toxicity independent of the lysosomal status or intracellular levels of Tau. It will be 
interesting to study whether endogenously produced Aβ, particularly Aβ42, would be more 
neurotoxic in Rab7 depleted conditions. 
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Conclusion: 
In all, we show that Rab7 silencing increases uptake of Aβ in BV2 microglia but the cells do 
not degrade the enguled Aβ as efficiently as in the control conditions. Moreover, Rab7 
silencing impairs lysosomal degradation pathway, increased steady-state Aβ and total-
Tau/phospho-Tau levels. Our study suggests that both Aβ and tau can be degraded 
intracellularly by the lysosomal pathway and its disruption could contribute significantly to 
the pathogenesis observed in AD.  
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Materials and Methods 
Cell culture 
BV2 microglia cells were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen) at 
37°C and 5% CO2 in a humidified incubator. Media were supplemented with 10% (v/v) fetal 
calf serum (Invitrogen), 1% (v/v) penicillin/streptomycin. HeLa cells expressing the Swedish 
mutant of APP (HeLa swAPP) cells were cultured in Dulbecco’s modified Eagle’s medium 
(Invitrogen) at 37°C and 5% CO2 in a humidified incubator. Media were supplemented with 
10% (v/v) fetal calf serum (Invitrogen), 1% (v/v) penicillin/streptomycin (Gibco) 0.1%(v/v) 
G418 antibiotic (Carl Roth) and 0.1%(v/v) selective antibiotic Zeocin (Invitrogen). Primary 
neurons isolated from E-16 embryos were cultured in NBM (Invirtogen) supplemented with 
B27 (Invitrogen) 
  
siRNAs 
All siRNAs are chemically synthesized stealthTM siRNAs from Invitrogen. A pool of 4 
different siRNA against all the proteases were transfected into HeLa swAPP cells, BV2 
microglia cells and primary neurons. 
 
siRNA Reverse Transfection (HeLa and BV2 microglia) 
For HeLa cells, transfection complexes in quadruplicates were prepared in Opti-mem serum-
free medium (Invitrogen) by mixing 0.3 µL of Oligofectamine (Invitrogen) and 5 nM of 
siRNA. Cells were seeded at a density of 3500 cells/well in 96-well format after addition of 
transfection complexes. For BV2 microglia cells, cells were seeded at a density of 4500 
cells/well in 96-well format the day before transfection (minimum 20 hours before 
transfection). On the day of transfection, complexes in quadruplicates were prepared in Opti-
mem serum-free medium (Invitrogen) by mixing 0.27 µL of Lipofectamine 2000 (Invitrogen) 
and 10 nM of siRNA. After 25 minutes of incubation transfection complexes were added on 
to the cells. 
 
siRNA Forward Transfection in primary neurons 
Transfection complexes in quadruplicates were prepared in NBM medium (Invitrogen) by 
mixing 0.35 µL of RNAi max (Invitrogen) and incubated for 5 mins (Reagent 1). 50 nM of 
siRNA was mixed in 10 ul of NBM medium (Invitrogen) and also incubated for 5 mins 
(Reagent 2). Both the reagents were mixed and incubated for 20 minutes followed by 
addition on primary neurons. Primary neurons were 5-6 days in culture before transfections. 
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Aβ clearance assay with BV2 microglia 
BV2 microglia cells were transfected with the respective siRNAs. After 48 hours, Aβ 
containing conditioned medium from HeLa sweAPP were placed on the BV2 microglia. 
After 16 hours, supernatant was collected and assayed for  Aβ40 levels by ECL ELISA.  
 
Cell proliferation assay   
69 h after siRNA transfection cell viability was analyzed with an alamar blue cell 
proliferation assay  (AbD Serotec BUF012B) using a Plate reader with excitation at 544nm 
and emission at 590nm (Molecular Devices Spectramax Gemini XS) according to the 
manufacturer’s recommended protocol. 
 
SDS-PAGE and Immunoblotting 
For detection of intracellular proteins, whole cell extracts were prepared using a lysis buffer 
(1%NP40 and 0.1% SDS) supplemented with proteinase inhibitors. Extracts were subjected 
to SDS-PAGE using pre-cast gels (Invitrogen). In all cases, gel loading was normalized to 
total protein content in the cell extract (Using BCA assay). Proteins were transferred onto 
nitrocellulose membranes, which were then blocked with PBS containing 5% (w/v) dry skim 
milk for at least 1 h at room temperature. The membranes were then incubated with different 
primary antibody followed by the appropriate horseradish peroxidase-conjugated secondary 
antibody for at least 1 h at room temperature. Both antibodies were diluted in 5% milk/PBS 
0.05% Tween-20. Immunoblotted proteins were detected using an enhanced 
chemiluminescence kit (Pierce). 
 
Electrochemiluminescence (ECL) Assay 
MSD 96-Well MULTI-ARRAY Human Multiplex Kits were used (Meso Scale Discovery) to 
measure the level of Aβ38, Aβ40 and Aβ42. For the measurment of Aβ40 and sAPPβ 384 
well MULTI-ARRAY Human Electrochemiluminescence plate was used following the 
instructions of the manufacturer.  
 
Aβ42 toxicity assay on neurons 
48 hours after siRNA transfection, primary neurons were treated with different 
concentrations of Aβ42 which were freshly prepared by separating aggregated proteins 
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through column chromatography. Only monomeric/oligomeric Aβ42 were added on the 
primary neurons. 
 
Cathepsin B assay 
Magic Red Cathepsin B assay kit from Immunochemistry Technologies (Cat no. 937) was 
used to perform cathepsin B assay according to the manufacturer’s protocol. 
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Figure 1 
 
 
Figure 1: RNAi screen for genome-wide Rabs to identify Aβ clearance regulators       
Z-score of Rab-GTPase RNAi screen for residual Aβ after Aβ uptake/clearance assay. BV2 
microglia cells transfected with siRNA for all the Rab-GTPases and incubated overnight (20 
h) with conditioned medium containing Aβ. Graph shows Z-scores of residual Aβ levels (Y 
axis) after all the mouse Rabs were knocked down (x-axis) and the Aβ uptake/clearance assay 
performed on these cells. Rab7 KD (knockdown) (red) shows the lowest level of residual Aβ 
compared to control (MEDGC, green) suggesting an increase uptake.  
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Figure 2 
 
 
Figure 2: Fluorescent Aβ uptake in BV2 microglia upon Rab7 depletion 
 A. BV2 microglia cells transfected with siRNA for Rab7 and incubated with Aβ40-TAMRA 
(5, 15, 60 min). Rab7 KD leads to increased uptake of Aβ40-TAMRA. B. Hela cells 
transfected with siRNA for Rab7 and incubated with LysoTracker for 1.15 h to stain acidic 
organelles. Rab7 KD leads to altered distribution and increased levels of LysoTracker 
positive organelles.  
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Figure 3 
 
 
 
Figure 3: Effect of Rab7 depletion on lysosomal function 
A. Hela cells were transfected with siRNA for Rab7 and incubated with Magic Red for 1 
hour. Rab7 KD leads to reduced cathepsin B activity. B. Hela cells transfected with siRNA 
for Rab7 and pulse-chased with EGF-TAMRA. Rab7 KD leads to increased accumulation of 
EGF-TAMRA upon 45 minutes of chase indicating decreased degradation of EGF-TAMRA. 
C. Hela cells were transfected with siRNA for Rab7 and fixed and stained with Thio S dye. 
Rab7 KD leads to increase in general protein accumulation as evident by increased Thio S 
signal. D. HeLa cells expressing Swedish APP were transfected with siRNA for Rab7 and 
after 69 hours conditioned medium was collected. Aβ and sAPPβ in the conditioned medium 
was analyzed by ECL assay. Rab7 KD led to an increase in Aβ and sAPPβ levels. All 
statistics were performed using the 2 tailed t-tests. * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 4 
 
 
Figure 4: Effect of Rab7 depletion on neuronal tau levels 
A. Mouse primary neurons were transfected with siRNA against Rab7 and the lysates were 
processed for western blotting to analyze the levels of total-Tau/phospho-Tau. Rab7 silencing 
led to an increase in both total-Tau and phosphor-Tau. B. Mouse primary neurons were 
transfected with siRNA against Rab7 and after 60 hours the neurons were treated with Aβ42. 
LDH levels were measured in cell lysates and supernatant from the treated neurons.  C. 
Mouse primary neurons were transfected with siRNA against Rab7 and after 60 hours the 
neurons were treated with Aβ42. Cell viability was analyzed by monitoring metabolism of 
Alamar Blue dye. D.  Mouse primary neurons were transfected with siRNA against Rab7. 
After 60 hours the neurons were treated with Aβ42 and the lysates were processed for 
western blotting to analyze the levels of different proteins. * p<0.05, ** p<0.01, *** p<0.001. 
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Abstract 
β-Amyloid (Aβ) peptide, causatively linked to Alzheimer’s disease (AD), is generated from 
amyloid precursor protein (APP) by the β-and γ-secretases. γ-Secretase activity is conferred 
by an intramembrane protease complex, which contains either Presenilin-1 (PSEN1) or 
Presenilin-2 (PSEN2) as its catalytic component. While autosomal dominant mutations in 
both presenilins cause early onset AD, the functional origin of the existence of these 
paralogues is not yet known. In an unbiased genome-wide human protease siRNA screen, we 
identified PSEN2 as an unprecedented negative regulator of Aβ levels as opposed to PSEN1, 
whose silencing strongly reduced Aβ levels as previously reported. Mechanistically, PSEN2, 
unlike PSEN1, is localized in late-endosomes/ lysosomes and impacts the functionality of 
degradative lysosomal structures. PSEN2 deficiency reduced both lysosomal number and 
function and thus impaired Aβ degradation in neurons and microglia. PSEN2 knockout mice 
crossed with an AD mouse model showed exacerbated amyloid pathology. Our study, for the 
first time, shows a functional dichotomy between PSEN1 and PSEN2: while PSEN1 is 
largely responsible for Aβ production, PSEN2 controls Aβ clearance in lysosomes thus 
effecting homeostatic control in the process. Our results imply that disturbances in this 
balance could affect Aβ accumulation and thus confer the risk to develop AD. 
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Introduction 
Alzheimer’s disease (AD) is the most common form of neurodegenerative disease (De 
Strooper; Hardy and Higgins, 1992). A characteristic feature of the disease is the presence of 
amyloid-β (Aβ) containing plaques in the brain (Hardy, 1996). The soluble oligomeric form 
as well as the plaque-associated form of Aβ peptide is believed to cause the 
neurodegeneration observed in AD. Aβ is liberated from the amyloid precursor protein (APP) 
via proteolytic processing by β- and γ-secretases (Thinakaran and Koo, 2008). β-Secretase 
activity is conferred by a transmembrane aspartyl protease, also termed BACE1 (β-amyloid 
cleaving enzyme 1) and catalyzes the rate limiting reaction in the generation of Aβ (Haass 
and Selkoe, 2007; Vassar et al., 2009). γ-Secretase is a multi-component complex that is 
composed of presenilin (PSEN1/PSEN2), Nicastrin, APH-1 (APH1A/ APH1B) and PEN-2 
(De Strooper, 2003; Hartmann et al., 1997; Vetrivel et al., 2004). Familial mutations in APP 
or in the components of the γ-secretase complex that increase the production of a longer 
version of Aβ, Aβ42, have been associated with the early onset of the disease (Hardy and 
Crook, 2001; Tanzi and Bertram, 2005). All these data suggest amyloid-dependent 
mechanisms in the pathogenesis of familial AD (Borchelt et al., 1996; Hardy and Selkoe, 
2002). However, the cause of the late onset AD, which contributes 95% of the total AD 
cases, is still not understood (Hardy, 2006). Several lines of evidence suggest that genetic 
modifiers of late onset AD (the case of APOe4) also regulate Aβ metabolism, raising the 
possibility that genes regulating APP processing might influence the risk for AD (Harold et 
al., 2009)(Bali et al, PNAS, 2012).  Therefore, identification of genes involved in the 
regulation of Aβ level constitutes a necessary step towards understanding the pathogenesis of 
late onset AD and for designing effective therapy. In particular, not much is known about the 
proteases that regulate the key secretases in the amyloidogenic processing of APP. In 
addition, while mutations in both PSEN1 and PSEN2 cause early onset AD, not much is 
known about the functional distinction between these two paralogues. Here, through an RNAi 
screen of genome-wide proteases and an independent epistasis screen of all the γ-secretase 
components, we identify PSEN2 as a negative regulator of Aβ levels. 
 
 
 
 
 
 
 98 
Results and Discussion 
RNAi screen for genome-wide proteases identifies PSEN2 as a major negative regulator 
of Aβ (This section was part of Dr. Jitin Bali’s PhD thesis) 
To understand the role of the distinct proteases that regulate β-amyloid production, we 
performed an RNA interference (RNAi) screen of all the proteases of the human genome in a 
human cell model of AD (Rajendran et al, Science, 2008; Udayar et al, Cell reports, 2013), 
and analyzed the levels of Aβ using an electrochemiluminescence (ECL) assay (Fig.1A). 
Depletion of the β-secretase (BACE1; β-site APP cleaving enzyme 1) induced one of the 
strongest depletion of Aβ confirming that BACE1 is the β-secretase in the amyloidogenic 
processing of APP. Since presenilins (PSENs) are also critically involved in the production of 
Aβ (Annaert et al., 1999; De Strooper et al., 1998; Hartmann et al., 1997), we used both 
PSEN1 and PSEN2 as positive controls (Borchelt et al., 1996; Tomita et al., 1997). While 
PSEN1 silencing led to a significant decrease in Aβ levels, PSEN2 silencing had the opposite 
effect, resulting in a significant increase in Aβ levels (Fig.1A). In another set of experiments 
where we only silenced the different components of γ-secretase (PSEN1, PSEN2 and PEN-2) 
to study specifically the functional consequences of the two presenilin paralogues (PSEN1 
and PSEN2) on γ-secretase heterogeneity (Serneels et al., 2009), we again found that PSEN2 
silencing increased Aβ levels while PSEN1 silencing reduced Aβ levels (Fig.1B). On the 
other hand, silencing of PEN-2 completely abolished Aβ production which was similar to 
silencing both PSEN1 and PSEN2 together (Fig.1B,C). Importantly, the opposite effects of 
PSEN1 and PSEN2 silencing on Aβ levels were present for all major Aβ species (Aβ38, 
Aβ40 and Aβ42) (Sup Fig.1). In order to rule out that the observed effect of PSEN2 silencing 
was an ECL measurement artifact, we investigated whether a similar increase in Aβ levels 
could be detected by conventional western blotting from the plain conditioned medium or 
after immunoprecipitation (IP) of Aβ from conditioned medium. As shown in Fig. 1D, upon 
PSEN2 silencing an increase in Aβ was visible in the supernatant even without any IP 
required (4kDa band). After IP using 6E10 antibody, we could clearly detect an increase in 
Aβ levels upon PSEN2 silencing but not PSEN1/2 or PSEN1. To investigate whether PSEN2 
silencing would increase the levels of any secreted molecule, we analyzed secreted alkaline 
phosphatase (SEAP) in the different conditions and found that PSEN2 removal did not affect 
its secretion (Sup Fig.2).  
 
To rule out any siRNA mediated off-target effects, we performed three different validation 
experiments. First we used two different siRNA oligonucleotide sequences against PSEN2 
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and both of these increased Aβ levels independently (Sup Fig.1). As controls, we used two 
different sequences targeting PSEN1 and both of them significantly decreased Aβ levels. We 
then independently verified the findings through enzymatically produced RNAi, esiRNA 
(Kittler et al 2006). Consistently, we found that PSEN2 silencing induced a significant 
increase in Aβ levels, while PSEN1, as expected, lead to a reduction (Fig.1E). To validate 
these findings in the WT APP context, we silenced PSEN2 in HEK cells expressing the 
human WT APP and found that PSEN2 silencing dramatically increased Aβ levels (Sup 
Fig.3). Finally, we performed rescue experiments wherein we overexpressed the murine 
PSEN2 (mPSEN2), resistant to human siRNA, in cells depleted of the endogenous PSEN2. 
mPSEN2 overexpression clearly rescued Aβ levels in the PSEN2 silencing condition 
(Fig.1F). Interestingly, mPSEN2 overexpression also significantly reduced Aβ in the control 
condition (Fig.1F). All these results conclusively demonstrate that PSEN2 negatively 
regulates Aβ levels. 
 
PSEN2 deletion exacerbates amyloid pathology in AD transgenic mice  
(data from fig.2A-C was part of Dr. Jitin Bali’s PhD thesis) 
To validate our initial observations in the neuronal context, we silenced PSEN2 in primary 
mouse cortical neurons overexpressing human APP carrying the Arctic and Swedish 
mutations (Fig.2A). Consistent with the results from human cell lines, PSEN2 silencing 
significantly increased Aβ levels also in primary neuronal cultures (Fig.2A). Western blotting 
and immuno-fluorescence staining with anti-PSEN2 antibodies confirmed the efficiency of 
the knockdown (Fig.2A, B). We further validated our finding in primary neurons prepared 
from APP (arc/swe) transgenic mice crossed with PSEN2 deficient mice. We observed that 
PSEN2 (-/-) and to a lesser extent PSEN2 (+/-) neurons have higher Aβ levels compared to 
PSEN2 (+/+) neurons (Fig.2C). These results support that PSEN2 negatively regulates Aβ 
levels. To investigate whether PSEN2 regulates amyloid levels in an in vivo setting, we 
crossed AD transgenic mice co-expressing APP KM670/671NL and PSEN1 L166P (APPPS1 
mice, Radde et al., 2006) to PSEN2 knockout mice, to generate APPPS1 mice deficient for 
PSEN2. Thioflavin S (ThioS) staining, routinely employed to determine the presence of β-
sheet rich protein aggregates, revealed significantly increased amyloid plaque load in the 
brain of 6 months old APPPS1 mice lacking PSEN2, as compared to their PSEN2(+/+) 
littermates (Fig.2D). Detailed morphometric analysis of plaques by 3D reconstruction 
showed increased plaque number, volume and average size in PSEN(-/-) APPPS1 mice 
compared to PSEN2 (+/+) controls (Fig. 2D-H). Size distribution analysis of the plaques also 
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showed a specific increase in medium to large plaques (5000-40000 µm3), in APPPS1 mice 
lacking PSEN2 (Fig. 2I). The mean intensity of ThioS signal between the two groups was not 
changed, indicating no alterations of amyloid binding property of ThioS (Sup Fig.4). Overall, 
these findings provided in vivo evidence for a novel role for PSEN2 in regulating amyloid 
burden. 
 
Increased Aβ upon PSEN2 silencing is not due to increased γ-secretase activity 
(This section was part of Dr. Jitin Bali’s PhD thesis) 
To study the mechanism through which PSEN2 regulates Aβ levels, we first assessed 
whether silencing of PSEN2 increased PSEN1 levels or its activity in a compensatory way, 
thereby leading to an increase in Aβ production. Quantitative mRNA analysis (Fig. 3A-C) 
showed that PSEN2 knockdown did not significantly affect PSEN1 mRNA levels, however 
we see a slight increase in protein levels by Western blotting (Fig. 3D).  
 
Considering previous studies showing that PSEN2 provided only minimal contribution to 
APP cleavage (Franberg et al., 2011), we pondered over the attractive hypothesis that γ-
secretase complexes containing PSEN2 outnumber complexes containing PSEN1, which are 
more efficient in cleaving APP and thus producing Aβ.  
 
If this hypothesis were to be correct, PSEN2 depletion would increase PSEN1-complexes and 
hence Aβ production. To test whether PSEN1 activity is increased, we employed two 
independent approaches. In the first set of experiments, we studied the amyloidogenic 
processing of APP and found, as expected, that it was significantly impaired by depletion of 
PSEN1, as seen by the accumulation of the CTFs (Fig. 3E). Contrary to the hypothesis, a 
similar impairment was also observed when PSEN2 was silenced (Fig.3E), suggesting that 
PSEN2 also contributes to the cleavage of APP-CTFs and Aβ generation (Sannerud et al, 
2016). We cannot still rule out a possibility that PSEN2 determines the half-life of PEN2, 
which can in turn affect both presenilins/ γ-secretase activity. Silencing of PSEN1 and 
PSEN2 together further increased the accumulation of the APP-CTFs suggesting that γ-
secretase activity is fully abolished (Fig.3E). This showed that PSEN2, like PSEN1, could 
efficiently process APP in the cellular context. In a second set of experiments, we studied 
whether PSEN2 loss affected the γ-secretase activity by using a fluorescently labeled 
inhibitor (GSI) that specifically labeled active γ-secretase complexes (Fig.3F). Validation 
experiments confirmed that GSI was indeed able to prevent Aβ production in a cellular 
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context, leaving unaltered sAPPβ levels (Fig.3G). Mouse embryonic fibroblasts from 
wildtype mice showed labeling with the fluorescent GSI in punctate and diffuse structures, 
while the signal was massively reduced in fibroblasts deficient for both PSEN1 and PSEN2, 
thus demonstrating the specificity of the inhibitor (Fig.3H). Notably, cells that lacked either 
PSEN1 or PSEN2 showed decreased fluorescent GSI labeling compared to the WT, 
indicating that both PSEN1 and PSEN2 contribute to the cellular pool of active γ-secretase 
complexes (Fig.3H). This clearly suggests that the increased Aβ observed upon PSEN2 
silencing cannot be attributed to increased overall γ-secretase activity. All these results 
demonstrated that PSEN2 indeed contributes to the cleavage of APP similar to PSEN1 in the 
cellular context but nevertheless negatively regulates total Aβ levels.  
 
PSEN2 silencing impairs starvation-induced lysosomal pathway, Aβ clearance and leads 
to general protein accumulation 
Having ruled out an increased γ-secretase activity as the cause for increased Aβ production 
upon PSEN2 silencing, we investigated whether PSEN2 regulates Aβ clearance. Recently, we 
identified nutrient sensing mechanisms as a novel way that regulates lysosomal degradation 
of Aβ (Mondal and Bali et al., to be submitted). To test the possibility that PSEN2 plays a 
role in regulating nutrient signaling dependent degradation of Aβ, we measured Aβ levels in 
nutrient rich (Fed) and nutrient limiting (Starved) conditions, upon PSEN2 depletion. We 
observed that in fed conditions, PSEN2 silencing led to a significant increase in Aβ compared 
to control, confirming the results from our screen. When analyzing the effects of starvation, 
we observed a massive reduction (58.66 %, MEDGC FED vs MEDGC Starved) in Aβ levels 
compared to fed control (Fig.4A). However, in cells lacking PSEN2, nutrient limitation 
reduced Aβ only by 30.19 % (Fig.4A). This suggests that PSEN2 contributes to the 
regulation of nutrient signaling-mediated clearance of Aβ. Additionally, when we analyzed 
APP and APP-CTF levels upon PSEN2 silencing under different nutrient conditions, we 
observed that not only Aβ, but also APP levels were increased upon PSEN2 silencing 
(Fig.4B). In line with this, APP levels were shown to be regulated by the lysosomal 
degradation pathway (Xiao et al., 2015). Thus, we hypothesized that PSEN2 most likely 
regulates lysosomal function.  
 
Since our findings pointed towards a general rather than an Aβ-specific degradative 
impairment, we hypothesized that PSEN2 regulates the whole lysosomal protein degradation 
process. We therefore investigated whether general amyloid load was altered upon PSEN2 
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silencing. To this end we used ThioS staining and optimized the use of ThioS to detect 
amyloid in the cellular context (Mondal, Bali et al, under revision). Though there was not a 
significant difference in ThioS signal between PSEN2-depleted cells and control in fed 
condition, significantly higher ThioS-positive structures were detected upon PSEN2 silencing 
in the absence of nutrients (Fig.4C), again supporting a critical role for PSEN2 in modulating 
nutrient signaling-mediated protein degradation. Intracellular protein clearance driven by 
nutrient limitation is thought to occur through the autophagy-lysosomal pathway, and thus we 
asked whether PSEN2 has a role in its regulation (Lee et al, Cell, 2010 for PSEN1 role in 
autophagy). First, we investigated the status of LC3I-to-LC3II conversion, as index of 
autophagosomes maturation, eventually degraded in lysosomes. In presenilins depleted cells, 
we observed accumulation of LC3II in baseline conditions (in the absence of chloroquine), 
indicative of impairment in the autophagic pathway (Fig. 4D). As autophagic cargo 
degradation requires functional lysosomes, and considering that lysosomal pathway is also 
the major degradative pathway for luminal cargoes, we investigated the lysosomal status of 
cells lacking PSEN2. Since lysosomal acidification is linked to its function, we first assessed 
the state of acidic organelles in the cells (late endosomes and lysosomes), by using the pH-
sensitive dye LysoTracker-DND-99. No significant differences in LysoTracker levels were 
found upon PSEN2 silencing in fed conditions (Fig.4E). However, upon nutrient depletion, 
cells lacking PSEN2 completely failed to show the starvation-induced increase in 
LysoTracker levels that can be observed in control cells (Fig.4E). Consistent with our 
previous results, these data suggest that PSEN2 critically regulates nutrient sensing-mediated 
lysosomal degradation. 
 
 Under nutrient deprivation, lysosomal levels can be transcriptionally regulated by activation 
of the Coordinated Lysosomal Expression and Regulation (CLEAR) genes. Analysis of 
mRNA levels of CLEAR genes-network after PSEN2 silencing, in fed or starved conditions 
did not reveal major changes of the whole network. However, we observed a significant 
decrease specifically in the mRNA levels of ATP6V0E1, one of the subunits of the v-ATPase 
complex, required for lysosomal acidification, specifically under nutrient deprivation (Sup 
Fig.5). This finding could explain the reduction in LysoTracker positive structures in starved 
PSEN2-depleted cells. To verify the lysosomal status further, we analyzed the lysosomal 
marker Lysosomal Associated Membrane Protein 2 (LAMP2) by immunofluorescence and 
found that, while starvation strongly induced LAMP2 levels in scrambled condition, this was 
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not the case for PSEN2 depleted cells (Fig.4F), indicating that PSEN2 is required to mediate 
lysosomal function upon nutrient deprivation.  
 
Lysosomal acidification and Ca2+ efflux impairment upon deletion of PSEN2 
To understand the molecular mechanisms underlying lysosomal dysfunction in PSEN2 
depleted cells, we performed another set of focused experiments in mouse embryonic 
fibroblast (MEF) cells. First, we conducted lysosomal acidity analyses using LysoTracker 
and quantified lysosomal pH using fluorometric analysis with LysoSensor blue/yellow 
dextran. We observed a marked reduction in numbers of LysoTracker positive puncta in 
PSEN2 KO cells although the intensity of some of the remaining puncta achieved a normal 
LysoTracker signal intensity (Fig.5A). To confirm acidification impairment more directly, we 
assessed lysosomal pH using Lysosensor and observed a significantly increased lysosomal 
pH in PSEN2 KO cells (pH 5.20) compared to WT cells (pH 4.87) (Fig.5B). In addition, we 
found the v-ATPase activity to be markedly reduced in PS2KO MEF cells (Fig 5C). 
Furthermore, CTSD activity as assessed by Bodipy-FL-Pepstatin A assay was significantly 
reduced compared to that in WT cells (Fig. 5D). Increased lysosomal pH upon PSEN1 
deletion was shown to cause decreased lysosomal Ca2+ levels due to increased lysosomal Ca2+ 
efflux in a TRPML1 dependent manner (Lee et al., 2015). We investigated if PSEN2 loss 
also leads to a similar effect on Ca2+ homeostasis. Indeed, the abnormally elevated pH led to a 
significant reduction in lysosomal Ca2+ levels, as measured by low-affinity rhod-dextran 
(Fig.5E). This lysosomal Ca2+ decrease was associated with an elevation of cytosolic Ca2+ 
levels, as measured by Fura-2 (Fig.5E). We further investigated if, similar to PSEN1 deletion, 
loss of PSEN2 also led to decreased lysosomal Ca2+ levels due to hyperactive calcium 
channel, TRPML1. To this end, we tested if blocking the lysosomal NAADP dependent 
calcium channels by Ned-19 could prevent the increased cytosolic Ca2+ levels upon PSEN2 
deletion. The cytosolic Ca2+ elevation observed by OGB-AM (Oregon-Green 488 Bapta-1 
AM) in untreated PS2KO MEF cells was now corrected back to WT levels in the lysosomal 
NAADP dependent calcium channel inhibitor, Ned-19 treated PS2KO MEF cells (Fig.5F). 
Since TRPML1 is the main lysosomal NAADP dependent calcium channel, our data indicate 
that the increased cytosolic Ca2+ levels in PSEN2 KO are due to hyperactive TRPML1 
channel. Overall, we provide mechanistic evidence for a critical role of PSEN2 in regulating 
lysosomal Ca2+ in a TRPML1 dependent manner.  
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Dysfunctional lysosomes in mice lacking PSEN2 
Since APPPS1;PSEN2 KO mice displayed a significantly higher amyloid load than 
APPPS1;PSEN2 WT littermates, and having shown in a cellular context that PSEN2 
critically regulates lysosomes, we hypothesized that the augmented plaque pathology in the 
AD mouse model lacking PSEN2 could originate from defective lysosomal function. 
To our surprise, when assessed by western blotting, brain homogenates from APPPS1 mice 
lacking PSEN2 exhibited significantly higher levels of lysosomal proteins LAMP1 and 
LAMP2, as compared to APPPS1 PSEN2 WT littermates (Fig.6A-C). These findings were in 
apparent contrast with the decrease in LAMP2 observed upon PSEN2 silencing in vitro. 
However, further immunofluorescence examinations on APPPS1 mice brain slices revealed 
that conspicuous lysosomal structures (LAMP2 positive) were deposited around amyloid 
plaques (Fig.6D). It was previously shown that the majority of lysosomes surrounding 
plaques reside within swollen neuronal axons and lack functional proteases (Gowrishankar et 
al., 2015). Indeed, we found significantly higher amount of such plaque-associated LAMP2-
positive organelles in PSEN2 KO mice (Fig.6E, F). 
 
Of note, when we examined cortical areas devoid of plaques, we found that not only 
perinuclear levels of LAMP2 were significantly lower in neurons of PSEN2 KO mice, but 
were also associated with increased intraneuronal amyloid (Fig.6G-I), supporting defective 
intracellular Aβ clearance. We further validated this finding in primary neurons, where 
siRNA mediated silencing of PSEN2 led to decrease in LAMP2 protein levels (Sup Fig.6. 
Overall, these data indicate an impaired lysosomal function in the absence of PSEN2. We 
further looked at microglia specific lysosomal marker in these brain slices and found PSEN2 
KO mice have significantly lower level of CD68 compared to PSEN2 WT mice (Fig.6J). This 
result infers that microglia lacking PSEN2 have lower lysosomal levels. 
 
Impaired microglial clearance of amyloid upon PSEN2 depletion 
Microglia are the resident brain macrophages and represent the major phagocytes of the CNS. 
Once phagocytosed, the cargoes are eventually degraded in lysosomes. Hence, a functional 
lysosomal degradation pathway is crucial for the maintenance of microglial phagocytosis. 
Since PSEN2 has been shown to be the predominant presenilin in microglia we hypothesized 
that depletion of PSEN2 could impair lysosomal pathway and thereby its phagocytic capacity 
(Jayadev et al., 2010). To understand whether presenilin depletion in microglia affects 
lysosomal function and if this has an impact on its amyloid clearance capacity, we performed 
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siRNA-mediated silencing of PSEN1, PSEN2 or PEN2 in BV2-microglia cells. The 
efficiency of the knockdown was confirmed by Western blotting (Fig. 7A, B).  
 
Consistently with our previous data, depletion of either PSEN1 or PSEN2 led to a significant 
decrease in LAMP2 immunoreactivity (Fig.7C, D) as well as  LysoTracker- signal (Fig. 7E, 
F). Of note, 3D reconstruction and quantification of the LysoTracker puncta confirmed the 
reduction in number of lysotracker-positive organelles upon PSEN1 and PSEN2 depletion 
(Fig.7G), but not upon other γ-secretase components, such as PEN2, APH1 and NCT (Sup 
Fig.7). We also validate our findings in primary microglia from WT and PSEN2 KO mice 
and found primary microglia lacking PSEN2 to have significantly less LysoTracker signal 
(Fig.7H, I). Importantly, interference with γ-secretase enzymatic activity without altering 
PSEN levels does not impair lysosomal acidification, as demonstrated by the treatment of 
BV2 cells with the γ-secretase inhibitor DAPT which even led to a slight increase in 
LysoTracker signal compared to controls (Fig.7J, K).These finding indicate that, apart from 
their well-documented role in the production of Aβ through the γ-secretase complex, 
presenilins have additional γ-secretase independent roles in maintaining the cells’ degradative 
organelles.  
 
Next, we investigated whether the impaired lysosomal state observed upon PSEN2 depletion 
would affect the microglial phagocytic capacity. To this end, we assessed microglia-mediated 
Aβ clearance by measuring residual levels of Aβ upon overnight incubation (Sup Fig.8). 
Interestingly, depletion of PSEN2 significantly reduced the microglial phagocytic capacity, 
as evidenced by the increase in residual Aβ in the assay medium as compared to control 
condition (Fig.7L). PSEN1 silencing also impaired Aβ clearance albeit to a much lesser 
extent as compared to PSEN2, whereas silencing of other γ-secretase components, such as 
PEN2, APH1 and NCT did not alter Aβ clearance (Fig.7L). In addition, BV2 microglia 
treated with DAPT also showed normal Aβ clearance rates (Fig.7M), again supporting a γ-
secretase independent mechanism for presenilin-mediated control of lysosomal function. 
 
Taken together our results demonstrate for the first time, that PSEN2, unlike PSEN1, 
negatively regulates Aβ levels. Till this date, no specific function of PSEN2 in APP cleavage 
is assigned. Our results, for the first time, demonstrate that these paralogues have 
diametrically opposite function – antagonizing each other- not at the catalytic level of the γ-
secretase cleavages but at the regulation of the end product, namely, Aβ. It was demonstrated 
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recently by Sannerud et al., that PSEN2 localization is majorly restricted to late 
endosomes/lysosomes whereas PSEN1 is more broadly distributed in the cell (Sannerud et 
al., 2016). Taking into account our present data on the effect of PSEN2 silencing on 
lysosomal function and our recent finding linking nutrient sensing and lysosomal degradation 
we propose the following model to explain the functional dichotomy of the two presenilins. 
According to this model, PSEN1 is predominantly located in organelles in the biosynthetic 
pathway and is mainly involved in the production of Aβ. PSEN2 on the other hand is located 
in late endosome/lysosomes where it regulates lysosomal degradation pathway by possibly 
integrating nutrient signaling. Presenilin double knock-out cells have been shown to have 
dysfunctional nutrient sensing ability along with an impaired lysosomal degradation pathway 
which were rescued by expressing PSEN1 or PSEN2 (Reddy et al., 2016). Though the 
authors imply functional redundancy for the two presenilins, we believe that in homeostatic 
conditions, PSEN2, by virtue of its presence on late endosomes/lysosomes, regulates nutrient 
signaling and lysosomal degradation pathway.  
 
Transcription factor TFEB is one of the major regulators of lysosomal biogenesis upon 
nutrient deprivation and was shown to be involved in mediating presenilin-loss induced 
lysosomal dysfunction (Reddy et al., 2016).  We investigated whether starvation-induced 
nuclear translocation of TFEB, required for its transcriptional activity, was impaired in 
PSEN2 depleted cells. By using HeLa cells stably expressing GFP-tagged TFEB, we found 
that TFEB nuclear translocation was not significantly affected upon PSEN2 depletion (Sup 
Fig. 9A, B). This is in line with our data from the analysis of TFEB-mediated CLEAR 
network genes activation, which was not altered upon PSEN silencing. These data so far 
seem to exclude an impairment of TFEB-mediated lysosomal biogenesis, however the 
contribution of other transcription factors (such as TFE3, MITF and FOXO3), either 
individually or in concert, might explain the observed decrease in lysosomal markers. One of 
the upstream signaling cascades that could link nutrient signaling, lysosomal function and 
protein level is the mTOR signaling pathway. mTOR is the central kinase, which regulate 
protein synthesis and higher mTOR activity suppresses protein clearance. To investigate 
mTOR activity, we looked at 1) phosphorylation status of downstream substrate of mTOR 
and 2) mTOR/LAMP2 localization. We found no significant changes in mTOR activity 
assessed by phosphorylation status of its downstream substrates (S6K, Ulk1, 4EBP1), 
suggesting that mTOR signaling does not mediate the lysosomal dysfunction observed upon 
nutrient deprivation in PSEN2 depletion (Sup Fig.9C). Additionally, we also did not observe 
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any significant difference in mTOR/LAMP2 localization between control and PSEN2 
depleted condition (Sup Fig.9D). Considering that mTOR pathway also regulates TFEB-
mediated lysosomal biogenesis, we could rule out a direct involvement of TFEB/mTOR 
pathway in the PS2 depletion-induced lysosomal defects. 
 
We observed the effect of PSEN2 deficiency on Aβ clearance both in neuronal as well as 
microglial cells. Neurons are generally thought to be involved in Aβ generation and microglia 
in Aβ clearance. Our results, however, show the existence of an intracellular lysosomal Aβ 
degradation pathway in both neurons and microglia and a crucial role for PSEN2 in the 
regulation of this pathway. We believe that our results also suggest that inhibition of γ-
secretase should be carried out not on PSEN2-containing γ-secretase but on PSEN1-
containing complexes. Interestingly, PSEN2-sparing inhibitors are available (Borgegård et 
al., 2012). Since γ-secretase inhibitors (GSIs) produced adverse effects on cognition in the 
recent clinical trials (Karran et al., 2011; Sambamurti et al., 2011; Schor, 2011) and also that 
GSIs are potentially toxic compounds, our results caution that specific or more PSEN2-
inhibition could cause adverse effects or even worsen the pathology.  
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Materials and Methods 
Cell culture and AD mouse model 
HeLa cells expressing the Swedish mutant of APP (HeLa swAPP) cells were cultured in 
Dulbecco’s modified Eagle’s medium (Invitrogen) at 37°C and 5% CO2 in a humidified 
incubator. Media were supplemented with 10% (v/v) fetal calf serum (Invitrogen), 1% (v/v) 
penicillin/streptomycin (Gibco) 0.1%(v/v) G418 antibiotic (Carl Roth) and 0.1%(v/v)  
selective antibiotic Zeocin (Invitrogen).Primary neurons isolated from E-16 embryos were 
cultured in NBM (Invirtogen) supplemented with B27 (Invitrogen). Mouse Embryonic 
Fibroblasts lines (MEFs), acquired from Dr. Bart De Strooper (Leuven Institute for 
Neurodegenerative Disease, Belgium), and Murine neuroblastoma (N2a) were maintained in 
DMEM (Invitrogen, 11995-073) with 10% FBS (Hyclone,), and penicillin/streptomycin 
(Invitrogen) at 37°C and 5% CO2. AD transgenic PS2 knockout mice were generated from 
B6-Tg (Thy1-APP KM670/671NLjuc; Thy1-PS1 L166Pjuc) mice (Radde et al., 2006) 
 
siRNAs 
All siRNAs are chemically synthesized stealthTM siRNAs from Invitrogen. A pool of 4 
different siRNA against all the proteases were transfected into HeLa swAPP cells.  
 
siRNA Reverse Transfection 
Transfection complexes in quadruplicates were prepared in Opti-mem serum-free medium 
(Invitrogen) by mixing 0.3 µL of Oligofectamine (Invitrogen) and 5 nM of siRNA. HeLa sw 
APP cells at a density of 3500 cells/well were seeded in 96-well format after addition of 
transfection complexes.  
 
siRNA Forward Transfection in primary neurons 
Transfection complexes in quadruplicates were prepared in NBM medium (Invitrogen) by 
mixing 0.35 µL of RNAi max (Invitrogen) and incubated for 5 mins (Reagent 1). 50 nM of 
siRNA was mixed in 10 ul of NBM medium (Invitrogen) and also incubated for 5 mins 
(Reagent 2). Both the reagents were mixed and incubated for 20 minutes followed by 
addition on primary neurons. Primary neurons were 5-6 days in culture before transfections. 
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Cell proliferation assay   
69 h after siRNA transfection cell viability was analyzed with an alamar blue cell 
proliferation assay  (AbD Serotec BUF012B) using a Plate reader with excitation at 544nm 
and emission at 590nm (Molecular Devices Spectramax Gemini XS) according to the 
manufacturer’s recommended protocol. 
 
Treatment with γ-Secretase inhibitors 
10,000 HeLa-swe APP cells were seeded in each well of a 96 well plate (Nunc) a day prior to 
inhibitor treatment. On the day of inhibitor treatment medium was replaced with fresh 
medium containing DAPT (Sigma) or fluorescent γ- secretase inhibitor . Cells were incubated 
with these inhibitors for 3 hours. Alamar blue measurements were taken to determine cell 
viability using SpectraMAX GeminiXS (Molecular Devices) at an excitation wavelength of 
544nm and emission at 590nm. Supernatant was collected and frozen at -20°C. 
Electrochemiluminescence assay was performed to determine the amount of Aβ and sAPPβ 
secreted by these cells. 
 
SDS-PAGE and Immunoblotting 
For detection of intracellular proteins, whole cell extracts were prepared using a lysis buffer 
(1%NP40 and 0.1% SDS) supplemented with proteinase inhibitors. Extracts were subjected 
to SDS-PAGE using pre-cast gels (Invitrogen). In all cases, gel loading was normalized to 
total protein content in the cell extract (Using BCA assay). Proteins were transferred onto 
nitrocellulose membranes, which were then blocked with PBS containing 5% (w/v) dry skim 
milk for at least 1 h at room temperature. The membranes were then incubated with different 
primary antibody 6E10 (Covance), APP C terminal antibody (Sigma), BACE1 (Prosci), 
PSEN1 (Epitomics), PSEN2 (Epitomics), GAPDH (Meridian life sciences) followed by the 
appropriate horseradish peroxidase-conjugated secondary antibody for at least 1 h at room 
temperature. Both antibodies were diluted in 5% milk/PBS 0.05% Tween-20. Immunoblotted 
proteins were detected using an enhanced chemiluminescence kit (Pierce). 
 
Electrochemiluminescence (ECL) Assay 
MSD 96-Well MULTI-ARRAY Human Multiplex Kits were used (Meso Scale Discovery) to 
measure the level of Aβ38, Aβ40 and Aβ42. For the measurment of Aβ40 and sAPPβ 384 
well MULTI-ARRAY Human Electrochemiluminescence plate was used following the 
instructions of the manufacturer.  
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Plasmid  Transfection 
HeLa swAPP cells were transfected with mock plasmid (pCDNA), or plasmid expressing 
mouse wild type Presenilin2 (PSEN2) using Lipofectamine 2000 reagent (Invitrogen), 
according to the manufacturer's protocol. 24 h after transfection the medium exchanged and 
conditioned medium was collected for 3 h and this was analyzed for Aβ40 using the Meso 
Scale Discovery Electrochemiluminescence (ECL) platform as described in the previous 
section. 
 
RT-PCR analysis 
72 h after transfection, RNA was prepared using the RNeasy Plus Mini kit (Qiagen cat. 
74136). Purity of RNAs (A260/A280 , A260/A230) and concentration was measured using 
Nanodrop spectrophotometer. 2 µg of total RNA was used for reverse transcription with 
oligo-dT primer using Superscript first-strand synthesis system for RT-PCR (Invitrogen) 
according to the manufacturer’s recommended protocol. RT-PCR analysis was performed 
uing Taq man probes following manufacturer’s instructions using a 7900HT Fast Real-Time 
PCR system (Applied Biosystems). 
Assays were performed in Quadruplicates and expression levels of genes were normalized 
against GAPDH controls. Levels of Med-GC cDNA as an internal control were normalized to 
GAPDH cDNA according to the ΔΔCt method. 
 
Localization of active γ-secretase complexes by fluorescently tagged γ-secretase 
inhibitor. 
Mouse embryonic fibroblast cells with Presenilin 1 KO, Presenilin 2 KO, Presenilin 1/2 KO 
or Wild-type were treated with the γ-secretase inhibitor derivative L-685,458 tagged with 
Quasar 670 at a final concentration of 1 µM for 10 minutes. The cells were fixed, stained 
with DAPI and mounted. The cells were visualized using the Confocal Laser Scanning 
Microscope Leica TCS SP8. 
 
LysoTracker and active CTSD imaging 
Immunocytochemistry was performed as previously described (Lee et al 2010).  Organelles 
with low internal pH were labeled by LysoTracker DND-99 dye at a final concentration of 
100 nM for 60 min. Active CTSD was labeled by adding Bodipy-FL-pepstatin A directly to 
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the medium at a final concentration of 1 mg/ml for 1 hr. Following wash with PBS, add new 
medium for live imaging. 
Lysosomal pH measurement 
Cells (2 x 103) were plated in 96well-plate for 48 hrs. Lysosensor yellow/blue-dextran (250 
mg) was incubated for 24 hrs. Un-uptaken Lysosensor were washed with PBS then read in a 
Wallac Victor 2 fluorimeter (Perkin Elmer) with Ex. 355nm and Em. 440nm/535nm. The pH 
values were determined from the standard curve generated via the pH calibration samples. 
 
Vacuolar-type H+-ATPase activity assay 
Activities were measured by v-ATPase assay kit (Novus Bio, 601-0120) base on 
manufactures manual. 4 mg of microsomal proteins were used for each ATPase assay. Assay 
samples were incubated with ATP contained substrate buffer mix and after 30 min 
incubation, ATP hydrolysis activity was measured with 650 nm.  
 
Ca2+ Measurements 
Cells were plated on glass bottom dishes the night before treatment. For baseline calcium 
measurements, cells were incubated with 25mg/mL rhod-dextran for 12 hrs before imaging. 
After incubation, cells were chased for 30 mins in complete media before it was exchanged 
for calcium-free HBSS (Invitrogen) and then cells were imaged. The mean intensity of the 
rhod signal of single cells was analyzed using ImageJ (NIH). For all cytosolic measurements, 
cells were incubated with 2µM Fura-2 AM (Life Technologies) for 1 hour and then chased 
with complete medium for 30 minutes. Cells were washed with HBSS (Invitrogen) and 
imaged and analyzed using ImageJ (NIH). 
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Figure 1 
(This figure was part of Dr. Jitin Bali’s PhD thesis) 
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Figure 1: RNAi of human proteases identify PSEN2 as a negative regulator of Aβ levels 
 
A) Scheme of the protease screen. B) HeLa-swe APP cells transfected with all the proteases 
present in human genome and graph showing Z-scores of Aβ levels from the siRNA protease 
screen. PSEN2 KD leads to an increase in Aβ levels. C) HeLa-swe APP cells transfected with 
siRNA against APP, BACE1, PSEN1, PSEN2 and PSEN1+2 show an increase in Aβ only in 
PSEN2 knock down cells. Western blot probed against PSEN2 show effective knockdown. 
GAPDH was used as a loading control. D) Increased Aβ upon PS2 silencing detected in 
conditioned medium by blotting with 6E10 antibody. HeLa cells stably expressing swe-APP 
were transfected with siRNA against PSEN1, PSEN2 or PSEN1/2. Conditioned medium were 
used to perform immunoprecipitation with 6E10 antibody followed by western blot analysis. 
E) HeLa-swe APP cells transfected with esiRNA against APP, BACE1, PSEN1, PSEN2, 
NCT and probed for Aβ level. F) HeLa-swe APP cells transfected with siRNA against 
PSEN2 and rescued with mice PSEN2 leads to the reduction of Aβ levels. MEDGC and 
PCDNA were used as controls. * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 2 
(sub-figures A, B and C were part of Dr. Jitin Bali’s  PhD thesis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D 
WT KO WT 
KO 
WT KO
0
2000
4000
6000
8000
10000
Pl
aq
ue
 S
iz
e 
(
m
3 )
****
0
50
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
55
00
0
60
00
0
65
00
0
70
00
0
75
00
0
0
2
4
100
200
300
400
500
N
um
be
r o
f v
al
ue
s
Histogram of Plaque Size Distribution
WT
KO
m3WT KO
0
1 105
2 105
3 105
4 105
5 105
Pl
aq
ue
 V
ol
um
e/
 F
ie
ld
 (
m
3 )
 
****
WT KO
0
10
20
30
40
50
N
o.
 P
la
qu
es
 / 
Fi
el
d
**
E F 
G H I 
J 
Abeta ELISA from APPPS1 mice 
ThioS
Fig. 2
0 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
 
Arc PS2(+/+) 
 
Arc PS2(+/-) 
 
Arc PS2(-/-) 
Ab
et
a 
le
ve
ls
 (A
.U
)
**
***
A B C
 118 
Figure 2: PSEN2 deletion aggravates amyloid pathology in AD transgenic mice 
 
A) PSEN2 knockdown leads to an increase in Aβ level in mouse primary neurons. Mouse 
primary neurons were transfected with siRNA against PSEN2. Aβ was measured in 
conditioned medium from the neurons and the neuronal lysates were used for western 
blotting. B) Immunostaining was performed to further validate the knockdown efficiency C) 
Aβ levels in Arc AD mice with heterozygous or homozygous PS2 deletion D) Thioflavin S 
staining in brain slices. Thioflavin S (Thio S) staining was performed to stain for amyloid 
plaques in brain slices from 6 month old AD PSEN2 WT (WT) and AD PSEN2 KO (KO) 
mice. E and F) 3D reconstruction of amyloid plaques from the brain slices. 3D reconstruction 
of amyloid plaques in brain slices from 6-month-old AD PSEN2 WT (WT) and AD PSEN2 
KO (KO) mice was performed by Imaris software. G and H) Amyloid plaque volume and 
size from the brain slices in brain slices from 6 month old AD PSEN2 WT (WT) and AD 
PSEN2 KO (KO) mice. I) Amyloid plaque mean intensity in brain slices from 6 month old 
AD PSEN2 WT (WT) and AD PSEN2 KO (KO) mice. I) Histogram depicting amyloid 
plaque size distribution in brain slices from 6 month old AD PSEN2 WT (WT) and AD 
PSEN2 KO (KO) mice. * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 3 
(This figure was part of Dr. Jitin Bali’s PhD thesis) 
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Figure 3: Increased Aβ upon PSEN2 silencing is not due to increased γ-secretase activity 
A) Efficient knockdown of mRNA levels revealed by real-time RT-PCR showing a reduction 
in PSEN2 mRNA level only in PSEN2 knockdown condition. MEDGC was used as a 
transfection control and mRNA levels were normalized to GAPDH. B) Efficient knockdown 
of mRNA levels revealed by real-time RT-PCR showing a reduction in PSEN1 mRNA level 
only in PSEN1 knockdown condition. MEDGC was used as a transfection control and 
mRNA levels were normalized to GAPDH. C) Efficient knockdown of mRNA levels 
revealed by real-time RT-PCR showing a reduction in PSEN2 mRNA level in PSEN2 
knockdown condition. No change in PSEN2 mRNA was observed in APP, BACE1, PS1, 
APH1a and NCT knock down cells. MEDGC was used as a transfection control and mRNA 
levels were normalized to GAPDH. D) HeLa-sweAPP cells were transfected with pooled 
siRNAs (4 different siRNAs) against PSNE1, PSEN2 or PSEN1+2 or a control-siRNA 
(MEDGC) and cell lysates were analyzed by Western Blot using the respective antibodies. 
GAPDH was used as a protein loading control. E) HeLa-sweAPP cells were transfected with 
pooled siRNAs (4 different siRNAs) against PSNE1, PSEN2 or PSEN1+2 or a control-
siRNA (MEDGC) and cell lysates were analyzed by Western Blot using APP C terminal 
specific antibody. GAPDH was used as a protein loading control. F) HeLa-sweAPP cells 
treated with γ-secretase inhibitors (DAPT and fluorescent labelled γ-secretase  inhibitor) and 
probed for Aβ (black) and sAPPβ (grey) levels. G) MEF cells treated with fluorescent 
labelled γ-secretase inhibitor (red). DAPI (blue) was used to stain nucleus. H) HeLa Kyoto 
BAC-Nicastrin cells were transfected with pooled siRNAs (4 different siRNAs) against 
PSEN2 or control-siRNA (MEDGC). Cell lysates were used for immnuoporecipitation 
followed by Western Blot analysis using PSEN1 and PSEN2 specific antibody. * p<0.05, ** 
p<0.01, *** p<0.001. 
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Figure 4 
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Figure 4: PSEN2 silencing impairs starvation induced lysosomal pathway, Aβ clearance 
and leads to general protein accumulation 
A) HeLa-Swe APP cells were transfected with siRNA against PSEN1 or PSEN2. After 69 
hours the medium was replaced with either nutrient rich (fed) or nutrient deprived (starved) 
medium for 3 hours. Aβ levels in the conditioned medium were analyzed by an ECL assay. 
B) HeLa-Swe APP cells were transfected with siRNA against PSEN1 or PSEN2. After 69 
hours the medium was replaced with either nutrient rich (fed) or nutrient deprived (starved) 
medium for 3 hours. Cell lysates were analyzed by Western Blot using APP C terminal 
specific antibody and PSEN2 antibody. GAPDH was used as a loading control. C) HeLa-Swe 
APP cells were transfected with siRNA against PSEN1 or PSEN2. After 69 hours the 
medium was replaced with either nutrient rich (fed) or nutrient deprived (starved) medium for 
3 hours. Cells were fixed and stained with ThioS (green) and processed for confocal imaging. 
D) PSEN silencing leads to impaired Autophagic flux. HeLa-Swe APP cells were transfected 
with siRNA against PSEN1, PSEN2 or PSEN1/2. After 69 hours the medium was replaced 
with either nutrient rich (fed) or nutrient deprived (starved) medium for 3 hours with or 
without chloroquine (CQ). Cell lysates were analyzed by Western Blot using antibody against 
LC3 and PSEN2. GAPDH and β-actin were used as loading control. E) HeLa-Swe APP cells 
were transfected with siRNA against PSEN1 or PSEN2. After 69 hours the medium was 
replaced with either nutrient rich (fed) or nutrient deprived (starved) medium for 3 hours. 
Cells were incubated with LysoTracker Red DND-99 (red) for 1.5 hours and processed for 
confocal imaging. F) HeLa-Swe APP cells were transfected with siRNA against PSEN1 or 
PSEN2. After 69 hours the medium was replaced with either nutrient rich (fed) or nutrient 
deprived (starved) medium for 3 hours. Cells were fixed and probed with anti-Lamp2 
antibody (red) and processed for confocal imaging. * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 5 
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Figure 5: Lysosomal acidification and Ca2+ efflux impairment in PS2KO MEF cells 
(A) Lysosomal acidification visualized by LysoTracker is reduced in PS2KO MEF cells. 
Scale bars 50, 10µm. (B) Lysosomal pH is increased in PS2KO MEF cells (n=12). (C) v-
ATPase activity is reduced in PS2KO MEF cells (n=5). (D) In vivo CTSD activity is reduced 
in PS2KO MEF cells. Scale bars 20µm. (E) Lysosomal Ca2+ is reduced (WT: n=30; PS2KO 
n=28) and cytosolic Ca2+ (WT: n=30; PS2KO n=30) is elevated in PS2KO MEF cells. F. The 
cytosolic Ca2+ elevation induced by OGB-AM in untreated PS2KO MEF cells (Control; WT 
vs PS2KO) was reduced back to WT levels in the lysosomal NAADP dependent calcium 
channel inhibitor, Ned-19 treated PS2KO MEF cells (Ned-19; WT vs PS2KO). * p<0.05, ** 
p<0.01, *** p<0.001. 
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Figure 6 
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Figure 6: Dysfunctional lysosomes in mice lacking PSEN2 
A) Western blot analysis of lysates from cortex of wild-type AD and PSEN2 KO-AD mice. 
SDS soluble fractions of cortical samples were analyzed by western blotting with antibodies 
against Lamp1 and Lamp2. B & C) Graph showing quantification in A. D) 6E10 and Lamp2 
antibody staining on brain slices of wild-type AD and PSEN2 KO-AD mice. E & F) Graph 
showing the quantification in D. G) 6E10 and Lamp2 antibody staining on brain slices of 
wild-type AD and PSEN2 KO-AD mice in areas devoid of plaques. H & I) Graph showing 
quantification in G. J) CD68 and Iba1 staining on brain slices of wild-type AD and PSEN2 
KO-AD mice. CD 68 levels are significantly reduced in microglia from PSEN2 KO-AD mice 
compared to wild-type AD mice, indicating lower lysosomal levels in these microglia. * 
p<0.05, ** p<0.01, *** p<0.001. 
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Figure 7 
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 128 
Figure 7: Impaired microglial clearance of amyloid upon PSEN2 depletion 
A) Western blot showing confirmation of siRNA knockdown in BV microglia. BV2 
microglia cells were transfected with control siRNA (MEDGC) or siRNA against PSEN1, 
PSEN2 or Pen2. After 65 hours the cells were lysed and the cell lysates were used for 
western blotting. B) Graph showing quantification for the western blot. C) LAMP2 
immunostaining in BV2 microglia cells. BV2 microglia cells were transfected with control 
siRNA (MEDGC) or siRNA against PSEN1or PSEN2. After 65 hours, cells were PFA fixed, 
immunostained and processed for confocal imaging. D) Graph showing quantification for 
LAMP2 immunostaining in BV2 microglia cells. E) LysoTracker staining in BV2 microglia 
cells. BV2 microglia cells were transfected with control siRNA (MEDGC) or siRNA against 
PSEN1, PSEN2 or Pen2. After 48 hours, cells were incubated with LysoTracker Red DND-
99 (red) for 1.5 hours and processed for confocal imaging. F) Graph showing quantification 
for LysoTracker staining in BV2 microglia cells. G) 3D reconstruction of LysoTracker 
puncta in BV2 microglia. BV2 microglia cells were transfected with control siRNA 
(MEDGC) or siRNA against PSEN1, PSEN2 or Pen2. After 48 hours, cells were incubated 
with LysoTracker Red DND-99 (red) for 1.5 hours and processed for confocal imaging. 3D 
reconstruction of LystoTracker puncta was performed by Imaris software. H) LysoTracker 
staining in primary microglia isolated from WT and PS2 KO mice. Cells were incubated with 
LysoTracker Red DND-99 (red) for 1.5 hours and processed for confocal imaging. I) Graph 
showing quantification in H. J & K) LysoTracker staining in BV2 microglia cells and graph 
showing quantification of the lysotracker signal. BV2 microglia cells were treated with 
DMSO or DAPT for 23 hours, cells were incubated with LysoTracker Red DND-99 (red) for 
1.5 hours and processed for confocal imaging. A) Graph showing residual Aβ levels after Aβ 
clearance assay in BV2 microglia. BV2 microglia cells were transfected with control siRNA 
(MEDGC) or siRNA against PSEN1, PSEN2, PEN2, APH1 (a,b and c) and Nicastrin. After 
48 hours, cells were incubated with 5 % serum containing conditioned medium from Hela 
sweAPP cells for 16 hours. Residual Aβ was measured by ECL assay. B) Graph showing 
residual Aβ levels after Aβ clearance assay in BV2 microglia. BV2 microglia cells were 
treated with DMSO or DAPT for 6 hours, cells were then incubated with 5 % serum 
containing conditioned medium (DMSO or DAPT) from Hela sweAPP cells for 16 hours. 
Residual Aβ was measured by ECL assay. * p<0.05, ** p<0.01, *** p<0.001. 
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Supplementary Figure 1 (This figure was part of Dr. Jitin Bali’s PhD thesis) 
 
Supplementary Figure 1: PSEN2 deficiency increased all versions of the major Aβ 
species  
HeLa-swe APP cells were transfected with individual siRNAs for PSEN1, PSEN2 and pooled 
siRNA against APP, BACE, PEN2, PSEN1, PSEN2 and PSEN1+2. The three different 
species of Aβ (38, 40 and 42) are increased upon PSEN2 silencing. 
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Supplementary Figure 2 (This figure was part of Dr. Jitin Bali’s  PhD thesis) 
 
 
Supplementary Figure 2: PSEN2-loss does not impair secretion of secreted alkaline 
phosphatase (SEAP) 
Graph showing SEAP levels. Different MEF cell lines (PSEN1KO, PSEN2KO, PSEN-1/2 
KO) were transfected with pSEAP. 24 hours after transfection conditioned medium were 
assayed for SEAP levels. 
 
Supplementary Figure 3 (This figure was part of Dr. Jitin Bali’s  PhD thesis) 
 
 
 
Supplementary Figure 3: PSEN2 silencing in HEK-wt APP cells leads to increased Aβ 
levels 
Graph showing Aβ and sAPPβ levels. HEK-wt APP cells were transfected with siRNA 
against PSEN2 and APP. Conditioned medium were used to analyze Aβ (dark grey) and 
sAPPβ (light grey) levels by ECL assay. 
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Supplementary Figure 4 
 
 
Supplementary Figure 4: Plaque mean intensity in wild-type AD and PS2KO-AD mice 
Graph showing quantification of amyloid plaques measured by ThioS staining in wild-type 
Ad and PS2KO-AD mice.  
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Supplementary Figure 5 
 
Supplementary Figure 5: PSEN silencing does not impair expression of CLEAR 
network (lysosomal biogenesis) genes 
HeLa-Swe APP cells were transfected with siRNA against PSEN2 or control (MEDGC). 
After 48 hours the medium was replaced with either nutrient rich (fed) or nutrient deprived 
(starved) medium. Cells were processed for RNA extraction followed by cDNA preparation. 
CLEAR network gene expression analysis was performed using. Fold change increase 
(green) or fold change decrease (red) for different genes are indicated.  
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Supplementary Figure 6 
 
Supplementary Figure 6: PSEN silencing in mouse primary neurons reduces LAMP2 
levels 
Mouse primary neurons were transfected with siRNA against PSEN1, PSEN2 or PSEN1+2. 
Cell lysates were analyzed by western blot using antibody against LAMP2 and PSEN2. 
GAPDH was used as loading control  
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Supplementary Figure 7 
 
Supplementary Figure 7: LysoTracker staining in BV2 microglia cells and graph 
showing quantification of the lysotracker signal.  
BV2 microglia cells were transfected with control siRNA (MEDGC) or siRNA against 
PSEN1, PSEN2 or PEN2. After 64 hours, cells were incubated with LysoTracker Red DND-
99 (red) for 1.5 hours and processed for confocal imaging. * p<0.05, ** p<0.01, *** p<0.001. 
 
 
Supplementary Figure 8 
 
Supplementary Figure 8: Schematic representation of .Aβ clearance assay in BV2 
microglia 
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Supplementary Figure 9: 
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Supplementary Figure 9: PSEN2-loss dependent lysosomal deficiency is not due to 
defective mTOR/TFEB signaling 
A) HeLa cells stably expressing TFEB-GFP were transfected with siRNA against PSEN2 or 
control (MEDGC). After 69 hours the medium was replaced with either nutrient rich (fed) or 
nutrient deprived (starved) medium for 1, 2 or 3 hours. Cells were fixed and processed for 
confocal imaging. DAPI (blue) is used to stain the nucleus. B) Graph showing levels of 
TFEB-GFP translocated into the nucleus (1hr, 2 hr, 3hr) relative to control (fed). C) HeLa-
Swe APP cells were transfected with siRNA against PSEN2 or control (MedGC). Cells were 
incubated with either nutrient rich medium (NM), amino acid starved medium (AA) or serum 
starved medium (SM). Lysates were analyzed by Western Blot with antibody against 
phosphor/total TSC2, S6 kinase, ULK1, 4EBP1. Lysates from cells treated with either Torin 
or PI103 were used as controls. β-Actin was used as loading control. D) HeLa-Swe APP 
cells were transfected with siRNA against PSEN2 or control (MEDGC). 69 hours after 
transfection cells were incubated with either nutrient rich medium (Fed) or nutrient deficient 
medium (Starved) for 3 hours. Cells were fixed. Cells were stained with antibody against 
Lamp2 (green) or mTOR (red) and processed for confocal imaging. 
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Chapter 4 
 
γ-Secretase Activating Protein (GSAP) does not specifically regulate γ-cleavage of APP 
but regulates APP levels in HeLa cells. 
 
This chapter was published in two parts: (Udayar and Rajendran, Matters 2016 and Udayar 
and Rajendran, Matters Select 2016) 
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Abstract 
Alzheimer’s disease (AD) is characterized by the cerebral accumulation of β-amyloid (Aβ) 
peptide, which is generated by proteolytic processing of the amyloid precursor protein (APP) 
by β- and γ-secretases. γ-Secretase is an attractive therapeutic target for the treatment of 
AD; however, it also cleaves several other protein substrates including Notch. A recent study 
reported a novel γ-secretase activating protein (GSAP) that is processed from a holoprotein to 
a 16 kDa active form, which interacts with the γ-secretase complex to selectively regulate β-
amyloid peptide generation from APP, without affecting Notch[1]. Since this finding implies 
that the GSAP processing might be an important target for AD, we tested if this finding could 
be reproducible. Here we show that processing of GSAP is not required for Aβ production, 
and rather than specifically regulating γ-secretase cleavage of APP, GSAP also regulated the 
levels of sAPPβ, the ectodomain shedded by the β-secretase processing of APP. Thus, our 
results caution the validity of GSAP as the γ-secretase-specific therapeutic target for Aβ 
production in AD. 
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Introduction 
γ-Secretase is an attractive therapeutic target for the treatment of Alzheimer’s disease (AD); 
however, it also cleaves several other protein substrates including Notch. γ-Secretase is a 
multimeric transmembrane protein complex composed of presenilin-1 (PS1)/presenilin-2 
(PS2), Nicastrin, Aph-1, and Pen2[2]. Familial mutations in APP, PS1, or PS2 that increase 
the production of the amyloidogenic Aβ42 peptide have been associated with early-onset 
AD[3][4]. Thus, γ-secretase is an attractive therapeutic target for AD. However, γ-secretase 
inhibition affects the cleavage of physiologically important substrates such as Notch, and also 
the ε-cleavage of APP that releases the APP intracellular domain (AICD). The failure of 
recent clinical trials with γ-secretase inhibitors highlights the need for Aβ-specific inhibitors 
that spare the cleavage of Notch and the release of AICD[5][6][7]. Recent studies discovered 
that an anti-cancer compound, imatinib (also known as Gleevec), inhibited Aβ peptides 
without affecting AICD cleavage. In a hunt for the mechanism through which imatinib 
produced this effect, He et al. identified a novel γ-secretase activating protein (GSAP)[7]. The 
authors demonstrated that GSAP is synthesized as a holoprotein called pigeon homologue 
protein (PION) that is readily processed to a 16 kDa fragment. The authors further showed 
that this 16 kDa GSAP is the predominant form under steady-state conditions, which 
interacted with γ-secretase to modulate Aβ production. They also showed that overexpression 
of GSAP increased, whereas its silencing decreased, Aβ levels. Since this finding implies that 
the GSAP processing might be an important target for AD, we tested if this finding could be 
reproducible so that GSAP can be established as a reliable target for the treatment of AD. 
 
Objective 
Here we wanted to study if processing of GSAP is required for Aβ production, and if GSAP 
specifically affects the γ-secretase processing of APP. 
 
Results and Discussion 
Since GSAP has been shown to be processed to a 16 kDa fragment by an unknown protease 
and since this protease could be an ideal therapeutic target for AD[8], we intended to perform 
a protease RNA interference (RNAi) screen to identify the protease(s) responsible for the 
cleavage of GSAP. To establish conditions for detecting GSAP cleavage, we first expressed 
full-length GSAP (also called PION) in cells that produced robust amounts of Aβ[9]. 
Unexpectedly, we did not detect any 16 kDa cleavage product of GSAP/PION, and the full-
length levels of GSAP/PION remained largely unaltered in all the cells that we tested, namely 
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N2a cells expressing the Swedish mutant of APP (N2a-695), HEK cells and HeLa cells 
expressing the Swedish mutant of APP (HeLa-swAPP) cells (Fig. 1A) in contrast to the 
findings of He et al. We used the GSAP construct that He et al. used but failed to see any 
cleavage of GSAP. We also used bioinformatics analysis to predict protease cleavage sites in 
GSAP and used the sequence of human GSAP as entry in Expassy’s Peptide Cutter tool, a 
standard protease prediction online tool. First, there were only two enzymes that were 
predicted to cut GSAP once, but neither of them would liberate a 16 kDa fragment (Caspase 
1 at residue 8 and Thrombin at residue 591) (data not shown). Second, even when we relaxed 
the number of times that the enzymes (and also chemicals) could cleave GSAP to up to 20 
sites, there were no cleavage sites at the residue 733 predicted by He et al., to release a 16 
kDa fragment, suggesting that GSAP is most likely not processed to a 16 kDa fragment by a 
cellular protease, one of the two core findings of He et al., i.e., GSAP is processed to a 16 
kDa fragment that binds to γ-secretase and it is a γ-secretase activating protein, which 
implied that this protease could be a therapeutic target. Importantly, even in the absence of 
proteolytic processing of GSAP, the cells still produced robust amounts of Aβ suggesting that 
cleavage of GSAP is not essential for its putative γ-secretase-promoting activity (Fig. 1B). 
To study the role of GSAP in APP processing and Aβ production, we silenced GSAP using a 
pool of four siRNAs and assayed for secreted Aβ and sAPPβ levels, the soluble fragment of 
APP that is generated after β-secretase-(BACE1)-mediated cleavage. As controls, we used 
siRNAs against APP, BACE1, Pen2, and a scrambled medium GC oligo (MedGC). RT-PCR 
analyses confirm efficient silencing of GSAP upon siRNA transfection (Fig. 1C). The 
measurements to monitor APP processing were performed using a multiplexed system to 
quantitatively measure both Aβ and sAPPβ levels from the sample[10]. This system allows one 
to investigate if a particular perturbation (via siRNAs or plasmid overexpression) affects at 
the level of β-cleavage of APP or at the level of γ-secretase/Aβ . As reported by He et al., we 
found that GSAP silencing significantly inhibited Aβ levels (Fig. 1D). However, we also 
found a similar decrease in sAPPβ levels (Fig. 1D). Since both the measurements come from 
the same samples and even from the same wells of the assay plates, the decrease in both 
sAPPβ and Aβ were not due to intermeasurement variations or use of different assays[10]. 
This decrease in both sAPPβ and Aβ was unexpected as it was claimed that GSAP regulated 
only γ-secretase cleavage of APP (He et al.). To ensure that our assay can recapitulate 
specific γ-secretase-affecting events, as a control, we silenced the expression of Pen2, a bona 
fide γ-secretase associated/activating protein[11], and found that it affected specifically Aβ 
levels without affecting sAPPβ levels (Fig. 1D). As additional controls, we silenced the 
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expression of APP and BACE1, which reduced both sAPPβ and Aβ levels as expected (Fig. 
1D). siRNA-mediated silencing of genes works very efficiently in these cells ([12]Fig. 1C). 
Similar results were obtained when GSAP was silenced in HEK cells, which express 
wildtype APP (Fig. 1E). To rule out that the effect on sAPPβ was caused by off-target effects 
through siRNA silencing with pooled siRNAs, we silenced GSAP using four independent 
siRNA oligos individually and assayed for sAPPβ and Aβ levels. All individual siRNAs 
decreased both sAPPβ and Aβ, clearly demonstrating that GSAP regulates both sAPPβ and 
Aβ levels, and not just the γ-cleavage product, Aβ (Fig. 1F), as reported by He et al. The 
probability that all four oligos would work through an off-target is infinitesimally small and 
this clearly demonstrates that GSAP affects both Aβ and sAPPβ levels. Moreover, using the 
multiplexing system for measuring the peptides Aβ38, 40 and 42[12] we found that all three 
Aβ species were significantly reduced upon GSAP knockdown (Fig. 1G). 
 
Conclusions 
We show that GSAP is not processed to a 16 kDa fragment and it does not specifically alter 
γ-secretase cleavage of APP as claimed by He et al. 
 
Limitations 
One main limitation that we can think of is that our study used only cultured cells, but we 
used three different systems and found exactly the same result: that we could not replicate the 
He et al. studies, in line with the findings from Hussain et al.[1]. 
 
Conjectures 
Since GSAP silencing also reduced the levels of sAPPβ in addition to Aβ, it could affect 
either the levels of APP or β-secretase (BACE) (in the case of β-secretase it could also affect 
the activity). In the next studies, we will follow up by studying whether GSAP regulated the 
levels/activity of APP/BACE1. If other labs are also interested, we invite them so that they 
can also investigate to know how GSAP affected sAPPβ and Aβ levels. We will provide the 
reagents we have used here. 
 
Methods 
cDNA constructs 
For GSAP overexpression, mammalian expression vector pReceiverM07 with the full-length 
GSAP and a C-terminal-HA tag was purchased from Genecopoeia (same source as He et al.). 
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Cells 
Hela-sweAPP and HEK-wtAPP cells are cultured and used as described 20. N2a-695-APP 
cells are a kind gift of Prof. G. Thinakaran, University of Chicago. 
 
siRNA 
siRNAs were purchased from Invitrogen (stealth siRNA).  
 
siRNA transfection for HeLa-swAPP cells 
RNAi silencing was performed in HeLa cells expressing the Swedish APP mutation (HeLa-
swAPP). siRNAs were transfected with a final concentration of 5 nM using Oligofectamine 
(Invitrogen) as a transfection reagent at a concentration of 0.3 µl in a total volume of 100 µl 
following the manufacturer’s instructions. Each siRNA transfection was performed in 
quadruplicate. After 24 h the transfection mix was replaced with fresh culture medium. 69 h 
after transfection, medium was again replaced with 100 µl fresh medium containing 10% 
Alamar Blue (AbD Serotec). Supernatants were collected and assayed for Aβ and sAPPβ, as 
described below. The cells were lysed with 50 µl lysis buffer (1% NP-40, 0.1% SDS and 
protease inhibitor cocktail tablet) for 20 min on ice. 
 
siRNA transfection of HEK-wtAPP cells 
Lipofectamine RNAiMAX (Invitrogen) was used as a transfection reagent. 24 h prior to 
transfection, cells were seeded at an initial seeding density of 3500 cells per well in a 96 well 
plate pre-coated with poly D lysine (Sigma Aldrich). siRNAs were transfected at a final 
concentration of 5 nM using 0.3 µl Lipofectamine RNAiMAX in a total volume of 100 µl. 
Each siRNA transfection was performed in quadruplicate. After 48 h the transfection mix 
was replaced with fresh medium containing 10% Alamar Blue. Supernatants were collected 
and assayed for Aβ and sAPPβ as described below. The cells were lysed with 35 µl lysis 
buffer for 20 min on ice. 
 
Plasmid transfection 
The plasmid transfection for GSAP/PION-HA was performed in HeLa-swAPP cells. 
Lipofectamine 2,000 (Invitrogen) was used as a transfection reagent. Cells were seeded in a 
96 well plate at an initial seeding density of 6,000 cells per well 24 h prior to the transfection. 
0.3 µg of plasmid DNA was transfected using 0.3 µl of Lipofectamine 2,000 in a total volume 
of 100 µl. Transfection mix was replaced after 3 h by fresh culture medium. 21 h after 
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transfection, medium was again replaced with fresh medium containing 10% Alamar Blue. 
24 h after transfection, Alamar Blue measurements were taken. Supernatant was collected 
and assayed for Aβ and sAPPβ. The cells were lysed with 35 µl lysis buffer, incubated for 20 
min on ice, and stored at -20°C. 
 
Alamar Blue assay 
For cell viability measurements using Alamar Blue, the medium of transfected cells (siRNA 
or plasmid) was replaced with normal medium containing 10% Alamar Blue. The final 
volume in each well was 100 µL. 3 h after medium change, cell viability was monitored using 
Fluoroscan Ascent Cf (Labsystems), with excitation wavelength 544 nm and emission at 
590 nm. Cell viability was measured using the Alamar Blue assay (Serotec Ltd., Kidlington, 
Oxford, UK), where the absorbance was monitored at the end of the reaction (after 3 h) 
(Labsystems Multiscan MS UV visible spectrophotometer). 
 
Electrochemiluminescence (ECL) detection of Aβ and sAPPβ 
An electrochemiluminescence assay (Meso Scale Discovery, MD) was performed to 
determine the amount of secreted Aβ40 and sAPPβ in the cell culture medium. For the 
measurement of Aβ38, 40 and 42, triplex plates were used from conditioned supernatants 
collected for 12 h. Pre-coated plates were blocked with TBST (Tris Buffered Saline 
containing Tween), containing 3% Blocker A, for 1 h at room temperature on a shaker at 750 
rpm. After washing, 10 µl of the cell culture supernatant was added to each well along with 
10 µl of detection antibody followed by incubation for 2 h at room temperature on a shaker at 
750 rpm. After washing, detection was performed in 35 µl of 2x MSDT read buffer and read 
with the Sector Imager 6000. 
 
Western blotting 
After 72 h of siRNA transfection, cells were lysed in buffer containing 1% NP-40 and 0.1% 
SDS and protease inhibitors (Roche). Equal amounts of the lysate (according to the protein 
content quantified by BCA assay; Pierce) were run on 4–12% BIS-TRIS gels (Invitrogen). 
The gel was blotted onto a nitrocellulose membrane (BioRad) and probed with the respective 
antibodies (anti-HA antibody: Roche diagnostics; GAPDH antibody: Meridian Science). 
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Real-time RT-PCR 
Total RNA from cultured cells was isolated using TRIzol® Reagent (Life Technologies) 
following manufacturer’s protocol. 1 µg of total RNA was used for reverse transcription with 
oligo-dT primer using the Superscript III first-strand synthesis system (Invitrogen) according 
to the manufacturer’s protocol. Real-time PCR was performed using iTaqTM Universal 
SYBR® Green supermix (Bio-Rad) following manufacturer’s instructions. Relative gene 
expression levels were calculated with the ΔΔCt method using GAPDH for normalization. 
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Figure 1 
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Figure 1. Full-length γ-secretase activating protein (GSAP) is not processed to a 16 kDa 
protein and its silencing leads to reduction in both β- and γ-secretase cleavage of APP 
(A) Western blot analysis showing absence of the processed 16 kDa C-terminal fragment of 
GSAP: N2a-695 cells, HEK cells and HeLa-swAPP cells were transfected with either the 
pReceiverM07 construct expressing the full-length GSAP with a C-terminal-HA tag or 
pcDNA as the control plasmid and immunoblotted with anti-HA  and anti-GAPDH 
antibodies. (B) Graph showing the levels of Aβ and sAPPβ after overexpression of GSAP-
HA plasmids: HeLa-swAPP cells were transfected with pcDNA (negative control) or the 
plasmid expressing GSAP, and the supernatants were analyzed for sAPPβ and Aβ levels 
using an electrochemiluminescence (ECL)-based assay. (C) Graph showing GSAP 
knockdown efficiency: HeLa-swAPP cells were transfected with either MEDGC oligos 
(negative control) or siRNAs against GSAP and the knockdown efficiency was estimated by 
quantitative RT-PCR. (D) Graph showing the reduced levels of Aβ and sAPPβ after siRNA-
mediated silencing of GSAP in Hela-swAPP cells: HeLa-swAPP cells were transfected with 
MedGC oligos (negative control) and with siRNA pools for silencing the expression of APP, 
BACE1, PEN2 and GSAP, and assayed for Aβ and sAPPβ using ECL. (E) Graph showing 
the reduced levels of Aβ and sAPPβ after siRNA-mediated silencing of GSAP in HEK-
wtAPP expressing cells: HEK-wtAPP cells were transfected with MedGC oligos and siRNAs 
against APP, BACE1, and GSAP and assayed for Aβ and sAPPβ. (F) Graph showing the 
levels of Aβ and sAPPβ after siRNA-mediated silencing of GSAP using four different 
GSAP-specific siRNAs: HeLa-swAPP cells were transfected with MedGC oligos and 
siRNAs against APP, BACE1, and four different siRNAs against GSAP and assayed for Aβ 
and sAPPβ. (G) Graph showing the levels of Aβ38, Aβ40 and Aβ42 after siRNA-mediated 
silencing of GSAP: HeLa-swAPP cells were transfected with MedGC oligos and siRNAs 
against APP, BACE1, PEN2, and GSAP and assayed for Aβ38, Aβ40, and Aβ42. For Fig. 
1D–1F and Fig. 1I–1K, **p < 0.05, ***p < 0.005, n.s., not significant. All statistics are 
performed using a two-tailed t-test. Error bars indicate SD. 
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Abstract 
Recently, it was shown that the γ-secretase activating protein (GSAP) regulates specifically 
the γ-cleavage of the β-amyloid precursor protein (APP), whose amyloidogenic processing is 
causatively linked to Alzheimer's disease (AD)[1]. This paper was contradicted by many 
groups refuting the reproducibility of the core findings; and recently, it was shown that GSAP 
did not specifically affect the γ-cleavage of APP but also that the levels of the β-cleaved 
product of APP (sAPPβ) was reduced in cells depleted of GSAP using siRNA[2]. Here we 
confirm these findings that GSAP silencing also reduced Aβ and sAPPβ levels but also 
showed, for the first time, that rather than specifically regulating γ-secretase cleavage of 
APP, GSAP regulates the levels of full-length APP, thus affecting the processing of APP by 
all three proteases, i.e., α-, β- and γ-secretases. This could explain why GSAP silencing 
reduces both Aβ and sAPPβ levels. Furthermore, imatinib, an anti-cancer drug that 
selectively reduces Aβ levels, which was shown to occur by inhibiting the GSAP-γ-secretase 
interaction, reduced Aβ levels also in the absence of GSAP. Thus, our results not only 
uncover a new aspect of GSAP function but also continue to caution the validity of GSAP as 
a specific therapeutic target for Aβ production in AD. 
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Introduction 
GSAP was identified to be a specific regulator of γ-secretase cleavage of the amyloid 
precursor protein that is linked to Alzheimer's disease. This paper published in Nature in 
2010[1] was refuted by several groups questioning the validity and reproducibility of the 
findings[2][3][4]. Recently, Udayar and Rajendran[2] showed that GSAP depletion did not only 
reduce Aβ but also reduced sAPPβ. Here we replicate these findings now but also show that 
silencing of GSAP reduced APP levels, thus explaining how GSAP could have regulated Aβ 
levels. These results question once again the validity of GSAP's specific role in γ-secretase 
cleavage of APP also uncover new insights into the role of GSAP in regulating APP levels. 
 
Objective 
To study the role of γ-secretase activating protein (GSAP) in regulating APP processing and 
to study the reproducibility of GSAP's role in specific γ-secretase cleavage of APP. 
 
Results & Discussion 
He et al.[1] showed that GSAP silencing specifically inhibited γ-cleavage of APP. This study 
was recently refuted by Udayar and Rajendran[2] showing that GSAP silencing did not 
specifically inhibit Aβ, but it also lowered the sAPPβ levels, which is a product of β-cleavage 
of APP and not γ-cleavage. To reproduce this finding, we silenced GSAP using a pool of four 
siRNAs and assayed for secreted Aβ and sAPPβ levels. As controls, we used siRNAs against 
APP, BACE1, Pen-2, and a scrambled medium GC oligo (MedGC). The measurements to 
monitor APP processing were performed using a multiplexed system to quantitatively 
measure both Aβ and sAPPβ levels from the sample[5]. We observed that GSAP silencing led 
to a decrease in both Aβ and sAPPβ levels, in agreement with the previously published 
finding[2] (Fig. 1A). To study how GSAP affected both Aβ and sAPPβ levels, we first 
examined APP processing by Western blotting with anti-APP C-terminus-specific antibody. 
Surprisingly, GSAP silencing dramatically decreased full-length APP levels (Fig. 1B) (see 
independent replicate data in supplementary information; Suppl. Fig. 1A). As a control, we 
used siRNAs against APP and found that it significantly reduced APP protein levels (Fig. 
1B), as expected. To rule out that the reduction in APP was due to general cell toxicity or 
defective cell viability, we performed a number of controls. First, we analyzed the levels of a 
cellular protein, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and found these to be 
unchanged in GSAP-silenced cells (Fig. 1B; Suppl. Fig. 1A) in the same blot along with anti-
APP antibody. Second, the levels of Nicastrin, another type 1 transmembrane protein, were 
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not affected in GSAP-silenced cells (Suppl. Fig. 1B). Third, cell viability measurements (of 
20 replicates) by Alamar Blue™ from GSAP-silenced and scrambled oligo-treated control 
cells did not show any difference demonstrating that GSAP silencing did not induce any cell 
toxicity (Suppl. Fig. 1C). However, silencing Kif11, a kinesin involved in cell division, 
severely induced cell death, serving as a positive control for the cell toxicity assay measured 
by Alamar Blue (Suppl. Fig. 1C). Fourth, general morphological characterization showed no 
distinguishable effect of GSAP silencing on cell shape, structure, and number (Suppl. Fig. 
1D). Fifth, release of the cytosolic protein, lactate dehydrogenase (LDH), was monitored to 
detect any membrane leakages or subtle cellular membrane defects. GSAP silencing did not 
affect the release of LDH (Suppl. Fig. 1E). We confirmed the efficiency of GSAP silencing 
by RT-PCR (Suppl. Fig. 1F). Together, our results conclusively show that GSAP silencing 
reduced full-length APP levels and thus altered both β- and γ-cleavage and not specifically γ-
cleavage of APP or induced any cytotoxicity. To independently validate the effect of GSAP 
on APP levels and also to rule out any epitope-specific effects due to the use of the C-
terminal antibody of APP that we used for Western blotting, we checked the cellular levels of 
APP using immunofluorescence with another anti-APP antibody, 6E10, that recognises the 
N-terminus of the Aβ domain. Again, silencing of GSAP substantially reduced APP levels 
(Fig. 1C) demonstrating that indeed GSAP regulates APP levels. Consistent with the 
observation that GSAP silencing reduces full-length APP levels, GSAP silencing also 
significantly reduced the levels of sAPPα, which is produced by the non-amyloidogenic (α-
secretase) pathway (Fig. 1D). This reduction was not due to cell death, as the viability of 
GSAP-silenced cells was not affected (Fig. 1D; Suppl. Fig. 1). To rule out any off-target 
effects, we silenced GSAP using four different siRNAs singly and analyzed its effect on APP 
levels. We observed that each of the four siRNAs reduced APP levels individually (Suppl. 
Fig. 2A and Suppl. Fig. 2B), thus demonstrating the specificity of the observed effect of 
GSAP silencing on APP levels. Thus, GSAP regulates full-length APP levels and not 
specifically γ-secretase activity. To further validate our findings, we used yet another 
approach by using the anti-cancer drug, imatinib. Imatinib inhibits Aβ production, which was 
concluded to occur via binding to GSAP by blocking its activity[1]. Since our results indicate 
that GSAP does not specifically regulate the γ-secretase activity, we then asked whether 
imatinib could regulate γ-secretase activity in a GSAP-independent manner. Treatment of 
cells with imatinib indeed selectively decreased Aβ levels without affecting sAPPβ levels or 
cell viability, as has been previously shown by several laboratories[6][7][8](Fig. 1E; Suppl. Fig. 
1G). However, while cells silenced with GSAP siRNA again showed a reduction in both Aβ 
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and sAPPβ levels, treatment with imatinib (10 mM[1], same concentration used in He et al.) 
caused a further significant and specific decrease in Aβ levels, suggesting that imatinib 
regulates Aβ levels independently of GSAP. Recent studies on imatinib and Aβ also fail to 
see an effect, further casting doubt that GSAP is an imatinib target[9][3]. We have tried to 
reproduce the results[1] using the cells, plasmids, experimental conditions, concentrations of 
inhibitors as identical as those employed by He et al.,[1] but we failed to reproduce many of 
their findings. Due to the unavailability of a working anti-GSAP antibodies, we were unable 
to look at the cleavage of endogenous GSAP. However, in large-set experiments, using RNAi 
against GSAP, we studied the functionality of the endogenous GSAP. The only one result 
that we can reproduce is the effect of GSAP on Aβ levels, which we discovered to be not due 
to the effect of GSAP on γ-secretase activity as claimed by He et al.,[1] but we have shown 
that this is rather due to GSAP’s effect on APP. 
 
Conclusions 
These results conclusively shows that processing of GSAP is not necessary for Aβ production 
and that GSAP is inappropriately named as it affects Aβ levels via regulating the levels of 
full-length APP and not through activating the γ-secretase, as reported earlier[1]. Since APP 
and the fragments of APP have physiological functions[10], our work cautions the validity of 
GSAP as a therapeutic target for AD. This work also highlights the need for more efforts into 
reproducibility of the published data. 
 
Limitations 
It is largely a cell culture study. 
 
Conjectures 
With all the published data on this subject, it is clear that GSAP is not a specific activator of 
γ-secretase cleavage of APP and further characterization of GSAP function is needed. 
However, it will be interesting to pursue how GSAP silencing reduces APP levels. One 
possibility is that APP transcript levels are reduced or APP protein degradation is enhanced. 
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Methods 
Cells 
Hela-sweAPP are cultured and used as described[11]. 
 
siRNA 
siRNAs were purchased from Invitrogen (stealth siRNA).  
 
siRNA transfection for HeLa-swAPP cells 
Cells were transfected with a final concentration of 5 nM using Oligofectamine (Invitrogen) 
as a transfection reagent at a concentration of 0.3 mL in a total volume of 100 mL following 
the manufacturer’s instructions. Each siRNA transfection was performed in quadruplicate. 
After 24 h the transfection mix was replaced with fresh culture medium. 69 h after 
transfection, medium was again replaced with 100 mL fresh medium containing 10% Alamar 
Blue™ (AbD Serotec). Supernatants were collected and assayed for Aβ and sAPPβ, as 
described below. The cells were lysed with 50 mL lysis buffer (1% NP-40, 0.1% SDS and 
protease inhibitor cocktail tablet) for 20 min on ice. 
 
Alamar Blue assay 
For cell viability measurements using Alamar Blue, the medium of transfected cells (siRNA 
or plasmid) was replaced with normal medium containing 10% Alamar Blue. The final 
volume in each well was 100 mL. 3 h after the medium change, cell viability was monitored 
using Fluoroscan Ascent Cf (Labsystems), with excitation wavelength 544 nm and emission 
at 590 nm. 
 
Electrochemiluminescence (ECL) detection of Aβ, sAPPβ, and sAPPα 
An electrochemiluminescence assay (Meso Scale Discovery, MD) was performed to 
determine the amount of secreted Aβ40, sAPPα, and sAPPβ in the cell culture medium 10. 
For the measurement of Aβ38, 40 and 42, triplex plates were used from conditioned 
supernatants collected for 12 h. Pre-coated plates were blocked with Tris Buffered Saline 
containing Tween, containing 3% Blocker A, for 1 h at room temperature on a shaker at 750 
rpm. After washing, 10 mL of the cell culture supernatant was added to each well along with 
10 mL of detection antibody followed by incubation for 2 h at room temperature on a shaker 
at 750 rpm. After washing detection was performed in 35 mL 2X MSDT read buffer and read 
with the Sector Imager 6000. 
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Western blotting 
After 72 h of siRNA transfection, cells were lysed in buffer containing 1% NP-40 and 0.1% 
SDS and protease inhibitors (Roche). Equal amounts of the lysate (according to the protein 
content quantified by BCA assay (Pierce)) were run on 4–12% BIS-TRIS gels (Invitrogen). 
The gel was blotted onto a nitrocellulose membrane (BioRad) and probed with the respective 
antibodies: anti-APP, C-terminal antibody: SIGMA (F3165-1MG); 6E10 anti-Aβ recognizing 
APP antibody: Covance; anti-Nicastrin antibody (2332-1): Epitomics; GAPDH antibody: 
Meridian Science. 
 
Immunofluorescence 
Cells were reverse-transfected either with MEDGC or siRNAs against APP or GSAP on 
chambered coverslides and 72 h later fixed, permeabilised, blocked and immunostained with 
6E10 anti-APP antibody. The signal was visualised by the use of Alexa488 or Alexa546-
coupled anti-mouse secondary antibody. Nuclei were visualised by DAPI staining. 
 
Imatinib treatment 
Cells were reverse-transfected either with MEDGC or siRNAs against GSAP, and 69 h later, 
cells were treated with DMSO or Imatinib (10 µM, Enzo Life Sciences) for 3 h. Treatment 
was done with culture medium containing 10% Alamar Blue. The final volume of culture 
medium in each well was 100 µL. After 72 h, cell viability was assessed by Alamar Blue 
assay, supernatants were collected and assayed for Aβ and sAPPβ. 
 
Cell cytotoxicity assay 
The cell cytotoxicity assay was carried out using the Cytotoxicity Detection Kit (Roche) by 
measuring the activity of released lactate dehydrogenase into the culture medium. The culture 
supernatant was collected from the cells (with and without Triton X-100 treatment). Samples 
were further diluted and processed according to manufacturers’ protocol. The increase in 
amount of enzyme activity in the supernatant directly correlates with the amount of formazan 
formed, which is proportional to the number of lysed cells. Absorbance was measured at 492 
nm with reference wavelength at 620 nm on a plate reader spectrophotometer. 
 
Real-time RT-PCR 
Total RNA from cells was isolated using TRI Reagent® (Sigma-Aldrich) following 
manufacturer’s protocol. 1 µg of total RNA was used for reverse transcription with iScript™ 
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cDNA synthesis kit (Bio-Rad) according to the manufacturer’s protocol. Real-time PCR was 
performed using iTaq™ Universal SYBR® Green supermix (Bio-Rad) following 
manufacturer’s instructions. Relative gene expression levels were calculated with the ΔΔCt 
method using GAPDH for normalization. 
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Figure 1. γ-secretase activating protein (GSAP) silencing leads to reduction in full-
length APP levels and not specifically γ-secretase cleavage of APP 
(A) Graph showing the reduced levels of Aβ and sAPPβ after siRNA-mediated silencing of 
GSAP in Hela-swAPP cells: HeLa-swAPP cells were transfected with MedGC oligos 
(negative control) and with siRNA pools for silencing the expression of APP, BACE1, PEN2, 
and GSAP, and assayed for Aβ and sAPPβ using ECL. (B) Western blot analysis showing 
full-length APP protein levels after siRNA-mediated silencing of GSAP in HeLa-swAPP 
cells: HeLa-swAPP cells were transfected with MedGC oligos and siRNAs against APP and 
GSAP and the cell lysates were probed for the protein levels of APP (C-terminus specific 
antibody) and GAPDH. (C) Immunofluorescence-based detection of APP levels after siRNA-
mediated silencing of GSAP: HeLa-swAPP cells were transfected with MedGC oligos and 
siRNAs against APP and GSAP, and the cells were fixed and assayed for APP (green) using 
an APP-specific antibody (6E10). Nuclei (gray) were stained using DAPI. (D) Graph 
showing the levels of sAPPα and cell viability after siRNA-mediated silencing of GSAP: 
HeLa-swAPP cells were transfected with MedGC oligos and siRNAs against APP and GSAP 
and assayed for sAPPα and cell viability. (E) Graph showing the levels of Aβ and sAPPβ 
after siRNA-mediated silencing of GSAP followed by imatinib treatment: HeLa-swAPP cells 
were transfected with MedGC oligos or siRNA against GSAP followed by treatment with 
DMSO or imatinib (10 µM). * p<0.05, ** p<0.01, *** p<0.001, n.s., not significant. All 
statistics are performed using a two-tailed t-test. Error bars indicate SD. 
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Supplementary Figure 1 
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Supplementary Figure 1: A. Replicate Western blot analysis showing protein levels of APP 
are reduced in GSAP silenced conditions. HeLa-swAPP cells were transfected with either 
MedGC oligos or siRNAs against GSAP or APP and the cell lysates were probed for APP 
and GAPDH in the same blot. B. Western blot analysis showing protein levels of Nicastrin 
upon GSAP knockdown: HeLa-swAPP cells were transfected with either MedGC oligos or 
siRNAs against GSAP or APP and the cell lysates were probed for Nicastrin and GAPDH. C. 
Graph showing cell viability upon GSAP knockdown: HeLa-swAPP cells were transfected 
with MedGC oligos (20 replicates) or siRNAs against GSAP (20 replicates) or Kif11 
(positive control, 6 replicates) and assayed for cell viability represented by the flourescence 
intensity upon metabolism of Alamar Blue by viable cells. D. Microscopy analysis of cell 
viability upon GSAP knockdown: Representative images of HeLa-swAPP cells after 
transfection with MedGC oligos or siRNAs against GSAP. E. Graph showing levels of 
secreted and intracellular LDH upon GSAP knockdown: HeLa-swAPP cells were transfected 
with MedGC oligos or siRNAs against GSAP and were assayed for the levels of secreted and 
intracellular LDH to assess cytotoxicity. F. Graph showing GSAP knockdown efficiency: 
HeLa-swAPP cells were transfected with either MEDGC oligos (negative control) or siRNAs 
against GSAP and the knockdown efficiency was analyzed by quantitative Reverse 
Transcriptase (RT)-PCR. G. Graph showing cell viability upon Imatinib treatment: HeLa-
swAPP cells were transfected with MedGC oligos or siRNA against GSAP followed by 
treatment with DMSO or Imatinib (10 µM) and assayed for cell viability represented by the 
fluorescence intensity upon metabolism of Alamar Blue by viable cells. * p<0.05, ** p<0.01, 
*** p<0.001, n.s., not significant. 
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Supplementary Figure 2 
 
Supplementary Figure 2: A. Immunofluorescence based detection of APP levels after 
siRNA mediated silencing of GSAP with four different Oligos: HeLa-swAPP cells were 
transfected with MedGC oligos or four different siRNAs against GSAP, and the cells were 
fixed and assayed for APP (Red) using an APP specific antibody (6E10). Nuclei (Blue) were 
stained using DAPI. B. Graph showing quantification of APP levels after siRNA mediated 
silencing of GSAP with four different Oligos: The fluorescence signal were quantified using 
ImageJ software and normalized to the total cell number. * p<0.05, ** p<0.01, *** p<0.001. 
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Outlook 
The main aim of this thesis was to create a cellular “roadmap” for membrane trafficking 
pathways that regulate Aβ metabolism, including its production and degradation. This work 
entailed both, the identification of trafficking regulators of Aβ as well as mechanistic 
characterization of the most interesting candidates. By focusing on Rab-GTPase family of 
proteins (60 in all) we were able to perform robust RNAi screens and validate the hit 
candidates in multiple cellular models. Using elegant cell and molecular biology techniques, 
we mechanistically characterized the top hits. By integrating our RNAi and experimental cell 
biology data, we established a “trafficking roadmap” for Aβ metabolism and identified novel 
regulators of Aβ levels. Majority of the works in this thesis were performed in cellular 
models and as a logical extension, one can test the relevance of these findings in animal 
models as well as their therapeutic potential. Below, I have discussed a few potential lines of 
investigation and strategies that stem out of this thesis. 
 
We identified Rab11 as a novel positive regulator of Aβ production in cell lines and in mouse 
primary neurons. Rab11 silencing/dysfunction led to significant decrease in Aβ level. It will 
be interesting to see whether this effect of Rab11 depletion on Aβ production is also observed 
in mouse models of AD. General Rab11 knockout (ko) mice are embryonically lethal 
whereas brain-specific Rab11 ko (Nestin-cre-Rab11 ko) mice do not present overt brain 
abnormalities (Sobajima et al., 2014). One strategy would be to cross the brain-specific 
Rab11 ko mice with one of the many AD mouse models available and analyze amyloid 
status, neurodegeneration and behavior in these mice. According to our hypothesis, AD mice 
with brain-specific Rab11 deletion should have lower soluble Aβ and consequently lower 
amyloid plaques compared to control AD mice. This can then be complemented by 
behavioral studies to assess if reducing Aβ by depletion of Rab11 improved cognitive 
function in these mice. When designing such studies, one must consider that Rab11 has been 
previously implicated in the maintenance of spine morphology and function (Giorgini and 
Steinert, 2013). Taking this into account, an alternative strategy would be to use 
heterozygous brain-specific Rab11 knockout mice and cross it to AD mice. These could 
allow us to partly preserve the physiological functions of Rab11 and yet reduce the brain Aβ 
levels to a certain extent. This approach however, assumes that haploinsufficiency of Rab11 
will sufficiently reduce Aβ levels while still maintaining physiological processes dependent 
on vesicle recycling. Nevertheless, both the above-mentioned approach can be tested to 
validate Rab11’s role in regulating Aβ level in vivo. This is important as compared to the in 
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vitro models many more factors affect Aβ level in an organism. In vivo validation of Rab11’s 
role in Aβ metabolism would allow us to design therapeutic strategies to lower Aβ in AD 
animal models. 
 
Currently, there are no Rab11-specific inhibitors available and development of specific Rab 
inhibitors has been a long standing challenge. Watanabe and colleagues identified inhibitors 
that specifically target the geranylgeranylation of Rab proteins, a process that is critical for 
Rab function (Watanabe et al., 2008). However, these inhibitors are still not specific enough, 
though they are a step in the right direction. A promising approach to identify Rab11 specific 
inhibitors would be a screen for inhibitors of transferring receptor (TfR) recycling in cellular 
models. TfR is recycled from recycling endosomes to plasma membrane by the Rab11 
pathway, very much the same way as BACE1 recycling. Using fluorescently-labeled TfR we 
have established TfR recycling assays that can be used for high-throughput screens for 
compounds that inhibit the recycling pathway. Once such an inhibitor(s) is identified, we can 
test if inhibiting the recycling pathway is a viable therapeutic option in AD. 
 
In the second part of our study we identified the lysosomal pathway as a major route for 
intracellular Aβ degradation. Our data implicated the Rab7-regulated intracellular lysosomal 
pathway as an important route for Aβ degradation. We also identified PS2 as novel negative 
regulator of Aβ levels and showed that PS2 positively regulates Aβ degradation also by 
regulating the lysosomal pathway. It will be important to validate these finding in animal 
models of AD. We have validated our finding of PS2 depletion and increased Aβ in an AD 
mouse model and currently we are assessing whether this increase in Aβ and amyloid load 
leads to worsening of cognitive function in these mice. This would imply that boosting 
lysosomal function is a viable therapeutic option for AD. This leads to the question: Are there 
ways to boost lysosomal function in an organism? Indeed, there are inhibitors that can be 
used to stimulate the autophagy-lysosomal pathway. Rapamycin, a potent inhibitor of 
mammalian target of rapamycin (mTOR) is one such candidate. mTOR inhibition by 
rapamycin has been shown to activate the autophagy-lysosomal pathway. Studies on mice 
and other model systems have also demonstrated the beneficial effect of rapamycin on 
lifespan and aging (Cai and Yan, 2013; Harrison et al., 2009). However, we must thread with 
caution, as mTOR is the central regulator of many cellular pathways that are important for 
normal cellular function. Indeed, studies have shown that mTOR inhibition by rapamycin is 
detrimental (Lafay-Chebassier et al., 2006; Zhang et al., 2010). 
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Interestingly, there is an alternative approach to stimulate autophagy and lysosomal function 
that is non-invasive and has the potential to mitigate the pathology of protein accumulation. 
Our lab and others have shown that starvation/caloric restriction leads to an increase in 
clearance of amyloid through the autophagosome and lysosomal pathway. Our data from the 
PS2 study showed that starvation induced lysosomal degradation is dependent on PS2. This 
suggest that caloric restriction/starvation can boost lysosomal function and help clear amyloid 
in a PS2 dependent manner. Currently we are testing this hypothesis in PS2 knockout mice 
that have been crossed to ArcAD mice (Knobloch et al., 2007). 
 
Our data on PS2 suggests that pan-inhibition of γ-secretase is a problematic approach as PS1 
and PS2 have diametrically opposite roles in the regulation of Aβ levels. While PS1 is 
predominantly involved in the production of Aβ, PS2 is mostly involved in the clearance of 
Aβ. Pan inhibition by γ-secretase will also inhibit PS2-containing γ-secretase complexes and 
thereby interfere with Aβ degradation. Taking this into account, we can design strategies to 
target the γ-secretase inhibitors specfically to PS1 containing complexes. This would entail 
further research on understanding γ-secretase heterogeneity with respect to its subcellular 
localization and substrate specificity.  
 
In line with our finding on the relevance of endo-lysosomal pathway in Aβ metabolism, 
recent late-onset AD (LOAD) GWAS studies have implicated the endosomal pathway in 
LOAD. Moreover, cholestrol metabolism and inflammation are two other major pathways 
that are implicated in these LOAD GWAS studies (Selkoe and Hardy, 2016). It will be 
interesting to study if and how these different pathways interact with each other in conferring 
disease risk. Cholestrol metabolism is intimately linked to endosomal processes such as 
endocytosis, vesicle recycling and lysosomal degradation. Inflammation is also known to 
regulate endosomal processes such as phagocytosis and exocytosis. Hence, an interactional 
network between these different pathways is plausible and could help us further unravel the 
molecular complexity of AD. 
 
As mentioned before, early-onset (EOAD), which corresponds to less than 5% of the cases, is 
caused by autosomal dominant mutations that increase the overall production of Aβ. Both 
EOAD and LOAD (also called “sporadic” AD) are characterized by amyloid protein 
aggregates in the brain, which lead to synaptic dysfunction and neurodegeneration. Given 
that LOAD is not associated with strong disease-causing mutations, it likely arises from 
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distinct, and lesser-understood mechanisms such as amyloid clearance. My work has 
identified the cellular underpinnings of amyloid clearance, which could be the leading 
mechanism for LOAD. My work also shows the importance of lysosomal biogenesis and 
function in amyloid clearance and since lysosomal biogenesis is intrinsically coupled with 
nutrient sensing and assimilation, deliberations for therapy and prevention could be made.  
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LTD. Long-term depression 
LTP. Long-term potentiation, Long-term 
potentiation 
MAP. Mitogen-activated protein kinase 
MCI. Mild cognitive impairment 
MMP. Matrix-metalloproteinases 
MVB. Multivesicular bodies 
MRI. Magnetic resonance imaging 
NEP. Neprilysin 
NFT. Neurofibrillary tangle 
NMDA. N-Methyl-D-aspartate 
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p75NTR. p75 neurotrophin 
PAR1. Prader-Willi/Angelman region 1 
PET. Positon emission tomography 
PHF. Paired helical filament 
PiB. Pittsburg compound-B 
PICALM. Phosphatidylinositol binding 
clathrin assembly protein 
PKA. Protein kinase A 
PP. Protein phosphatases 
PS1. Presenilin 1 
PS2. Presenilin 2 
PSP. Progressive supranuclear palsy 
RNAi. RNA interference 
SAD. Sporadic Alzheimer's disease 
SCARA. Scavenger receptor A1 
siRNA. Small interfering RNA  
SNAP25. Synaptosomal-associated protein 
25 
SNP. Single-nucleotide polymorphism 
SorLA. Sortilin related receptor 1 
Tg. Transgenic 
TLR. Toll-like receptor 
TREM2. Triggering receptor expressed on 
myeloid cells 2 
UDP. Uridine diphosphate 
VPS. Vacuolar protein sorting-associated 
protein 
 171 
References 
Acx, H., Serneels, L., Radaelli, E., Muyldermans, S., Vincke, C., Pepermans, E., Muller, U., 
Chavez-Gutierrez, L., and De Strooper, B. (2017). Inactivation of gamma-secretases leads to 
accumulation of substrates and non-Alzheimer neurodegeneration. EMBO Mol Med 9, 1088-
1099. 
Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., Gamst, A., 
Holtzman, D.M., Jagust, W.J., Petersen, R.C., et al. (2011). The diagnosis of mild cognitive 
impairment due to Alzheimer's disease: recommendations from the National Institute on 
Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. 
Alzheimers Dement 7, 270-279. 
Alonso Adel, C., Mederlyova, A., Novak, M., Grundke-Iqbal, I., and Iqbal, K. (2004). 
Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 
279, 34873-34881. 
Alzheimer, A., Stelzmann, R.A., Schnitzlein, H.N., and Murtagh, F.R. (1995). An English 
translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin 
Anat 8, 429-431. 
Andersen, O.M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, 
C.A., Breiderhoff, T., Jansen, P., Wu, X., et al. (2005). Neuronal sorting protein-related 
receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad 
Sci U S A 102, 13461-13466. 
Avila, J., Simon, D., Diaz-Hernandez, M., Pintor, J., and Hernandez, F. (2014). Sources of 
extracellular tau and its signaling. J Alzheimers Dis 40 Suppl 1, S7-S15. 
Baki, L., Marambaud, P., Efthimiopoulos, S., Georgakopoulos, A., Wen, P., Cui, W., Shioi, 
J., Koo, E., Ozawa, M., Friedrich, V.L., Jr., et al. (2001). Presenilin-1 binds cytoplasmic 
epithelial cadherin, inhibits cadherin/p120 association, and regulates stability and function of 
the cadherin/catenin adhesion complex. Proc Natl Acad Sci U S A 98, 2381-2386. 
 172 
Bali, J., Gheinani, A.H., Zurbriggen, S., and Rajendran, L. (2012). Role of genes linked to 
sporadic Alzheimer's disease risk in the production of beta-amyloid peptides. Proc Natl Acad 
Sci U S A 109, 15307-15311. 
Bateman, R.J., Xiong, C., Benzinger, T.L., Fagan, A.M., Goate, A., Fox, N.C., Marcus, D.S., 
Cairns, N.J., Xie, X., Blazey, T.M., et al. (2012). Clinical and biomarker changes in 
dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804. 
Bayer, T.A., Cappai, R., Masters, C.L., Beyreuther, K., and Multhaup, G. (1999). It all sticks 
together--the APP-related family of proteins and Alzheimer's disease. Mol Psychiatry 4, 524-
528. 
Bednarski, E., and Lynch, G. (1996). Cytosolic proteolysis of tau by cathepsin D in 
hippocampus following suppression of cathepsins B and L. J Neurochem 67, 1846-1855. 
Bell, R.D., Sagare, A.P., Friedman, A.E., Bedi, G.S., Holtzman, D.M., Deane, R., and 
Zlokovic, B.V. (2007). Transport pathways for clearance of human Alzheimer's amyloid 
beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood 
Flow Metab 27, 909-918. 
Ben Halima, S., Mishra, S., Raja, K.M.P., Willem, M., Baici, A., Simons, K., Brustle, O., 
Koch, P., Haass, C., Caflisch, A., et al. (2016). Specific Inhibition of beta-Secretase 
Processing of the Alzheimer Disease Amyloid Precursor Protein. Cell Rep 14, 2127-2141. 
Benilova, I., Gallardo, R., Ungureanu, A.A., Castillo Cano, V., Snellinx, A., Ramakers, M., 
Bartic, C., Rousseau, F., Schymkowitz, J., and De Strooper, B. (2014). The Alzheimer 
disease protective mutation A2T modulates kinetic and thermodynamic properties of 
amyloid-beta (Abeta) aggregation. J Biol Chem 289, 30977-30989. 
Bentahir, M., Nyabi, O., Verhamme, J., Tolia, A., Horre, K., Wiltfang, J., Esselmann, H., and 
De Strooper, B. (2006). Presenilin clinical mutations can affect gamma-secretase activity by 
different mechanisms. J Neurochem 96, 732-742. 
Blennow, K. (2004). CSF biomarkers for mild cognitive impairment. J Intern Med 256, 224-
234. 
 173 
Blennow, K., Hampel, H., Weiner, M., and Zetterberg, H. (2010). Cerebrospinal fluid and 
plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144. 
Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. 
Acta Neuropathol 82, 239-259. 
Brinkmalm, A., Brinkmalm, G., Honer, W.G., Frolich, L., Hausner, L., Minthon, L., 
Hansson, O., Wallin, A., Zetterberg, H., Blennow, K., et al. (2014). SNAP-25 is a promising 
novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol 
Neurodegener 9, 53. 
Caceres, A., Potrebic, S., and Kosik, K.S. (1991). The effect of tau antisense oligonucleotides 
on neurite formation of cultured cerebellar macroneurons. J Neurosci 11, 1515-1523. 
Cai, Z., and Yan, L.J. (2013). Rapamycin, Autophagy, and Alzheimer's Disease. J Biochem 
Pharmacol Res 1, 84-90. 
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A.Y., Seubert, P., Vigo-Pelfrey, 
C., Lieberburg, I., and Selkoe, D.J. (1992). Mutation of the beta-amyloid precursor protein in 
familial Alzheimer's disease increases beta-protein production. Nature 360, 672-674. 
Coppola, G., Chinnathambi, S., Lee, J.J., Dombroski, B.A., Baker, M.C., Soto-Ortolaza, A.I., 
Lee, S.E., Klein, E., Huang, A.Y., Sears, R., et al. (2012). Evidence for a role of the rare 
p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. 
Hum Mol Genet 21, 3500-3512. 
Crehan, H., Hardy, J., and Pocock, J. (2013). Blockage of CR1 prevents activation of rodent 
microglia. Neurobiol Dis 54, 139-149. 
Das, U., Scott, D.A., Ganguly, A., Koo, E.H., Tang, Y., and Roy, S. (2013). Activity-induced 
convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent 
pathway. Neuron 79, 447-460. 
 174 
Das, U., Wang, L., Ganguly, A., Saikia, J.M., Wagner, S.L., Koo, E.H., and Roy, S. (2016). 
Visualizing APP and BACE-1 approximation in neurons yields insight into the 
amyloidogenic pathway. Nat Neurosci 19, 55-64. 
Daugherty, B.L., and Green, S.A. (2001). Endosomal sorting of amyloid precursor protein-P-
selectin chimeras influences secretase processing. Traffic 2, 908-916. 
David, D.C., Layfield, R., Serpell, L., Narain, Y., Goedert, M., and Spillantini, M.G. (2002). 
Proteasomal degradation of tau protein. J Neurochem 83, 176-185. 
Dawson, H.N., Ferreira, A., Eyster, M.V., Ghoshal, N., Binder, L.I., and Vitek, M.P. (2001). 
Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J 
Cell Sci 114, 1179-1187. 
De Felice, F.G., Velasco, P.T., Lambert, M.P., Viola, K., Fernandez, S.J., Ferreira, S.T., and 
Klein, W.L. (2007). Abeta oligomers induce neuronal oxidative stress through an N-methyl-
D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug 
memantine. J Biol Chem 282, 11590-11601. 
De Strooper, B. (2007). Loss-of-function presenilin mutations in Alzheimer disease. Talking 
Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8, 141-146. 
de Wilde, M.C., Overk, C.R., Sijben, J.W., and Masliah, E. (2016). Meta-analysis of synaptic 
pathology in Alzheimer's disease reveals selective molecular vesicular machinery 
vulnerability. Alzheimers Dement 12, 633-644. 
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, 
B., Hu, H.W., et al. (2004). LRP/amyloid beta-peptide interaction mediates differential brain 
efflux of Abeta isoforms. Neuron 43, 333-344. 
Dejaegere, T., Serneels, L., Schafer, M.K., Van Biervliet, J., Horre, K., Depboylu, C., 
Alvarez-Fischer, D., Herreman, A., Willem, M., Haass, C., et al. (2008). Deficiency of 
Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be 
reversed with antipsychotic treatment. Proc Natl Acad Sci U S A 105, 9775-9780. 
 175 
Dickey, C.A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R.M., Dunmore, J., Ash, P., 
Shoraka, S., Zlatkovic, J., Eckman, C.B., et al. (2007). The high-affinity HSP90-CHIP 
complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 
117, 648-658. 
Ebneth, A., Godemann, R., Stamer, K., Illenberger, S., Trinczek, B., and Mandelkow, E. 
(1998). Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, 
mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 
143, 777-794. 
Eckman, E.A., and Eckman, C.B. (2005). Abeta-degrading enzymes: modulators of 
Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 
33, 1101-1105. 
Eckman, E.A., Watson, M., Marlow, L., Sambamurti, K., and Eckman, C.B. (2003). 
Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-
converting enzyme. J Biol Chem 278, 2081-2084. 
Edbauer, D., Winkler, E., Regula, J.T., Pesold, B., Steiner, H., and Haass, C. (2003). 
Reconstitution of gamma-secretase activity. Nat Cell Biol 5, 486-488. 
Ehehalt, R., Keller, P., Haass, C., Thiele, C., and Simons, K. (2003). Amyloidogenic 
processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell 
Biol 160, 113-123. 
Elliott, M.R., Chekeni, F.B., Trampont, P.C., Lazarowski, E.R., Kadl, A., Walk, S.F., Park, 
D., Woodson, R.I., Ostankovich, M., Sharma, P., et al. (2009). Nucleotides released by 
apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282-286. 
Falkevall, A., Alikhani, N., Bhushan, S., Pavlov, P.F., Busch, K., Johnson, K.A., Eneqvist, 
T., Tjernberg, L., Ankarcrona, M., and Glaser, E. (2006). Degradation of the amyloid beta-
protein by the novel mitochondrial peptidasome, PreP. J Biol Chem 281, 29096-29104. 
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E.A., Frosch, M.P., Eckman, 
C.B., Tanzi, R.E., Selkoe, D.J., and Guenette, S. (2003). Insulin-degrading enzyme regulates 
 176 
the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein 
intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167. 
Farris, W., Schutz, S.G., Cirrito, J.R., Shankar, G.M., Sun, X., George, A., Leissring, M.A., 
Walsh, D.M., Qiu, W.Q., Holtzman, D.M., et al. (2007). Loss of neprilysin function promotes 
amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 171, 241-
251. 
Fitz, N.F., Cronican, A.A., Saleem, M., Fauq, A.H., Chapman, R., Lefterov, I., and 
Koldamova, R. (2012). Abca1 deficiency affects Alzheimer's disease-like phenotype in 
human ApoE4 but not in ApoE3-targeted replacement mice. J Neurosci 32, 13125-13136. 
Frenkel, D., Wilkinson, K., Zhao, L., Hickman, S.E., Means, T.K., Puckett, L., Farfara, D., 
Kingery, N.D., Weiner, H.L., and El Khoury, J. (2013). Scara1 deficiency impairs clearance 
of soluble amyloid-beta by mononuclear phagocytes and accelerates Alzheimer's-like disease 
progression. Nat Commun 4, 2030. 
Fukumoto, H., Rosene, D.L., Moss, M.B., Raju, S., Hyman, B.T., and Irizarry, M.C. (2004). 
Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J 
Pathol 164, 719-725. 
Giorgini, F., and Steinert, J.R. (2013). Rab11 as a modulator of synaptic transmission. 
Commun Integr Biol 6, e26807. 
Gong, C.X., Singh, T.J., Grundke-Iqbal, I., and Iqbal, K. (1993). Phosphoprotein phosphatase 
activities in Alzheimer disease brain. J Neurochem 61, 921-927. 
Griciuc, A., Serrano-Pozo, A., Parrado, A.R., Lesinski, A.N., Asselin, C.N., Mullin, K., 
Hooli, B., Choi, S.H., Hyman, B.T., and Tanzi, R.E. (2013). Alzheimer's disease risk gene 
CD33 inhibits microglial uptake of amyloid beta. Neuron 78, 631-643. 
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, 
C., Sassi, C., Kauwe, J.S., Younkin, S., et al. (2013). TREM2 variants in Alzheimer's disease. 
N Engl J Med 368, 117-127. 
 177 
Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E.M., and Mandelkow, E. (1994). Domains 
of tau protein and interactions with microtubules. Biochemistry 33, 9511-9522. 
Haass, C., Hung, A.Y., Selkoe, D.J., and Teplow, D.B. (1994). Mutations associated with a 
locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein 
precursor. J Biol Chem 269, 17741-17748. 
Hamano, T., Gendron, T.F., Ko, L.W., and Yen, S.H. (2009). Concentration-dependent 
effects of proteasomal inhibition on tau processing in a cellular model of tauopathy. Int J Clin 
Exp Pathol 2, 561-573. 
Hampel, H., Blennow, K., Shaw, L.M., Hoessler, Y.C., Zetterberg, H., and Trojanowski, J.Q. 
(2010). Total and phosphorylated tau protein as biological markers of Alzheimer's disease. 
Exp Gerontol 45, 30-40. 
Hanger, D.P., Anderton, B.H., and Noble, W. (2009a). Tau phosphorylation: the therapeutic 
challenge for neurodegenerative disease. Trends Mol Med 15, 112-119. 
Hanger, D.P., Seereeram, A., and Noble, W. (2009b). Mediators of tau phosphorylation in the 
pathogenesis of Alzheimer's disease. Expert Rev Neurother 9, 1647-1666. 
Harrison, D.E., Strong, R., Sharp, Z.D., Nelson, J.F., Astle, C.M., Flurkey, K., Nadon, N.L., 
Wilkinson, J.E., Frenkel, K., Carter, C.S., et al. (2009). Rapamycin fed late in life extends 
lifespan in genetically heterogeneous mice. Nature 460, 392-395. 
He, X., Li, F., Chang, W.P., and Tang, J. (2005). GGA proteins mediate the recycling 
pathway of memapsin 2 (BACE). J Biol Chem 280, 11696-11703. 
Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A., and Evans, D.A. (2003). Alzheimer 
disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60, 
1119-1122. 
Hebert, S.S., Serneels, L., Dejaegere, T., Horre, K., Dabrowski, M., Baert, V., Annaert, W., 
Hartmann, D., and De Strooper, B. (2004). Coordinated and widespread expression of 
 178 
gamma-secretase in vivo: evidence for size and molecular heterogeneity. Neurobiol Dis 17, 
260-272. 
Hemming, M.L., Elias, J.E., Gygi, S.P., and Selkoe, D.J. (2009). Identification of beta-
secretase (BACE1) substrates using quantitative proteomics. PLoS One 4, e8477. 
Hickman, S.E., Allison, E.K., and El Khoury, J. (2008). Microglial dysfunction and defective 
beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 28, 8354-
8360. 
Hoover, B.R., Reed, M.N., Su, J., Penrod, R.D., Kotilinek, L.A., Grant, M.K., Pitstick, R., 
Carlson, G.A., Lanier, L.M., Yuan, L.L., et al. (2010). Tau mislocalization to dendritic spines 
mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067-1081. 
Hung, S.Y., and Fu, W.M. (2017). Drug candidates in clinical trials for Alzheimer's disease. J 
Biomed Sci 24, 47. 
Hutton, M., Lendon, C.L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, 
S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998). Association of missense and 5'-
splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705. 
Iliff, J.J., Wang, M., Liao, Y., Plogg, B.A., Peng, W., Gundersen, G.A., Benveniste, H., 
Vates, G.E., Deane, R., Goldman, S.A., et al. (2012). A paravascular pathway facilitates CSF 
flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid 
beta. Sci Transl Med 4, 147ra111. 
Ito, S., Ueno, T., Ohtsuki, S., and Terasaki, T. (2010). Lack of brain-to-blood efflux transport 
activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta 
peptide(1-40) in mouse: involvement of an LRP-1-independent pathway. J Neurochem 113, 
1356-1363. 
Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S., Stefansson, 
H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012). A mutation in APP protects 
against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99. 
 179 
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., Bjornsson, 
S., Huttenlocher, J., Levey, A.I., Lah, J.J., et al. (2013). Variant of TREM2 associated with 
the risk of Alzheimer's disease. N Engl J Med 368, 107-116. 
Kaether, C., Schmitt, S., Willem, M., and Haass, C. (2006). Amyloid precursor protein and 
Notch intracellular domains are generated after transport of their precursors to the cell 
surface. Traffic 7, 408-415. 
Kanatsu, K., Morohashi, Y., Suzuki, M., Kuroda, H., Watanabe, T., Tomita, T., and 
Iwatsubo, T. (2014). Decreased CALM expression reduces Abeta42 to total Abeta ratio 
through clathrin-mediated endocytosis of gamma-secretase. Nat Commun 5, 3386. 
Kester, M.I., Teunissen, C.E., Crimmins, D.L., Herries, E.M., Ladenson, J.H., Scheltens, P., 
van der Flier, W.M., Morris, J.C., Holtzman, D.M., and Fagan, A.M. (2015). Neurogranin as 
a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. 
JAMA Neurol 72, 1275-1280. 
Kim, S.M., Mun, B.R., Lee, S.J., Joh, Y., Lee, H.Y., Ji, K.Y., Choi, H.R., Lee, E.H., Kim, 
E.M., Jang, J.H., et al. (2017). TREM2 promotes Abeta phagocytosis by upregulating 
C/EBPalpha-dependent CD36 expression in microglia. Sci Rep 7, 11118. 
Kinoshita, A., Fukumoto, H., Shah, T., Whelan, C.M., Irizarry, M.C., and Hyman, B.T. 
(2003). Demonstration by FRET of BACE interaction with the amyloid precursor protein at 
the cell surface and in early endosomes. J Cell Sci 116, 3339-3346. 
Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergstrom, M., 
Savitcheva, I., Huang, G.F., Estrada, S., et al. (2004). Imaging brain amyloid in Alzheimer's 
disease with Pittsburgh Compound-B. Ann Neurol 55, 306-319. 
Knobloch, M., Konietzko, U., Krebs, D.C., and Nitsch, R.M. (2007). Intracellular Abeta and 
cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol 
Aging 28, 1297-1306. 
Koo, E.H., and Squazzo, S.L. (1994). Evidence that production and release of amyloid beta-
protein involves the endocytic pathway. J Biol Chem 269, 17386-17389. 
 180 
Kouri, N., Carlomagno, Y., Baker, M., Liesinger, A.M., Caselli, R.J., Wszolek, Z.K., 
Petrucelli, L., Boeve, B.F., Parisi, J.E., Josephs, K.A., et al. (2014). Novel mutation in MAPT 
exon 13 (p.N410H) causes corticobasal degeneration. Acta Neuropathol 127, 271-282. 
Kress, B.T., Iliff, J.J., Xia, M., Wang, M., Wei, H.S., Zeppenfeld, D., Xie, L., Kang, H., Xu, 
Q., Liew, J.A., et al. (2014). Impairment of paravascular clearance pathways in the aging 
brain. Ann Neurol 76, 845-861. 
Kuhn, P.H., Koroniak, K., Hogl, S., Colombo, A., Zeitschel, U., Willem, M., Volbracht, C., 
Schepers, U., Imhof, A., Hoffmeister, A., et al. (2012). Secretome protein enrichment 
identifies physiological BACE1 protease substrates in neurons. EMBO J 31, 3157-3168. 
Kvartsberg, H., Duits, F.H., Ingelsson, M., Andreasen, N., Ohrfelt, A., Andersson, K., 
Brinkmalm, G., Lannfelt, L., Minthon, L., Hansson, O., et al. (2015). Cerebrospinal fluid 
levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal 
Alzheimer's disease. Alzheimers Dement 11, 1180-1190. 
Lafay-Chebassier, C., Perault-Pochat, M.C., Page, G., Rioux Bilan, A., Damjanac, M., Pain, 
S., Houeto, J.L., Gil, R., and Hugon, J. (2006). The immunosuppressant rapamycin 
exacerbates neurotoxicity of Abeta peptide. J Neurosci Res 84, 1323-1334. 
Lai, A.Y., and McLaurin, J. (2012). Clearance of amyloid-beta peptides by microglia and 
macrophages: the issue of what, when and where. Future Neurol 7, 165-176. 
Lambert, J.C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., 
Zelenika, D., Bullido, M.J., Tavernier, B., et al. (2009). Genome-wide association study 
identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-
1099. 
Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., 
DeStafano, A.L., Bis, J.C., Beecham, G.W., Grenier-Boley, B., et al. (2013). Meta-analysis 
of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 
45, 1452-1458. 
 181 
Lausted, C., Lee, I., Zhou, Y., Qin, S., Sung, J., Price, N.D., Hood, L., and Wang, K. (2014). 
Systems approach to neurodegenerative disease biomarker discovery. Annu Rev Pharmacol 
Toxicol 54, 457-481. 
Lee, V.M., Goedert, M., and Trojanowski, J.Q. (2001). Neurodegenerative tauopathies. Annu 
Rev Neurosci 24, 1121-1159. 
Leissring, M.A. (2008). The AbetaCs of Abeta-cleaving proteases. J Biol Chem 283, 29645-
29649. 
Leissring, M.A. (2016). Abeta-Degrading Proteases: Therapeutic Potential in Alzheimer 
Disease. CNS Drugs 30, 667-675. 
Leissring, M.A., Farris, W., Chang, A.Y., Walsh, D.M., Wu, X., Sun, X., Frosch, M.P., and 
Selkoe, D.J. (2003). Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents 
plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093. 
Lichtenthaler, S.F. (2011). alpha-secretase in Alzheimer's disease: molecular identity, 
regulation and therapeutic potential. J Neurochem 116, 10-21. 
Liu, S., Liu, Y., Hao, W., Wolf, L., Kiliaan, A.J., Penke, B., Rube, C.E., Walter, J., Heneka, 
M.T., Hartmann, T., et al. (2012). TLR2 is a primary receptor for Alzheimer's amyloid beta 
peptide to trigger neuroinflammatory activation. J Immunol 188, 1098-1107. 
Louveau, A., Smirnov, I., Keyes, T.J., Eccles, J.D., Rouhani, S.J., Peske, J.D., Derecki, N.C., 
Castle, D., Mandell, J.W., Lee, K.S., et al. (2015). Structural and functional features of 
central nervous system lymphatic vessels. Nature 523, 337-341. 
Luo, Y., Bolon, B., Kahn, S., Bennett, B.D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., 
Zhang, J., Gong, Y., et al. (2001). Mice deficient in BACE1, the Alzheimer's beta-secretase, 
have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4, 231-232. 
Maloney, J.A., Bainbridge, T., Gustafson, A., Zhang, S., Kyauk, R., Steiner, P., van der Brug, 
M., Liu, Y., Ernst, J.A., Watts, R.J., et al. (2014). Molecular mechanisms of Alzheimer 
 182 
disease protection by the A673T allele of amyloid precursor protein. J Biol Chem 289, 
30990-31000. 
Marksteiner, J., Hinterhuber, H., and Humpel, C. (2007). Cerebrospinal fluid biomarkers for 
diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein. 
Drugs Today (Barc) 43, 423-431. 
McGeer, P.L., Akiyama, H., Itagaki, S., and McGeer, E.G. (1989). Immune system response 
in Alzheimer's disease. Can J Neurol Sci 16, 516-527. 
Mecozzi, V.J., Berman, D.E., Simoes, S., Vetanovetz, C., Awal, M.R., Patel, V.M., 
Schneider, R.T., Petsko, G.A., Ringe, D., and Small, S.A. (2014). Pharmacological 
chaperones stabilize retromer to limit APP processing. Nat Chem Biol 10, 443-449. 
Meilandt, W.J., Cisse, M., Ho, K., Wu, T., Esposito, L.A., Scearce-Levie, K., Cheng, I.H., 
Yu, G.Q., and Mucke, L. (2009). Neprilysin overexpression inhibits plaque formation but 
fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human 
amyloid precursor protein transgenic mice. J Neurosci 29, 1977-1986. 
Mohr, S., Bakal, C., and Perrimon, N. (2010). Genomic screening with RNAi: results and 
challenges. Annu Rev Biochem 79, 37-64. 
Mueller-Steiner, S., Zhou, Y., Arai, H., Roberson, E.D., Sun, B., Chen, J., Wang, X., Yu, G., 
Esposito, L., Mucke, L., et al. (2006). Antiamyloidogenic and neuroprotective functions of 
cathepsin B: implications for Alzheimer's disease. Neuron 51, 703-714. 
Mukrasch, M.D., Bibow, S., Korukottu, J., Jeganathan, S., Biernat, J., Griesinger, C., 
Mandelkow, E., and Zweckstetter, M. (2009). Structural polymorphism of 441-residue tau at 
single residue resolution. PLoS Biol 7, e34. 
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., and Lannfelt, 
L. (1992). A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-
terminus of beta-amyloid. Nat Genet 1, 345-347. 
 183 
Muller, U.C., Deller, T., and Korte, M. (2017). Not just amyloid: physiological functions of 
the amyloid precursor protein family. Nat Rev Neurosci 18, 281-298. 
Naj, A.C., Schellenberg, G.D., and Alzheimer's Disease Genetics, C. (2017). Genomic 
variants, genes, and pathways of Alzheimer's disease: An overview. Am J Med Genet B 
Neuropsychiatr Genet 174, 5-26. 
Neve, R.L., Harris, P., Kosik, K.S., Kurnit, D.M., and Donlon, T.A. (1986). Identification of 
cDNA clones for the human microtubule-associated protein tau and chromosomal 
localization of the genes for tau and microtubule-associated protein 2. Brain Res 387, 271-
280. 
Nilsson, P., Loganathan, K., Sekiguchi, M., Matsuba, Y., Hui, K., Tsubuki, S., Tanaka, M., 
Iwata, N., Saito, T., and Saido, T.C. (2013). Abeta secretion and plaque formation depend on 
autophagy. Cell Rep 5, 61-69. 
Nilsson, P., and Saido, T.C. (2014). Dual roles for autophagy: degradation and secretion of 
Alzheimer's disease Abeta peptide. Bioessays 36, 570-578. 
Nimmerjahn, A., Kirchhoff, F., and Helmchen, F. (2005). Resting microglial cells are highly 
dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318. 
Ohno, M., Sametsky, E.A., Younkin, L.H., Oakley, H., Younkin, S.G., Citron, M., Vassar, 
R., and Disterhoft, J.F. (2004). BACE1 deficiency rescues memory deficits and cholinergic 
dysfunction in a mouse model of Alzheimer's disease. Neuron 41, 27-33. 
Pant, S., Sharma, M., Patel, K., Caplan, S., Carr, C.M., and Grant, B.D. (2009). AMPH-
1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling. Nat Cell Biol 11, 
1399-1410. 
Paolicelli, R.C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., Giustetto, M., 
Ferreira, T.A., Guiducci, E., Dumas, L., et al. (2011). Synaptic pruning by microglia is 
necessary for normal brain development. Science 333, 1456-1458. 
 184 
Paolicelli, R.C., Jawaid, A., Henstridge, C.M., Valeri, A., Merlini, M., Robinson, J.L., Lee, 
E.B., Rose, J., Appel, S., Lee, V.M., et al. (2017). TDP-43 Depletion in Microglia Promotes 
Amyloid Clearance but Also Induces Synapse Loss. Neuron 95, 297-308 e296. 
Paresce, D.M., Ghosh, R.N., and Maxfield, F.R. (1996). Microglial cells internalize 
aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 
17, 553-565. 
Pascale, C.L., Miller, M.C., Chiu, C., Boylan, M., Caralopoulos, I.N., Gonzalez, L., 
Johanson, C.E., and Silverberg, G.D. (2011). Amyloid-beta transporter expression at the 
blood-CSF barrier is age-dependent. Fluids Barriers CNS 8, 21. 
Pericak-Vance, M.A., Bebout, J.L., Gaskell, P.C., Jr., Yamaoka, L.H., Hung, W.Y., Alberts, 
M.J., Walker, A.P., Bartlett, R.J., Haynes, C.A., Welsh, K.A., et al. (1991). Linkage studies 
in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet 48, 
1034-1050. 
Pfeil, A.M., Kressig, R.W., and Szucs, T.D. (2012). Alzheimer's dementia: budget impact and 
cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine 
in Switzerland. Swiss Med Wkly 142, w13676. 
Prince, M., Ali, G.C., Guerchet, M., Prina, A.M., Albanese, E., and Wu, Y.T. (2016). Recent 
global trends in the prevalence and incidence of dementia, and survival with dementia. 
Alzheimers Res Ther 8, 23. 
Probst, A., Gotz, J., Wiederhold, K.H., Tolnay, M., Mistl, C., Jaton, A.L., Hong, M., Ishihara, 
T., Lee, V.M., Trojanowski, J.Q., et al. (2000). Axonopathy and amyotrophy in mice 
transgenic for human four-repeat tau protein. Acta Neuropathol 99, 469-481. 
Prudencio, M., and Lehmann, M.J. (2009). Illuminating the host - how RNAi screens shed 
light on host-pathogen interactions. Biotechnol J 4, 826-837. 
Rajendran, L., Honsho, M., Zahn, T.R., Keller, P., Geiger, K.D., Verkade, P., and Simons, K. 
(2006). Alzheimer's disease beta-amyloid peptides are released in association with exosomes. 
Proc Natl Acad Sci U S A 103, 11172-11177. 
 185 
Rajendran, L., Schneider, A., Schlechtingen, G., Weidlich, S., Ries, J., Braxmeier, T., 
Schwille, P., Schulz, J.B., Schroeder, C., Simons, M., et al. (2008). Efficient inhibition of the 
Alzheimer's disease beta-secretase by membrane targeting. Science 320, 520-523. 
Refolo, L.M., Sambamurti, K., Efthimiopoulos, S., Pappolla, M.A., and Robakis, N.K. 
(1995). Evidence that secretase cleavage of cell surface Alzheimer amyloid precursor occurs 
after normal endocytic internalization. J Neurosci Res 40, 694-706. 
Rogaeva, E., Meng, Y., Lee, J.H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C.T., 
Cheng, R., Hasegawa, H., et al. (2007). The neuronal sortilin-related receptor SORL1 is 
genetically associated with Alzheimer disease. Nat Genet 39, 168-177. 
Rogers, S.L., and Friedman, R.B. (2008). The underlying mechanisms of semantic memory 
loss in Alzheimer's disease and semantic dementia. Neuropsychologia 46, 12-21. 
Rosseels, J., Van den Brande, J., Violet, M., Jacobs, D., Grognet, P., Lopez, J., Huvent, I., 
Caldara, M., Swinnen, E., Papegaey, A., et al. (2015). Tau monoclonal antibody generation 
based on humanized yeast models: impact on Tau oligomerization and diagnostics. J Biol 
Chem 290, 4059-4074. 
Rovelet-Lecrux, A., Hannequin, D., Raux, G., Le Meur, N., Laquerriere, A., Vital, A., 
Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2006). APP locus duplication 
causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. 
Nat Genet 38, 24-26. 
Runz, H., Rietdorf, J., Tomic, I., de Bernard, M., Beyreuther, K., Pepperkok, R., and 
Hartmann, T. (2002). Inhibition of intracellular cholesterol transport alters presenilin 
localization and amyloid precursor protein processing in neuronal cells. J Neurosci 22, 1679-
1689. 
Saido, T., and Leissring, M.A. (2012). Proteolytic degradation of amyloid beta-protein. Cold 
Spring Harb Perspect Med 2, a006379. 
Sannerud, R., Declerck, I., Peric, A., Raemaekers, T., Menendez, G., Zhou, L., Veerle, B., 
Coen, K., Munck, S., De Strooper, B., et al. (2011). ADP ribosylation factor 6 (ARF6) 
 186 
controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of 
BACE1. Proc Natl Acad Sci U S A 108, E559-568. 
Schafer, D.P., Lehrman, E.K., Kautzman, A.G., Koyama, R., Mardinly, A.R., Yamasaki, R., 
Ransohoff, R.M., Greenberg, M.E., Barres, B.A., and Stevens, B. (2012). Microglia sculpt 
postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691-
705. 
Schneider, A., Rajendran, L., Honsho, M., Gralle, M., Donnert, G., Wouters, F., Hell, S.W., 
and Simons, M. (2008). Flotillin-dependent clustering of the amyloid precursor protein 
regulates its endocytosis and amyloidogenic processing in neurons. J Neurosci 28, 2874-
2882. 
Schroeter, E.H., Ilagan, M.X., Brunkan, A.L., Hecimovic, S., Li, Y.M., Xu, M., Lewis, H.D., 
Saxena, M.T., De Strooper, B., Coonrod, A., et al. (2003). A presenilin dimer at the core of 
the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. 
Proc Natl Acad Sci U S A 100, 13075-13080. 
Schweers, O., Schonbrunn-Hanebeck, E., Marx, A., and Mandelkow, E. (1994). Structural 
studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-
structure. J Biol Chem 269, 24290-24297. 
Selkoe, D., and Kopan, R. (2003). Notch and Presenilin: regulated intramembrane proteolysis 
links development and degeneration. Annu Rev Neurosci 26, 565-597. 
Selkoe, D.J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-
766. 
Selkoe, D.J., and Hardy, J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 
years. EMBO Mol Med 8, 595-608. 
Serrano-Pozo, A., Frosch, M.P., Masliah, E., and Hyman, B.T. (2011). Neuropathological 
alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1, a006189. 
 187 
Seyhan, A.A., and Rya, T.E. (2010). RNAi screening for the discovery of novel modulators 
of human disease. Curr Pharm Biotechnol 11, 735-756. 
Shen, J., and Kelleher, R.J., 3rd (2007). The presenilin hypothesis of Alzheimer's disease: 
evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A 104, 403-
409. 
Shibata, M., Yamada, S., Kumar, S.R., Calero, M., Bading, J., Frangione, B., Holtzman, 
D.M., Miller, C.A., Strickland, D.K., Ghiso, J., et al. (2000). Clearance of Alzheimer's 
amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain 
barrier. J Clin Invest 106, 1489-1499. 
Sierra, A., Abiega, O., Shahraz, A., and Neumann, H. (2013). Janus-faced microglia: 
beneficial and detrimental consequences of microglial phagocytosis. Front Cell Neurosci 7, 6. 
Silverberg, G.D., Mayo, M., Saul, T., Rubenstein, E., and McGuire, D. (2003). Alzheimer's 
disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory 
physiology: a hypothesis. Lancet Neurol 2, 506-511. 
Sims, R., van der Lee, S.J., Naj, A.C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., 
Kunkle, B.W., Boland, A., Raybould, R., Bis, J.C., et al. (2017). Rare coding variants in 
PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's 
disease. Nat Genet 49, 1373-1384. 
Sinha, S., Anderson, J.P., Barbour, R., Basi, G.S., Caccavello, R., Davis, D., Doan, M., 
Dovey, H.F., Frigon, N., Hong, J., et al. (1999). Purification and cloning of amyloid 
precursor protein beta-secretase from human brain. Nature 402, 537-540. 
Sjogren, M., Vanderstichele, H., Agren, H., Zachrisson, O., Edsbagge, M., Wikkelso, C., 
Skoog, I., Wallin, A., Wahlund, L.O., Marcusson, J., et al. (2001). Tau and Abeta42 in 
cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. 
Clin Chem 47, 1776-1781. 
Sleegers, K., Brouwers, N., Gijselinck, I., Theuns, J., Goossens, D., Wauters, J., Del-Favero, 
J., Cruts, M., van Duijn, C.M., and Van Broeckhoven, C. (2006). APP duplication is 
 188 
sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 
129, 2977-2983. 
Small, S.A., and Gandy, S. (2006). Sorting through the cell biology of Alzheimer's disease: 
intracellular pathways to pathogenesis. Neuron 52, 15-31. 
Small, S.A., Kent, K., Pierce, A., Leung, C., Kang, M.S., Okada, H., Honig, L., Vonsattel, 
J.P., and Kim, T.W. (2005). Model-guided microarray implicates the retromer complex in 
Alzheimer's disease. Ann Neurol 58, 909-919. 
Sobajima, T., Yoshimura, S., Iwano, T., Kunii, M., Watanabe, M., Atik, N., Mushiake, S., 
Morii, E., Koyama, Y., Miyoshi, E., et al. (2014). Rab11a is required for apical protein 
localisation in the intestine. Biol Open 4, 86-94. 
Sontag, E., Hladik, C., Montgomery, L., Luangpirom, A., Mudrak, I., Ogris, E., and White, 
C.L., 3rd (2004). Downregulation of protein phosphatase 2A carboxyl methylation and 
methyltransferase may contribute to Alzheimer disease pathogenesis. J Neuropathol Exp 
Neurol 63, 1080-1091. 
Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., Iwatsubo, 
T., Jack, C.R., Jr., Kaye, J., Montine, T.J., et al. (2011). Toward defining the preclinical 
stages of Alzheimer's disease: recommendations from the National Institute on Aging-
Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. 
Alzheimers Dement 7, 280-292. 
Sperling, R.A., Laviolette, P.S., O'Keefe, K., O'Brien, J., Rentz, D.M., Pihlajamaki, M., 
Marshall, G., Hyman, B.T., Selkoe, D.J., Hedden, T., et al. (2009). Amyloid deposition is 
associated with impaired default network function in older persons without dementia. Neuron 
63, 178-188. 
Stalder, M., Deller, T., Staufenbiel, M., and Jucker, M. (2001). 3D-Reconstruction of 
microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. 
Neurobiol Aging 22, 427-434. 
 189 
Stefani, A., Bernardini, S., Panella, M., Pierantozzi, M., Nuccetelli, M., Koch, G., Urbani, A., 
Giordano, A., Martorana, A., Orlacchio, A., et al. (2005). AD with subcortical white matter 
lesions and vascular dementia: CSF markers for differential diagnosis. J Neurol Sci 237, 83-
88. 
Stenmark, H., and Olkkonen, V.M. (2001). The Rab GTPase family. Genome Biol 2, 
REVIEWS3007. 
Sun, L., Zhou, R., Yang, G., and Shi, Y. (2017). Analysis of 138 pathogenic mutations in 
presenilin-1 on the in vitro production of Abeta42 and Abeta40 peptides by gamma-secretase. 
Proc Natl Acad Sci U S A 114, E476-E485. 
Szaruga, M., Munteanu, B., Lismont, S., Veugelen, S., Horre, K., Mercken, M., Saido, T.C., 
Ryan, N.S., De Vos, T., Savvides, S.N., et al. (2017). Alzheimer's-Causing Mutations Shift 
Abeta Length by Destabilizing gamma-Secretase-Abetan Interactions. Cell 170, 443-456 
e414. 
Szodorai, A., Kuan, Y.H., Hunzelmann, S., Engel, U., Sakane, A., Sasaki, T., Takai, Y., 
Kirsch, J., Muller, U., Beyreuther, K., et al. (2009). APP anterograde transport requires 
Rab3A GTPase activity for assembly of the transport vesicle. J Neurosci 29, 14534-14544. 
Tarasoff-Conway, J.M., Carare, R.O., Osorio, R.S., Glodzik, L., Butler, T., Fieremans, E., 
Axel, L., Rusinek, H., Nicholson, C., Zlokovic, B.V., et al. (2015). Clearance systems in the 
brain-implications for Alzheimer disease. Nat Rev Neurol 11, 457-470. 
Tarawneh, R., D'Angelo, G., Crimmins, D., Herries, E., Griest, T., Fagan, A.M., Zipfel, G.J., 
Ladenson, J.H., Morris, J.C., and Holtzman, D.M. (2016). Diagnostic and Prognostic Utility 
of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurol 73, 561-571. 
Tcw, J., and Goate, A.M. (2017). Genetics of beta-Amyloid Precursor Protein in Alzheimer's 
Disease. Cold Spring Harb Perspect Med 7. 
Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A., and 
Katzman, R. (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse 
loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580. 
 190 
Tesco, G., Koh, Y.H., Kang, E.L., Cameron, A.N., Das, S., Sena-Esteves, M., Hiltunen, M., 
Yang, S.H., Zhong, Z., Shen, Y., et al. (2007). Depletion of GGA3 stabilizes BACE and 
enhances beta-secretase activity. Neuron 54, 721-737. 
Thies, E., and Mandelkow, E.M. (2007). Missorting of tau in neurons causes degeneration of 
synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci 27, 2896-2907. 
Thorsell, A., Bjerke, M., Gobom, J., Brunhage, E., Vanmechelen, E., Andreasen, N., 
Hansson, O., Minthon, L., Zetterberg, H., and Blennow, K. (2010). Neurogranin in 
cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res 
1362, 13-22. 
Tian, Y., Chang, J.C., Fan, E.Y., Flajolet, M., and Greengard, P. (2013). Adaptor complex 
AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal 
degradation via autophagy. Proc Natl Acad Sci U S A 110, 17071-17076. 
Tosto, G., and Reitz, C. (2013). Genome-wide association studies in Alzheimer's disease: a 
review. Curr Neurol Neurosci Rep 13, 381. 
Truman, L.A., Ford, C.A., Pasikowska, M., Pound, J.D., Wilkinson, S.J., Dumitriu, I.E., 
Melville, L., Melrose, L.A., Ogden, C.A., Nibbs, R., et al. (2008). CX3CL1/fractalkine is 
released from apoptotic lymphocytes to stimulate macrophage chemotaxis. Blood 112, 5026-
5036. 
Tucker, H.M., Kihiko, M., Caldwell, J.N., Wright, S., Kawarabayashi, T., Price, D., Walker, 
D., Scheff, S., McGillis, J.P., Rydel, R.E., et al. (2000). The plasmin system is induced by 
and degrades amyloid-beta aggregates. J Neurosci 20, 3937-3946. 
Turner, A.J., and Nalivaeva, N.N. (2007). New insights into the roles of metalloproteinases in 
neurodegeneration and neuroprotection. Int Rev Neurobiol 82, 113-135. 
Udayar, V., Buggia-Prevot, V., Guerreiro, R.L., Siegel, G., Rambabu, N., Soohoo, A.L., 
Ponnusamy, M., Siegenthaler, B., Bali, J., Aesg, et al. (2013). A paired RNAi and RabGAP 
overexpression screen identifies Rab11 as a regulator of beta-amyloid production. Cell Rep 5, 
1536-1551. 
 191 
Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., 
Ross, S., Amarante, P., Loeloff, R., et al. (1999). Beta-secretase cleavage of Alzheimer's 
amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-
741. 
Vassar, R., Kovacs, D.M., Yan, R., and Wong, P.C. (2009). The beta-secretase enzyme 
BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic 
potential. J Neurosci 29, 12787-12794. 
Velliquette, R.A., O'Connor, T., and Vassar, R. (2005). Energy inhibition elevates beta-
secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: 
possible early events in Alzheimer's disease pathogenesis. J Neurosci 25, 10874-10883. 
von Arnim, C.A., Spoelgen, R., Peltan, I.D., Deng, M., Courchesne, S., Koker, M., Matsui, 
T., Kowa, H., Lichtenthaler, S.F., Irizarry, M.C., et al. (2006). GGA1 acts as a spatial switch 
altering amyloid precursor protein trafficking and processing. J Neurosci 26, 9913-9922. 
Wake, H., Moorhouse, A.J., Jinno, S., Kohsaka, S., and Nabekura, J. (2009). Resting 
microglia directly monitor the functional state of synapses in vivo and determine the fate of 
ischemic terminals. J Neurosci 29, 3974-3980. 
Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., and Stella, 
N. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J 
Neurosci 23, 1398-1405. 
Wang, Y., Cella, M., Mallinson, K., Ulrich, J.D., Young, K.L., Robinette, M.L., Gilfillan, S., 
Krishnan, G.M., Sudhakar, S., Zinselmeyer, B.H., et al. (2015). TREM2 lipid sensing 
sustains the microglial response in an Alzheimer's disease model. Cell 160, 1061-1071. 
Watanabe, M., Fiji, H.D., Guo, L., Chan, L., Kinderman, S.S., Slamon, D.J., Kwon, O., and 
Tamanoi, F. (2008). Inhibitors of protein geranylgeranyltransferase I and Rab 
geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol 
Chem 283, 9571-9579. 
 192 
Weingarten, M.D., Lockwood, A.H., Hwo, S.Y., and Kirschner, M.W. (1975). A protein 
factor essential for microtubule assembly. Proc Natl Acad Sci U S A 72, 1858-1862. 
Weller, R.O., Subash, M., Preston, S.D., Mazanti, I., and Carare, R.O. (2008). Perivascular 
drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid 
angiopathy and Alzheimer's disease. Brain Pathol 18, 253-266. 
Wellington, H., Paterson, R.W., Portelius, E., Tornqvist, U., Magdalinou, N., Fox, N.C., 
Blennow, K., Schott, J.M., and Zetterberg, H. (2016). Increased CSF neurogranin 
concentration is specific to Alzheimer disease. Neurology 86, 829-835. 
Wen, L., Tang, F.L., Hong, Y., Luo, S.W., Wang, C.L., He, W., Shen, C., Jung, J.U., Xiong, 
F., Lee, D.H., et al. (2011). VPS35 haploinsufficiency increases Alzheimer's disease 
neuropathology. J Cell Biol 195, 765-779. 
Willem, M., Garratt, A.N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., 
Saftig, P., Birchmeier, C., and Haass, C. (2006). Control of peripheral nerve myelination by 
the beta-secretase BACE1. Science 314, 664-666. 
Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-
Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016). Defeating Alzheimer's 
disease and other dementias: a priority for European science and society. Lancet Neurol 15, 
455-532. 
Wisniewski, T., Ghiso, J., and Frangione, B. (1997). Biology of A beta amyloid in 
Alzheimer's disease. Neurobiol Dis 4, 313-328. 
Wolfe, M.S. (2008). Inhibition and modulation of gamma-secretase for Alzheimer's disease. 
Neurotherapeutics 5, 391-398. 
Wong, E.S., Tan, J.M., Soong, W.E., Hussein, K., Nukina, N., Dawson, V.L., Dawson, T.M., 
Cuervo, A.M., and Lim, K.L. (2008). Autophagy-mediated clearance of aggresomes is not a 
universal phenomenon. Hum Mol Genet 17, 2570-2582. 
 193 
Xie, L., Kang, H., Xu, Q., Chen, M.J., Liao, Y., Thiyagarajan, M., O'Donnell, J., Christensen, 
D.J., Nicholson, C., Iliff, J.J., et al. (2013). Sleep drives metabolite clearance from the adult 
brain. Science 342, 373-377. 
Yamada, K., Holth, J.K., Liao, F., Stewart, F.R., Mahan, T.E., Jiang, H., Cirrito, J.R., Patel, 
T.K., Hochgrafe, K., Mandelkow, E.M., et al. (2014). Neuronal activity regulates 
extracellular tau in vivo. J Exp Med 211, 387-393. 
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R.J., Cirrito, J.R., Xiao, Q., Hsu, F.F., Turk, 
J.W., Xu, J., et al. (2006). Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro 
and compact plaques in situ. J Biol Chem 281, 24566-24574. 
Yan, R., Bienkowski, M.J., Shuck, M.E., Miao, H., Tory, M.C., Pauley, A.M., Brashier, J.R., 
Stratman, N.C., Mathews, W.R., Buhl, A.E., et al. (1999). Membrane-anchored aspartyl 
protease with Alzheimer's disease beta-secretase activity. Nature 402, 533-537. 
Young, J.E., Fong, L.K., Frankowski, H., Petsko, G.A., Small, S.A., and Goldstein, L.S.B. 
(2018). Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's 
Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein. Stem 
Cell Reports 10, 1046-1058. 
Yu, W.H., Cuervo, A.M., Kumar, A., Peterhoff, C.M., Schmidt, S.D., Lee, J.H., Mohan, P.S., 
Mercken, M., Farmery, M.R., Tjernberg, L.O., et al. (2005). Macroautophagy--a novel Beta-
amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 171, 87-98. 
Yuyama, K., Yamamoto, N., and Yanagisawa, K. (2008). Accelerated release of exosome-
associated GM1 ganglioside (GM1) by endocytic pathway abnormality: another putative 
pathway for GM1-induced amyloid fibril formation. J Neurochem 105, 217-224. 
Zahraoui, A., Touchot, N., Chardin, P., and Tavitian, A. (1989). The human Rab genes 
encode a family of GTP-binding proteins related to yeast YPT1 and SEC4 products involved 
in secretion. J Biol Chem 264, 12394-12401. 
Zetterberg, H., Blennow, K., and Hanse, E. (2010). Amyloid beta and APP as biomarkers for 
Alzheimer's disease. Exp Gerontol 45, 23-29. 
 194 
Zhan, Y., Paolicelli, R.C., Sforazzini, F., Weinhard, L., Bolasco, G., Pagani, F., Vyssotski, 
A.L., Bifone, A., Gozzi, A., Ragozzino, D., et al. (2014). Deficient neuron-microglia 
signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci 
17, 400-406. 
Zhang, S., Salemi, J., Hou, H., Zhu, Y., Mori, T., Giunta, B., Obregon, D., and Tan, J. (2010). 
Rapamycin promotes beta-amyloid production via ADAM-10 inhibition. Biochem Biophys 
Res Commun 398, 337-341. 
Zhao, J., Fu, Y., Yasvoina, M., Shao, P., Hitt, B., O'Connor, T., Logan, S., Maus, E., Citron, 
M., Berry, R., et al. (2007). Beta-site amyloid precursor protein cleaving enzyme 1 levels 
become elevated in neurons around amyloid plaques: implications for Alzheimer's disease 
pathogenesis. J Neurosci 27, 3639-3649. 
Zhao, Z., Sagare, A.P., Ma, Q., Halliday, M.R., Kong, P., Kisler, K., Winkler, E.A., 
Ramanathan, A., Kanekiyo, T., Bu, G., et al. (2015). Central role for PICALM in amyloid-
beta blood-brain barrier transcytosis and clearance. Nat Neurosci 18, 978-987. 
Zlokovic, B.V. (2004). Clearing amyloid through the blood-brain barrier. J Neurochem 89, 
807-811. 
Zlokovic, B.V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer's disease 
and other disorders. Nat Rev Neurosci 12, 723-738. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 195 
Originality Report 
This thesis was tested for plagiarism with Plagscan, from the access provided by  University 
of Zurich. The prior published papers, bibliographies and materials and methods were 
removed before scan. 
 
 
 
 
 
 
 
 
 
 
 All sources 100  Internet sources 100
[0]
 https://www.researchgate.net/profile/Jitin_Bali
0.3%  7 matches 
[1]
 rsob.royalsocietypublishing.org/content/7/12/170228
0.3%  8 matches 
[2]
 https://www.researchgate.net/publication...lzheimer's_Disease
0.3%  8 matches 
[3]
 https://www.researchgate.net/profile/Ant...637a408799000000.pdf
0.2%  5 matches 
[4]
 https://www.dovepress.com/mutations-in-p...fulltext-article-CIA
0.2%  5 matches 
[5]
 https://www.researchgate.net/profile/San...08ae840a08d564a8.pdf
0.2%  5 matches 
[6]
 https://link.springer.com/article/10.1007/s12035-013-8620-6
0.2%  5 matches 
[7]
 https://pdfs.semanticscholar.org/9c03/59e3521f69740327b69fffcfa8dece49b96e.pdf
0.2%  6 matches 
[8]
 https://www.researchgate.net/publication...generative_Disorders
0.2%  7 matches 
[9]
 d1ssu070pg2v9i.cloudfront.net/pex/gre/20...ysosomal-pathway.pdf
0.2%  5 matches 
[10]
 https://www.researchgate.net/profile/Sebastian_Zurbriggen
0.2%  5 matches 
[11]
 https://pdfs.semanticscholar.org/05e2/dde69a4383f12d8a3378a8d3cda159ddc9fe.pdf
0.2%  4 matches 
[12]
 https://link.springer.com/content/pdf/10.1007/s00418-015-1366-7.pdf
0.2%  5 matches 
[13]
 https://synapse.koreamed.org/Synapse/Data/PDFData/0067KJPP/kjpp-18-447.pdf
0.2%  5 matches 
[14]
 https://idplagscan01.uzh.ch/view?581
0.2%  4 matches 
[15]
 https://www.researchgate.net/publication...about_neuronal_death
0.2%  5 matches 
[16]
 https://www.researchgate.net/publication...d_dysfunction_Review
0.2%  4 matches 
[17]
 https://www.researchgate.net/publication...of_Cognitive_Defects
0.2%  4 matches 
[18]
 https://www.researchgate.net/profile/Dav...ogical-disorders.pdf
0.1%  4 matches 
  1 documents with identical matches
[20]
 onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.2009.06420.x/full
0.1%  5 matches 
[21]
 https://www.researchgate.net/profile/Utta_Berchner-Pfannschmidt
0.1%  4 matches 
[22]
 https://www.researchgate.net/publication...lzheimer's_Disease
0.1%  3 matches 
[23]
 https://www.frontiersin.org/articles/10.3389/fncel.2015.00414/full
0.1%  4 matches 
[24]
 onlinelibrary.wiley.com/doi/10.1002/ana.22516/full
0.1%  4 matches 
[25]
 https://www.sciencedirect.com/science/article/pii/S1552526015030290
4.0%
 Results of plagiarism analysis from 2018-03-15 12:02 UTC
Thesis_Vinod_Plagscan_check.docx
Date: 2018-03-15 11:50 UTC
 196 
Acknowledgements 
As I walk towards an important personal milestone I would like to take a moment to express 
my gratitude and appreciation to several wonderful people that have helped me and made this 
journey a memorable one. 
 
I begin by expressing my sincerest gratitude to my supervisor, Prof. Lawrence Rajendran. I 
cannot thank him enough for giving me the opportunity to come and do great science in a 
top-tier University. I would like to thank him for his constant support, mentorship and 
teaching. I value and appreciate his creative thoughts and deep scientific insights. These are 
qualities that I would like to cultivate as a scientist and I feel lucky to have got such an 
opportunity. Thank you so much Lawrie! 
 
I would like to say thank you to my committee members, Prof Martin Schwab and Prof. 
Esther Stoeckli for their scientific advice and support. I would like to say thank you to Prof. 
Roger Nitsch and Prof. Christoph Hock for their advice and support. I would also like to say 
thank you to Dr. Cornelia Marty and Sebi Zurbriggen for all their help during the first years 
of my PhD. Thank you to all the members of IREM past and present alike. I also express my 
sincere gratitude to Dr. S. Vijayalakshmi for all her support and encouragement. 
 
PhD would not have been as much fun if not for the support and company of my wonderful 
labmates, past and current.  I would like to say special thank you to Gabi, Rosa, Saoussen, 
Mrityunjoy, Andrea, Fatma and Walther. You are the best labmates!  
 
I would like to say a big thank you to all my friends for making this an enjoyable experience. 
Special thank you to Julian, Laura, Manuel, Patrick and Berni for the great friendship!  
 
And last but never the least, I would like to express my love and gratitude to my family, my 
close friends and Anais. Thank you so much! 
 
 
 
 
 
 197 
Curriculum vitae 
 
Personal details 
 
Name:                                Vinod Udayar 
Date of Birth:                     October 20, 1986 
Nationality:                         Indian 
 
Education 
 
2002-2004                           Higher Secondary school Certificate (HSC) 
                                            G. N. Khalsa College, Mumbai, India 
 
 
09/2004 - 05/2008              Bachelor of Technology in Biotechnology 
                                            Specialization: Biochemistry, cell and molecular biology. 
                                            YCMO University, Mumbai, India 
 
 
08/2008 - 05/2010               Master of Technology in Biotechnology 
                                             Specialization: Medical Biotechnology 
                                             SRM University, Chennai, India 
                                             Master thesis: Role of SPR3 in septogenesis in E.ashbyii 
 
 
08/2011 – present                 Doctoral Thesis, University of Zurich (Switzerland) 
                                              Thesis: Membrane Trafficking Pathways in the Production and             
                                              Clearance of the Alzheimer’s Disease Aβ Peptide in Neurons     
                                              and in Microglia 
 
 
 
 
 
 
	
